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Abstract
Primary efficacy endpoints for interventional products targeting travelers’ diarrhea (TD)
prevention have been predominately based on stool frequency. However, reliance on
stool-based endpoints alone may obscure potentially meaningful differences in illness
profiles. A single, standardized scoring system optimized for use in adult travelers is
needed to accurately measure TD severity and enable more robust estimates of treatment
or intervention effectiveness. The purpose of this quantitative secondary data analysis
was to describe the variability in TD signs and symptoms across traditional severity
metrics such as stool output, identify which symptoms were significantly associated with
a negative impact on activity, and determine whether a TD scoring system that considers
other symptomology could be optimized for use in future studies using the IRT and CTT
frameworks. Data were obtained from two interventional studies: TrEAT TD, a multi-site
TD treatment trial, and OEV-118—a placebo-controlled ETEC vaccine efficacy trial in
travelers. Correlation, regression and multiple correspondence analyses were performed
across multiple signs and symptoms to assess impact on activity and a TD severity score
was established. Conclusions were (a) the new TD score significantly benefits the
estimation of impact on activity over any individual sign or symptom, and (b) there was a
benefit to reduction in overall TD disease severity when applied to a previously
conducted vaccine efficacy trial. The use of a single optimized scoring system may better
capture illness severity than commonly utilized metrics and moves the field towards
current recommendations for TD management. Additionally, the use of the TD severity
score may be an improved efficacy metric than stool frequency for future vaccine trials.
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Chapter 1: Introduction
Study Background
Travelers’ diarrhea (TD) is the most common travel-related illness, with an
estimated 10 million people afflicted annually and a reported attack rate of 30 to 70%
depending on destination and season (Centers for Disease Control and Prevention [CDC],
2015; Shah, DuPont, & Ramsey, 2009; Steffen, Hill, & DuPont, 2015). TD also
significantly affects deployed military populations, a unique subset of the travel
population, with an estimated attack rate of approximately 30 cases per 100-person
months (Jaep, 2016; Riddle, Sanders, Putnam, & Tribble, 2006; Porter, Olson, Hall &
Riddle, 2017). Numerous bacterial, viral, and protozoal pathogens cause diarrhea, with
approximately 80 to 90% of cases caused from bacterial etiology (Steffen et al., 2015).
While generally an acute, self-limiting illness with symptom resolution within 1 to 5
days, increasing evidence has linked significant chronic health conditions to these enteric
infections, the most common of which include reactive arthritis and post-infectious
functional gastrointestinal disorders (PI-FGDs) such as irritable bowel syndrome (Connor
& Riddle, 2013; Nair et al., 2014; Pitzurra, Steffen, Tschopp, & Mutsch, 2010; Porter,
Thura, & Riddle, 2013).
A future vaccine against the primary TD etiologic agents remains the most costeffective approach from a military and long-term traveler perspective (Cachafeiro, Szucs
& Behrens, 2008; Tallant et al., 2014). TD prevention in civilian travelers is driven
largely by the desire to not be inconvenienced by illness while traveling; however, in
military populations the objective is to minimize lost duty days, medical resources
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needed within the theater of operations, and post-infectious sequelae in returning troops
(PATH & BVGH, 2011). In fact, the US Department of Defense’s (DoD) strategy for
developing a vaccine for infectious diarrhea was listed among its top three priorities as
described in a 2003 technical and policy recommendations report issued by the Institute
of Medicine’s (IOM; Lemon, Thaul, Fisseha, & O’Maonaigh, 2003). The DoD currently
maintains three parallel vaccine development programs focused on Campylobacter jejuni,
enterotoxigenic Escherichia coli (ETEC), and Shigella with the goal of developing a
mono- or multipathogen vaccine against these common causes of TD (Naval Medical
Research Center, 2017; Riddle, Tribble, Cachafiero, Putnam, & Hooper, 2008). With the
significant morbidity of TD in travelers, especially long-term travelers and military
populations, a critical path to preventing acute cases as well as potential long-term
sequelae includes TD vaccine and other prevention development approaches.
TD Epidemiology
Initial symptoms of TD often begin within the first 2 weeks of travel and resolve
without treatment within 3 to 5 days (Diemert, 2006; Steffen et al., 2015). Nevertheless,
symptoms can force changes in travel/business plans, or more rarely, hospitalization
(Kollaritsch, 1998; Peltola & Gorbach, 1997; Diemert, 2006). TD has been traditionally
defined as the passage of three or more loose stools in a 24 hour period, often with an
associated gastrointestinal symptom such as fever, nausea, vomiting, abdominal pain,
tenesmus, fecal urgency, or bloody or mucoid stools (Broor & Singal, 1989; Diemert,
2006; Hill, 2010; Steffen et al., 2015). Conventionally, TD is used to reference an illness
that occurs in a resident from a high-income country traveling to a low- to middle-income

3
country (LMIC), but it is also applied to deployed military populations (Connor, 2017;
Steffen et al., 2015). Destination remains the most important TD risk factor, with regional
differences in risk and pathogen etiology. More developed areas such as North America,
Australia, New Zealand, Japan and Northern and Western Europe represent areas of
minimal to no-risk; intermediate risk countries include China, South Africa, some
Caribbean islands and countries in Eastern Europe, while highest risk areas include Asia,
the Middle East, Africa, and South America. While bacterial etiology accounts for 80 to
90% of TD cases, intestinal viruses and protozoa make up the remaining 5 to 8% and
10% of cases, respectively (Steffen et al., 2015). The leading bacterial causes of TD
include diarrheagenic Escherichia coli, Campylobacter jejuni, Shigella spp., and
Salmonella spp., with regional and population differences (Shah et al., 2009). Common
viral causes include rotavirus, astrovirus, and norovirus (Bohnker & Thornton, 2003;
Freeland, Vaughan, & Banerjee, 2016).
TD Interventions
There are four main strategies of primary prevention for TD: immunization,
nonpharmacological therapy, antibiotic prophylaxis, and avoidance. Vaccines against the
most common pathogenic causes of TD hold particular promise for preventing
gastroenteritis in individuals traveling to high-risk areas. Studies on the economic burden
of diarrheal diseases, the potential for vaccines under development, and the estimated
economic value of vaccines justify investment in the development and utilization of
candidates against the most common causes of TD (Bartsch & Lee, 2014; PATH &
BVGH, 2011; Riddle et al., 2008). Effective prophylaxis such as antibiotics or anti-
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diarrheals, like bismuth subsalicylate (BSS) (Pepto-Bismol tablets), are also attractive
primary and secondary prevention methods for TD (Taylor, Hamer & Shlim, 2017), with
efficacy of marketed agents having been demonstrated in various field and controlled
human infection model studies (DuPont et al., 2014; DuPont et al., 2009; Hu, Ren, Zhan,
Li, & Dai, 2012; Taylor et al., 2006; Zanger, Nurjadi, Gabor, Gaile, & Kremsner, 2013).
However, before interventions such as vaccines or prophylaxes can be used widely,
rigorous clinical trials are often required. Additionally, once vaccines are introduced into
the market, additional post marketing surveillance studies are typically performed to
monitor vaccine effectiveness and changes in disease epidemiology, burden, and duration
of protection (López-Gigosos, Segura-Moreno, Díez-Díaz, Plaza, & Mariscal, 2014).
With this in mind, well-established and more clinically meaningful endpoints are critical
to advancing vaccines through proof of principal studies, licensure, and pre-qualification,
and disease scoring algorithms aimed at disease severity should be developed (Porter,
Gutierrez & Kotloff, 2019).
Scoring Systems and Challenges
TD vaccines are meant to prevent moderate to severe disease caused by a specific
etiology (Lopez-Gigosos et al., 2014; Porter et al., 2019; World Health Organization,
2006). For this reason, efficacy studies focus on moderate to severe gastroenteritis as a
primary endpoint, which requires a standardized measure of disease severity. However,
the primary outcomes of interest in clinical trials of vaccine candidates and interventions
have varied. While most, if not all, TD vaccine and treatment studies have utilized a
diarrhea definition based on number of unformed stool in a 24-hour period, some
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incorporate an additional symptom such as abdominal pain or nausea to the endpoint
(Stoney et al., 2017; Wiwanitkit, 2007), and most do not consider the functional impact
(i.e., impact on daily activity). Measuring the efficacy of an intervention in these trials
involves accurately defining the clinical endpoint of interest, such as prevention of
moderate-to-severe TD. Furthermore, because vaccine efficacy may differ by disease
severity, the accuracy of measuring more severe disease impacts vaccine efficacy
estimates, thereby influencing future investment towards the continued development and
implementation of these interventions. Because conducting vaccine efficacy trials in lowresource settings or in a controlled human infection model is expensive and challenging,
the use of well-defined, validated primary endpoints is necessary.
Researchers have addressed a similar issue in pediatric studies of diarrheal
disease, and numerous scoring systems have been developed and validated for the
purpose of simplifying and standardizing clinical outcome measurements (Clark & Offit,
2004; Friedman, Goldman, Srivastava, & Parkin, 2004; Gorelick, Shaw, & Murphy,
1997; Jauregui et al., 2014; Kinlin & Freedman, 2012; Lee et al., 2016; Ruuska &
Vesikari, 1990; WHO and UNICEF Joint Statement, 2004). Furthermore, Porter and
colleagues have sought to standardize clinical endpoints and establish disease scoring
systems for use in controlled human infection models (CHIMs) for ETEC (Porter et al.,
2016), Shigella (Porter et al., 2017) and Campylobacter (Tribble et al., 2017).
In Chapter 2, I will discuss additional information about the history of TD disease
characterization, summary of scoring system challenges as it applies to pediatric
populations, and recent efforts to create similar etiologic-specific scoring systems for
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application in CHIMs. In the remainder of this chapter, I summarize the problem,
research design, and methodology. The purpose of the study, research questions, and
hypotheses are briefly presented. Measurement theories are explored as the conceptual
frameworks guiding the study. Further, I introduce key variables and identify the
assumptions, limitations, and significance of the study.
Problem Statement
The global diarrheal disease burden for travelers and military personnel has
prompted the development and assessment of primary and secondary disease prevention
efforts. The efficacy of these interventions is often based on the prevention of moderate
to severe diarrheal diseases, typically defined by maximum number of loose stools in a
24-hour period (e.g., mild = 1-2 stools; moderate = 3-5 stools; severe ≥ 6-9 stools)
(Behrans et al., 2014; Darsley, Harro, Chakraborty, Sack, & DeNearing, 2015; Frech et
al., 2008; Sack et al., 2007). However, reliance on stool-based endpoints alone may
obscure potentially meaningful differences in illness profiles. Attempts to address this
limitation have been advanced for pediatric populations and include the Vesikari and
Clark scores—both Rotavirus specific (Clark & Offit, 2004; Ruuska & Vesikari, 1990);
the Gorelick Score (Gorelick et al., 1997); the Clinical Dehydration Scale (CDS;
Friedman et al., 2004); and the WHO Integrated Management of Childhood Illness
(IMCI; WHO & UNICEF, 2004). Furthermore, more recent validation efforts have
pointed towards their potential utility on the front line using a more optimized endpoint
for interventional studies (Clark & Offit, 2004; Jauregui et al., 2014; Kinlin & Freedman,
2012; Lee et al., 2016). However, these scores are focused on pediatric populations with

7
limited utility for the adult traveler population. There is no standardized disease score for
diarrheal illness in adult travelers, limiting the interpretation of disease severity
differences within and across studies.
Purpose
A single, standardized scoring system optimized for use in adult travelers is
needed to accurately and consistently characterize TD severity. Such a score will enable
more accurate estimates of efficacy, effectiveness, and cost-effectiveness of primary and
secondary prevention efforts in adult populations. The purpose of this quantitative
secondary analysis was to:
1. Describe the TD disease complex and how the clinical signs and symptoms
co-occur.
2. Describe the variability in signs and symptoms of TD across more traditional
severity metrics (i.e., stool output).
3. Determine what individual clinical signs and symptoms of TD are
significantly associated with a negative impact on activity among adult
travelers.
4. Apply the disease complex score to a previously conducted TD vaccine field
trial to re-estimate vaccine efficacy.
Research Questions and Hypotheses
The research questions and associated hypotheses are as follows:
Research Question 1: What combination of clinical signs and symptoms best
characterizes TD severity in adult travelers?
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Ho1: There are no significant differences in the frequency and severity of clinical
signs and symptoms across disease severity classification.
Ha1: There are significant differences in the frequency and severity of clinical
signs and symptoms of TD on disease severity classification.
Research Question 2: What individual clinical signs and symptoms of TD are
significantly associated with a negative impact on activity among adult travelers?
Ho2: Individual clinical signs and symptoms of TD are not significantly
associated with a negative impact on activity.
Ha2: Individual clinical signs and symptoms of TD are significantly associated
with a negative impact on activity.
Research Question 3: Does a TD disease score better differentiate treatment
groups than prior estimates of vaccine efficacy when applied to a previously conducted
ETEC vaccine study (Protocol OEV-118)?
Ho3: The estimated vaccine efficacy of the ETVAX vaccine in the OEV-118
Phase 3 trial does not change as a result of using the new disease complex score.
Ha3: The estimated vaccine efficacy of the ETVAX inactivated whole cell vaccine
tested in the OEV-118 Phase 3 trial does change as a result of using the new disease
complex score.
Conceptual Framework
Two conceptual frameworks guided this research as it relates to scale
development and application. They are based on scale development theories and include
the item response theory (IRT) and classic test theory (CTT) that researchers often use to
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guide scale development through factor analysis and item selection. IRT was first used in
the field of psychometrics to evaluate instruments and assess subjects on their abilities,
attitudes, or other traits (Xinming & Yung, 2014). Commonly used aptitude tests like the
Scholastic Assessment Tests (SATs) and Graduate Record Exams (GREs) have been
developed using IRT, which has been shown to improve reliability and measurement
accuracy while also improving efficiency in assessment time (Xinming & Yung, 2014).
Over the years, IRT methodology has become increasingly popular and applied to health
outcomes, clinical research, and quality-of-life research (Hays, Morales, & Reise, 2000;
Xinming & Yung, 2014). Researchers have shown that IRT models better reflect actual
response patterns in sample populations, resulting in better estimates of self-reported
health outcomes that are more sensitive to true cross-sectional differences and more
responsive to changes in health over time (Hays et al., 2000). CTT is another
psychometric theory researchers use to predict the abilities of subjects, in which a
subject’s observed score on a test is the subject’s true score plus some error (since it is
unlikely that a subject will perform perfectly on a test; Tractenberg, 2010). Similar to the
IRT, CTS has also been widely used in development and selection of endpoint
measurements in clinical trials (Tractenberg, 2010), with advantages and disadvantages
cited for using one over the other (Hays et al., 2000). These frameworks have been
relevant to the development of various scales for gastroenteritis assessment (Cappelleri et
al., 2014) and thus remain an applicable framework for this research.
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Nature of the Study
This study consisted of a quantitative secondary data analysis in which I
compared two existing clinical trial datasets containing clinical signs and symptoms of
TD for consistent variables and subsequently analyzed them to develop and validate a TD
severity score for the target population. This study could also be considered
methodological research, as it involved the development and evaluation of data collection
scales (see Frankfort-Nachmias & Nachmias, 2008), or more specifically a scoring
system that better characterizes moderate to severe TD disease. The goal with such
research is to make an intangible concept tangible (Dancer, 1994). In this case, my goal
was to develop a standardized instrument for measuring a disease profile consisting of
both objective and subjective parameters. This optimized scoring system would be
available for additional validation and testing with currently existing datasets, in future
enteric vaccine or prophylaxis trials, post introduction effectiveness, and surveillance
studies, as well as in additional secondary analyses utilizing other vaccine or intervention
trial datasets.
Variables
Data for this analysis came from two clinical trial datasets (studies TrEAT TD
and OEV-118; Riddle et al., 2017; Bourgeois et al., 2011). The items that comprise both
datasets include the maximum number of loose stools in a 24-hour period, total number
of stool containing blood, number and duration of vomiting episodes, duration and
severity of abdominal cramping, duration and severity of nausea, duration and severity of
gas, duration and severity of tenesmus, duration and severity of malaise, highest recorded
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fever in a 24-hour period, and duration and severity of fecal incontinence/urgency of
defecation. The relative severity category assignment (i.e., mild, moderate, severe) based
on impact on activity was also included in the TrEAT TD dataset. I used these data and
sources, which I further described in Chapter 3, to determine which signs and symptoms
were most relevant for describing TD severity, develop a TD complex scoring system,
apply the score to a previously conducted Phase 3 study for re-determination of vaccine
efficacy, and ultimately propose an optimized TD scoring system for use in future
studies.
Definitions
The below terms are consistent with the clinical research protocol from which the
original data were collected and were used in this secondary analysis (see Riddle et al.,
2017).
Travelers Diarrhea: Three or more loose stools in 24 hours, or ≥ 2 loose stools in
24 hours with associated symptoms such as nausea, vomiting, abdominal cramps, or
tenesmus of ≤ 96 hours duration.
Diarrheal stools: Loose or liquid stools taking the shape of the container.
Diarrhea-associated signs/symptoms: Abdominal cramps, nausea, vomiting,
malaise, excessive gas, tenesmus, and fever temporally related to the diarrheal episode.
Signs/symptom severity was recorded on subject diary cards and based on functional
impact on subject duty performance (i.e., no impact, ≤ 50% impact, > 50% impact,
inability to function).

12
Temperature: Oral temperature obtained by a study clinician during a clinic visit
using a thermometer.
Fever: The oral equivalent of a higher than normal temperature (i.e., > 100.4oF)
as recorded upon assessment of temperature using a thermometer by a study clinician
during a clinic visit.
Assumptions
One major assumption in this study was that the items captured as part of the
original TrEAT TD and OEV-118 studies provide a holistic view of the major clinical
symptoms involved with TD gastroenteritis. Because this research was a secondary data
analysis, no further information beyond what was captured in the original clinical trial
datasets is available. However, as described in Chapter 2, the major clinical symptoms of
TD gastroenteritis identified in epidemiological and previous intervention studies remain
consistent with those captured in the original two datasets as well as the compiled
secondary dataset I used in this research. While both the TrEAT TD and OEV-118
studies allowed for collection of “other symptoms” as part of their daily diary card
assessments, providing for capture of signs beyond what has been historically associated
with TD, such symptomology was not included in this secondary data analysis.
Limitations
The first major limitation of this study is that it is based on a secondary data
analysis and thus limited to the sample size of gastroenteritis episodes experienced by
study participants in the TrEAT TD and OEV-118 studies. While both studies were
relatively large and contained an approximate combined total of 1800 participants, they
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were conducted across four regions (Mexico, Central America, South Asia, and Africa)
and six countries (Afghanistan, Djibouti, Kenya, Honduras, Mexico, and Guatemala).
The pooled sample size across and between regions is adequate to make some general
conclusions; however, the sample size may not be adequate to conduct a sufficiently
powered analysis at the country level, or other levels (i.e., by specific pathogens).
As this is a secondary data analysis, participants enrolled in the parent studies
were confined to the parameters of the original study protocols, potentially limiting the
generalizability of the results to a generally healthy adult population ≥ 18 years old.
Nevertheless, because the majority of travelers and military members who travel to highrisk areas are generally comprised of people of similar demographics, this limitation
might be considered minor.
While both original studies utilized diary cards to collect symptoms beginning
from the first day of an episode, thus limiting the risk of recall bias, it is possible that
response bias persisted in reporting of symptoms. For example, a participant who
experienced a severe symptom might also have been more likely to report other signs and
symptoms as he or she was more focused on what might have been making him or her
feel unwell. In contrast, a participant who experienced a mild symptom with little impact
on activity might have been less inclined to focus on feeling unwell and therefore record
additional symptoms.
Another potential limitation of this study is that the original datasets represent an
approximate ten-year time gap in data collection, and the regional variability of TD might
have changed over that period of time. However, as the literature review in Chapter 2
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highlights, the areas of most risk to potential travelers has remained consistent in the past
10 years and includes the study sites from both TrEAT TD and OEV-118 studies.
Delimitations
Delimitations of this study are partially included in the above limitations section.
Furthermore, this research benefitted from the methods used to collect the data contained
in each of the secondary analysis datasets. Both original studies (TrEAT TD and OEV118) utilized diary cards that allowed participants to collect symptoms beginning from
the first day of an episode in real-time as symptoms occurred, thus limiting potential for
recall bias and an over- or under-estimation of symptoms.
Regardless of the limitations and delimitation outlined in this section, it was
important that I conduct this study, as it built upon recent efforts to develop scoring
systems for etiology-specific challenge human infection models and provides timely and
relevant information to the field for future testing of TD interventions and treatments that
are fast approaching or currently undergoing field efficacy evaluation.
Significance
TD is the most common travel-related illness with an estimated 10 million people
afflicted annually (CDC, 2015), and is the second leading infectious disease cause of
death in children under the age of five in developing countries (PATH & BVGH, 2011).
Porter et al. (2016) highlighted the importance of including other clinical signs and
symptoms of clinical disease along with traditionally used stool output measures to more
accurately characterize ETEC disease as it applied to CHIMs. Similar to the development
and utilization of disease severity scales for pediatric diarrhea, using a validated score for
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TD could lead to more appropriate outcomes for epidemiological research and
interventional studies. Positive results from such efficacy studies would potentially lead
to licensure of a vaccine for use in traveler, military, and pediatric populations.
Meanwhile, both travelers and military populations represent important segments of a
potential TD interventions market that drives demand due to not wanting to be
inconvenienced by illness during travel, the desire to minimize lost duty days, and the
need to reduce post-infectious sequelae in returning travelers (PATH & BVGH, 2011).
Finally, development of a single optimized scoring system provides the field a more
clinically meaningful endpoint to utilize for future studies, thereby appropriately setting
the bar for advancement and licensure of TD vaccines and treatments.
This chapter provided a brief introduction regarding the epidemiology of TD
gastroenteritis, the importance of disease prevention through vaccination and other
methods, the use of existing scoring systems for measuring disease severity and vaccine
efficacy and associated challenges, the gap in knowledge with existing scoring systems,
especially in the context of assessing TD severity, and the benefits of creating a
simplified and standardized tool for measuring clinical outcomes. I also introduced the
research design, research questions, hypotheses, conceptual frameworks, assumptions,
limitations, and delimitations of the study, ending with a description of the social change
implications of this research. The following chapters provide (a) the methodology,
rationale, and need for this study; (b) the review of literature including more detailed look
into TD epidemiology; (c) the history and most current approach to measuring severity of
TD gastroenteritis; (d) the utility of measuring additional TD symptomology; (e)
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expansion on the conceptual framework; (f) the research methodology, including an indepth description of the design and analysis that were used in this study; (g) the results;
and (h) the conclusion, including recommendations for future research and social
implications.
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Chapter 2: Literature Review
Introduction
TD is the most common travel-related illness with an estimated 10 million people
afflicted annually and a reported attack rate of 30 to 70% depending on destination and
season (CDC, 2015; Shah et al., 2009; Steffen et al., 2015). TD typically begins within
the first 2 weeks of travel and often resolves without treatment within 3 to 5 days
(Diemert, 2006; Steffen et al., 2015). Nevertheless, symptoms can often manifest into
more severe sequalae, forcing change in travel plans or more rarely, hospitalization
(Kollaritsch, 1998; Peltola & Gorbach, 1997; Diemert, 2006). International tourism
represents 7% of the world’s exports in goods and services, often ranking as the first
export sector for developing countries (UNWTO, 2016). As a result, TD bears significant
economic costs to both travelers as well as to developing countries’ tourism industries. In
addition to the general traveler from a developed to a developing country, TD also
significantly affects deployed military populations, a unique subset of the travel
population, with an estimated attack rate of 30 cases per 100-person months (Porter et al.,
2017; Riddle et al., 2006; Steffen et al., 2015). TD is also one of the principal causes of
non-combat-related disease morbidity among deployed U.S. military personnel, including
those battling insurgencies in Iraq and Afghanistan (Sanchez, Gelnett, Petruccelli,
Defraites, & Taylor, 1998; Sanders et al., 2005). From a military public health standpoint,
its impact on troop health and readiness is larger than any other infectious disease
syndrome (Diemert, 2006). The impact of TD on both military and travel medicine as
well as the public health sector necessitates further investment in sanitation infrastructure,
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education about primary prevention, and development of prophylaxis and vaccines
against the various etiologic agents attributable to disease.
In the following in-depth analysis of the literature, I will demonstrate the
necessity of this research and its implications for social change, showing how it will
benefit future TD vaccine and treatment studies to enable more appropriate estimates of
efficacy. I (a) explain the background and epidemiology of TD and its clinical
presentation; (b) describe the history of TD classification; (c) detail scoring systems used
in pediatric populations, controlled human infection models, and earlier TD studies; (d)
provide information on the conceptual framework driving this research; (e) explain the
methodology used for answering the research questions; and (f) describe the implications
for social change resulting from this research.
I completed this literature review using library database searches to gather articles
optimally published within the last 5 years; however, original sources older than 5years
and seminal publications were also cited. I also reviewed references from each peerreviewed article for relevant literature. I began research at the PubMed website because it
is considered the premier scientific database for accessing articles relevant to the topic of
TD epidemiology, vaccine studies, and scoring systems. I also use other databases
available via the Walden University Library because they provided access to many
articles not otherwise available on PubMed. I used the following search terms alone or in
combination with other search terms in order to identify relevant articles: travelers’
diarrhea (travellers’ diarrhea), clinical trial, epidemiology, score, scale, clinical scoring
system, gastroenteritis, diarrhea (diarrhoea), Vesikari, travelers, challenge, and TD. I
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also contacted Walden University library staff in order to help with retrieving the oldest
articles describing the first descriptions of travelers’ diarrhea for which they were able to
provide.
Epidemiology
Place and time. Destination remains the most important risk factor for
developing TD, with regional differences dictating both risk for and particular etiologic
agents of TD. More developed areas such as North America, Australia, New Zealand,
Japan, and Northern and Western Europe represent areas of low-risk (< 8% attack rate);
intermediate risk countries include China, South Africa, some Caribbean islands, and
countries in Eastern Europe (10-40% attack rate); while highest risk areas (attack rates up
to 70%) include Southeast Asia, the Middle East, Latin America, Africa, and Central and
South America. Attack rates of up to 75% have been observed in travelers to high-risk
areas (Cobelens, Leentvaar-Kuijpers, Kleijnen, & Coutinho, 1998; Peltola & Gorbach,
1997; Diemert, 2006), with incidence rates ranging from 10 to 40% in travelers to areas
of intermediate risk (Steffen et al., 2015). There exist regional differences in the etiology
of TD, with enterotoxigenic Escherichia coli (ETEC) predominating worldwide as the
leading cause of TD in most regions except certain areas of Southeast Asia, including
Thailand, in which Campylobacter and Aeromonas are more common (Shah et al., 2009;
Steffen et al., 2015; Tribble et al., 2007). Enteroaggregative Escherichia coli is the
second most common bacterial enteropathogen in Latin America and the Caribbean, as
well as in South Asia, with less than 5% reported from Africa. In contrast, Salmonella,
Shigella, norovirus, and rotavirus are reported in approximately 5 to 25% of reported TD
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cases from Africa (Jiang et al., 2002; Riddle, Sanders, Putman, & Tribble, 2006; Steffen
et al., 2015). Enhanced diagnostic methods such as polymerase chain reaction (PCR) and
TaqMan are continuing to be developed to determine etiology and help identify a broader
array of pathogens in a single multiplex assay (Antikainen et al., 2013; Youmans et al.,
2014; Lertsethtakarn et al., 2016). However, a potential drawback of this newer
technology and the ability to detect multiple viable and non-viable pathogens is the
potential difficulty in differentiating the etiologic agent (Connor, 2018).
TD risk is also seasonal, with higher rates due to bacterial pathogens in summer
months and rainy seasons (Cobelens et al., 1998; Hoge et al., 1968); whereas dryer
seasons are associated with TD of viral etiology (de la Cabada Bauche, & DuPont, 2011).
Longer duration of travel has also been significantly associated with TD, with greater
than 1 week of stay associated with increased risk (Hill, 2000; Pitzurra et al., 2010;
Steffen et al., 2004; Vilkman, Pakkanen, Laaveri, Siikamaki, & Kantele, 2016). However,
it should be noted that in a study of Korean travelers visiting Southeast Asia, Ahn et al.
(2011) identified shorter duration of travel (less than 7 days) as more significantly
associated with higher TD incidence.
Demographic risk factors. Despite prior studies finding no effect of gender on
TD risk (Diemert, 2006; Evans, Shickle, & Morgan, 2001; Steffen et al., 2004), more
recent studies have shown gender to be a confounding factor in predisposition to
acquiring illness. In a study of Finnish travelers visiting outside the Nordic region (77
countries included), Vilkman et al. (2016) observed females were more predisposed to
illness than their male counterparts (OR = 1.5; 95% CI = 1.0-2.4, p = .008); however, in a
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study of Korean adults traveling to Southeast Asia, being male was associated with
higher TD rates (p = .007; Ahn et al., 2011). Age has long been established as playing a
significant role in diarrheal disease illness, with highest incidence rates among children
under the age of5 in developing countries (approximately 2.9 episodes/child year) and
younger adults traveling from industrialized nations to high-endemic areas
(approximately 1.6 illnesses/traveler; DuPont & DuPont, 2006; Fischer Walker, Perin,
Aryee, Boschi-Pinto, & Black, 2012; Hill, 2000; Steffen, 2005; Steffen et al., 2004;
WHO, 2017). The higher rates among the former subpopulation (i.e., endemic children)
is likely due to naïve immunity, lack of hygiene and sanitation infrastructure, high
pathogen co-infection rates, and increased fecal-oral contamination (Brown, Cairncross,
& Ensink, 2013; Fewtrell, & Colford, 2005; Oyekale, 2017; UNICEF/WHO, 2009;
WHO, 2017). The higher incidence rates in younger adult travelers is likely attributable
to propensity for more adventure travel (Kollaritsch, 1989; Steffen 2005; Steffen et al.,
2015) and lack of vigilance in eating contaminated foods (Diemert, 2006; Hoge et al.,
1996; Pitzurra et al., 2010). Interestingly, within the military subpopulation, the direction
of age effect is inverse to that of other traveler cohorts, in that risk of TD increases with
increased age; a finding consistent in military studies (Riddle et al., 2006; Sanders et al.,
2004) but in contrast to traditional traveler cohort studies as described above.
Etiologies/Causative Agents
The most important etiological agents of TD are bacterial, with approximately 80
to 90% of cases across various studies attributable to at least one bacterial agent (Ansdell
& Ericsson 1999; Diemert, 2006; Peltola, & Gorbach, 1997; Steffen et al., 1999; Taylor
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et al., 2006). Of the more prevalent bacterial causes, diarrheagenic enterotoxigenic
Escherichia coli (ETEC) remains the leading cause of TD, followed by Campylobacter
jejuni, Shigella spp., and Salmonella spp. Other Escherichia coli pathotypes, such as
enteroinvasive E. coli (EAIC) and enteroaggregative E. coli (EAEC), have also been
increasingly associated with TD (Adachi et al., 2001; Huang, Okhuysen, Jiang, &
DuPont, 2004; Steffen et al., 2015; Wanger, Murray, Echeverria, Mathewson, & DuPont,
1988). Emerging prevalence of Aeromonas species, Arcobacter species, and Plesiomonas
shigelloides have also been observed (Jiang et al., 2010; Kayman et al., 2012; Yamada,
Matsushita, Dejsirilert, & Kudoh, 1997; Steffen et al., 2015), and non-cholera vibrios less
commonly isolated in some TD cases (CDC, 2015).
Viruses account for 2 to 27% of TD, with norovirus, rotavirus, astrovirus, and
enteric adenovirus being the most commonly isolated pathogens (CDC, 2015; Diemert,
2006). However, their etiological importance is somewhat tempered by the fact that
bacterial pathogens are also concomitantly isolated in many TD cases, especially with
rotavirus. Norovirus has been implicated in a number of unique settings, such as cruise
ships (Bert et al., 2014; Freeland et al., 2016; Morillo et al., 2017; Wang et al., 2017) and
military deployments (Ahmed et al., 2012; Hameed et al., 2016; Surveillance Snapshot,
2017; Watier-Grillot et al., 2017), highlighting it as an important pathogen in certain
travel populations.
TD caused by parasites is more persistent and results in prolonged duration
compared to TD cases of bacterial etiologies (Connor, 2017; Ross & Crips, 2013;
Swaminathan et al., 2009). Giardia intestinalis is the most predominant protozoal cause
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of TD (Connor, 2017; Fullerton & Yoder, 2017; Hagmann et al., 2014; Harvey et al.,
2013; Swaminathan et al., 2009). Entamoeba histolytica, Cryptosporidium and
Cyclospora are less commonly isolated (Black, 1990; Diemert, 2006; Steffen et al.,
2015), the latter being highly geographically and seasonally dependent with highest risk
associated with travel to the mountainous regions of Peru and Nepal (Drenaggi, Cirioni,
Giacometti, Fiorentini, & Scalise, 1998; Jelinek, Loze, Eichenlaub, Loscher, &
Nothdurft, 1997; Pandey et al., 2011; Thapa & Basnyat, 2017). No pathogen is isolated in
10 to 50% of all TD cases, likely as a result of limited diagnostic methods or self-limiting
characteristics of infection (Diemert, 2006).
TD Costs
Though mostly self-limiting, TD can cause significant disruption to travel and/or
itineraries, business plans, and tourism revenues (Wang, Szucs, Steffen, 2008). Because
tourism is an important industry to many developing countries’ economies, associated
revenues in those areas with the highest attack rate for TD are significantly affected.
Wang et al. (2008) estimate that approximately 1 day of incapacitation per traveler due to
TD in developing countries would result in $500 million of missed tourism revenue. The
burden of medical costs and productivity losses is exacerbated if TD persists upon
returning home. In the United States it is estimated that approximately $300 million and
$650 million in medical costs and lost productivity costs, respectively, are incurred from
ill-returning travelers. Similarly, in the European Union, €200 million and €450 million
are incurred for medical and lost productivity costs, respectively, from travelers returning
with TD (Wang et al., 2008). Because of these financial implications, among others, a
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future vaccine against the primary TD-attributable etiologic agents remains as one of the
most cost-effective approaches from a military and long-term traveler perspective
(Cachafeiro et al., 2008; Tallant et al., 2014).
Clinical Syndromes/Presentation
TD has been traditionally defined in studies as the passage of three or more loose
stools in a 24-hour period, often with an associated gastrointestinal symptom such as
fever, nausea, vomiting, abdominal pain, tenesmus, fecal urgency, or bloody or mucoid
stools (Broor & Singal, 1989; Diemert, 2006; Hill, 2010; Steffen et al., 2015).
Conventionally, TD is used in reference to illness that develops in a resident from a
developed country who travels to a developing country; also applied to military
populations deployed from industrialized areas to low-resource regions (Connor, 2017;
Steffen et al., 2015). Symptoms typically present within the first week of travel, although
90% of cases are identified within the first two weeks (Diemert, 2006; Steffen, van der,
Gyr, & Schar, 1983).
The average course of untreated TD is about 4 to 5 days, often self-limiting and
requiring limited hospitalization (Connor, 2017; Diemert, 2006; Steffen et al., 2015). The
most commonly reported symptom is abdominal cramping in about 80% of TD cases,
followed by vomiting (20%), fever (10 to 25%) and blood and/or mucous in the stools (5
to 10%) (Cobelens et al., 1998; Diemert, 2006; Sanchez et al., 1998).
In addition to the morbidity of acute disease, there are associated chronic postinfectious sequelae. Post-infectious irritable bowel syndrome (PI-IBS) can occur in 3 to
17% of patients after TD (Okhuysen, Jiang, Carlin, Forbes, & DuPont, 2004; Mutsch,
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Pitzurra, Hatz, & Steffen, 2014; Schwille-Kiuntke et al., 2015; Stermer, Lubezky,
Potasman, Paster, & Lavy, 2006) while higher rates of other gastrointestinal symptoms,
such as chronic or persistent diarrhea, are also observed (Nair et al., 2014; Steffen et al.,
2015). Finally, reactive arthritis and Guillain-Barre syndrome have also been associated
with TD (Connor & Riddle, 2013; Jackson et al., 2014; Steffen et al., 2015).
Development of such chronic complications emphasizes the need for further
characterization of the risk factors and incidence of these syndromes to more effectively
determine prophylactic and/or treatment procedures to reduce their incidence.
Impact on Activity
Impact on activity varies across studies and travel populations. Some studies have
reported a significant impact of TD on daily activities, with 20% of travelers requiring
bed rest over 1-2 days (Hill, 2000; Sebeny et al., 2012; Soonawala, Vlot, & Visser, 2011;
Steffen et al., 2004; Steffen et al., 2015); up to 40% requiring modification to daily
activities during travel (Soonawala et al., 2011; Ryan & Kain, 2000; Diemert, 2006) and
only 1% requiring hospitalization (Kollaritsch, 1989; Peltola & Gorbach, 1997; Steffen et
al., 2015). In a study of healthy adults with TD during travel from the Netherlands to the
subtropics, 39% characterized their TD as mild, 34% as moderate and 27% as severe,
with those reporting major inconveniences having more severe symptoms and prescribing
to treatment protocols (either self-treatment or visiting health facilities). However,
travelers with TD reported it less problematic upon their return in country than how they
characterized it before departure (Soonawala et al., 2011).
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Within the military, travelers’ diarrhea remains the leading infectious cause of
disease non-battle injury (DNBI), lost duty days and reduced operational readiness
(Connor, Porter, Swierczewski, & Riddle, 2012; Riddle et al., 2011). Historically,
approximately 80,000 duty-days were lost due to diarrhea in deployed troops during the
Korean War; and diarrheal illness accounted more troops being hospitalized and confined
to quarters during the Vietnam War than due to Malaria by a 4:1 ratio (Connor &
Farthing, 1999). During the First Gulf War, 97% of American troops had TD and 20% of
troops suffered from TD that prevented reduced fighting effectiveness (Connor &
Farthing, 1999; Putnam et al., 2006). Approximately 70% of U.S. personnel deployed as
part of Operation Iraqi Freedom (OIF) and Operation Enduring Freedom (OEF) in Iraq
and Afghanistan, respectively, experienced at least one episode of TD, with >50%
experiencing multiple episodes (Putnam et al., 2006; Sanders et al., 2005; Sanders et al.,
2004). The implications of acute diarrhea on operational readiness is further compounded
with the abovementioned long-term chronic sequalae.
Most recently, a graded expert panel critically issued recommendations on
management of TD for use by health care providers when providing pre- and post-travel
consultation to travelers (Riddle et al., 2017). As part of those recommendations, the
panel advised accounting for functional impact in characterizing diarrhea severity rather
than the more traditional stool frequency-based algorithm that has been utilized in
practice and discussed throughout this Chapter (Riddle et al., 2017). Such an assessment
of illness based on functional impact as tolerable (mild), distressing (moderate), or
incapacitating (severe) could better delineate treatment options or tailor therapies for
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affected individuals (Riddle et al., 2017). Historically, TD severity was based on the
number of unformed stools passed in 24 hours (e.g., mild = 1-2 stools; moderate = 3-5
stools; severe = ≥ 6-9 stools). However, a traveler could be impacted by having TD with
a low frequency of loose stools along with fever or severe cramps compared to a traveler
experiencing six loose stools without additional symptoms. Meanwhile, additional
research into defining non-frequency-based outcomes in TD is needed. That was the
intent of this dissertation.
Prophylaxis and Treatment
General management of TD follows standard guidance, including avoiding
dehydration, mitigating associated symptoms (diarrhea, cramps, vomiting, nausea) and
reducing impact on interruption of travel plans (Al-Abri, Beeching, & Nye, 2005; Zaidi
& Wine, 2015). Antibiotics when taken prophylactically, reduce the incidence of TD by
80 to 90% (DuPont et al., 2009); when used for treatment during illness they shorten the
duration of disease by approximately 1.5 days (de Bruyn, Hahn, & Borwick 2000;
DuPont et al., 2014). Geographic region influences choice of antibiotic treatment;
ciprofloxacin is often recommended but where Campylobacter spp. are prevalent the drug
of choice is azithromycin (Steffen et al., 2015). Rifaximin and ciprofloxacin are both
effective in treatment of TD due to non-invasive agents; however, rifaximin should not be
used when invasive agents are suspected due to limited data on its effectiveness against
such pathogens.
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Prevention
There are four main categories of TD prevention: immunization,
nonpharmacological therapy, avoidance and antibiotic prophylaxis. While immunization
confers the most cost-effective method of protection, there are no US licensed products
for use the causative agents. Only recently has a vaccine against Vibrio cholerae
serogroup O1 (VaxchoraTM) been licensed by the US Food and Drug Administration
(FDA) for adults traveling to cholera-affected areas (Levine et al., 2017), although it
should be noted, and as previously described, Vibrio cholera is not a leading bacterial
cause of TD. For European and Canadian residents, there are two licensed products for
use against Vibrio cholera, a live attenuated oral candidate (Mutacol, Orochol) and an
inactivated whole cell vaccine (Dukoral). The former demonstrated up to 90% efficacy in
a challenge study in which participants were challenged with Vibrio cholerae three
months after vaccination (Tacket et al., 1999); whereas the latter candidate showed 5071% efficacy against V. cholerae as well as to ETEC in two large travelers’ studies
(Peltola et al., 1991; Sack et al., 2002; Svennerholm & Savarino, 2004). Nevertheless,
despite also being licensed in some countries for protection against ETEC, the estimated
efficacy of Dukoral against all-cause TD remains low and predicted to protect only
approximately 7% of travelers (Steffen et al., 2015). Similarly, vaccines against
Salmonella enterica serotype Typhi confer modest protection against enteric fever, but
this disease may not be associated with diarrhea (Steffen et al., 2015). Because these
pathogens are an uncommon cause of TD, available vaccines should only be considered
for high-risk populations traveling to endemic areas or used in outbreak campaigns.
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Numerous nonantibiotic and antibiotic agents have been evaluated for the
prevention of TD, including but not limited to Bismuth subsalicylate (commonly known
as Pepto-Bismol), rifaximin, ciprofloxacin, loperamide, and azythromycin. Bismuth
subsalicylate is mostly marketed in North America for the prevention of diarrhea and has
been shown to provide moderate protection by reducing diarrhea by 65% when taken four
times a day (DuPont et al., 1987; DuPont, Ericsson, Johnson, & de la Cabada, 1990). The
aforementioned antibiotics are highly effective in TD prevention and treatment; however,
their prophylactic use should be restricted to high-risk populations and only under special
circumstances (Gorbach & Edelman, 1986; Diemert, 2006; Steffen et al., 2015).
Rifaximin is a gut selective antibiotic that is poorly absorbed and has demonstrated
significant reduction in the incidence of noninvasive TD in a meta-analysis of four trials
(Dupont et al., 2005; Hu, Ren, Zhan, Li, & Dai, 2012). More recent studies continue to
show the moderate benefit of this antibiotic, including a Phase 3 study of a new oral
formulation of Rifamycin SV MMX (RIF-MMX) in which clinical cure of treated adult
travelers to Mexico or Guatemala was 81.4% compared to placebo recipients (DuPont et
al., 2014); one study confirming 48% protection against TD in travelers to South and
Southeast Asia compared to placebo (Zanger, Nurjadi, Gabor, Gaile, & Kremsner, 2013);
and a small challenge study in which the drug prevented shigellosis (Taylor et al., 2006),
thus suggesting an effect against this invasive pathogen. Rifaximin is approved for the
treatment of TD due to non-invasive enteric pathogens or specifically E. coli infections.
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Measuring the Severity of TD Gastroenteritis
Vaccines targeting the main bacterial causes of TD, including Campylobacter,
Shigella and enterotoxigenic Escherichia coli (ETEC), are currently in development and
may be ready for large-scale efficacy trials as soon as 2019 (Walker, 2015). The impact
of a vaccine is often best defined by its ability to prevent severe illness where impact of
vaccination will greatest on severe outcomes, such as hospitalization (World Health
Organization [WHO], 2008); as a result, clinical sponsors and/or need accurate and
reliable tools to characterize severity. Failure to properly define the severity endpoint in a
clinical trial could result in a reduced statistical power. In the specific case of rotavirus,
vaccine efficacy estimates vary by the severity of disease, often increasing with greater
severity; consequently, disease severity measurements directly affect vaccine efficacy
estimates and impacts the ability for inter-trial comparison when different scoring
systems or definitions of clinical disease endpoints are used (Das et al., 2013; WHO,
2008). For this reason, the symptom parameters that are obtained must be carefully
considered across studies and should appropriately characterize the illness.
While most, if not all, TD vaccine and treatment studies utilize a diarrhea
definition based on number of unformed stools in a 24-hour period, some incorporate an
additional symptom such as abdominal pain or nausea to the endpoint (Stoney et al.,
2017; Wiwanitkit, 2007). Reliance on stool-based endpoints alone without consideration
of other symptoms may obscure meaningful differences in illness profiles and
underestimate vaccine efficacy. This study aimed to explore the relationship between
clinical signs and symptoms of TD contained in two different clinical trial datasets and
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describe the variability in signs and symptoms across stool output, determining which
variables are required to accurately measure TD gastroenteritis and propose a single,
standardized scoring system optimized for use in adult travelers. The results from this
study will impact future TD vaccine and treatment studies enabling more appropriate
estimates of efficacy.
Utility of Additional TD Symptomology
TD historically emerged as a significant public health topic in relation to military
campaigns, where more soldiers were dying from diarrheal disease than from war-related
injury (Butler, Middleton, Earnest, & Strickland, 1973; Cook, 2001; Davison, 1922), or
other maladies, such as malaria (Connor & Farthing, 1999). Later TD came to light as a
problem for international travelers, students traveling to high-burden areas and
expatriates (Dupont, Ericsson, & Steffen, 2008). As mentioned before, the first
description of TD emerged through study of military populations engaged in campaigns.
An epidemiologic investigation of 2,500 travelers from the United States to Mexico by
Kean (1963) provided the first detailed clinical description of the syndrome obtained
from 75 participants. In that study, travelers’ diarrhea was named ‘turista’ and poetically
described as ‘a staccato ballet’ of watery bowel movements every 15 minutes during the
initial onslaught, accompanied by malaise, severe cramps, nausea and several episodes of
vomiting. The turista syndrome was identified as a definite clinical entity by Kean, and
hereafter has provided the clinical context on which the clinical profile of travelers’
diarrhea is based. In that same study Kean drew an association between outcomes of
competition of athletes participating in the Olympic Games to occurrence of diarrhea
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(1963). Students traveling to Mexico have served as a popular setting for extensive TD
study over the past sixty years (Ericsson, DuPont, & Mathewson, 1995; Kean, 1963;
Kean, Schaffner, Brennan, & Waters, 1962; Ko et al., 2005; Paredes-Paredes et al., 2011;
Varela, Kean, Barrett, & Keegan, 1959), and studies in persons living overseas in highrisk areas for prolonged periods of time has increased the evidence base to such
populations as expatriates, Peace Corps volunteers, and missionaries (Habergerger et al.,
1994; Herwaldt, de Arroyave, Roberts, & Juranek, 2000; Shlim et al., 1999). Between
1963 and 1983, epidemiologic features of TD such as risk factors, illness timing and
duration were further described. Based on the increased availability of published
research, Dupont & Dupont (1981) attempted to delineate the world into low, medium
and high-risk areas, after which further research continued to establish region-specific
attack rates in high-risk areas (Ericsson et al., 1995; Harvey et al., 2013; Steffen et al.,
2004; Steffen, van der, Gyr, & Schar, 1983).
Since the early descriptions of TD and subsequent evaluations of either vaccines,
prophylaxis or treatments, slightly different definitions of TD have been utilized as the
primary endpoint for determination of efficacy. Table 1 summarizes the variability in
clinical endpoints used for field trials testing various vaccines for prevention of TD. What
has remained consistent in those evaluations has been setting the primary endpoint
definition on stool number, while other clinical signs and symptoms factoring into the
primary endpoint definition rarely or not at all. As the leading bacterial cause of TD,
vaccines against ETEC have been a primary focus for vaccine developers and thus the
most evaluated in late stage efficacy trials to date. The most recent pivotal Phase 3 trial
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evaluating the safety and efficacy of a skin-patch vaccine against ETEC’s heat labile
toxin (LT) utilized a trial endpoint definition of moderate-to-severe diarrhea as four or
more unformed stools in a 24-hour period to determine efficacy (Behrens et al., 2014;
Steffen et al., 2013). While the study collected detailed symptomology from participants
during experienced diarrheal episodes, including their effect on daily activity, those
parameters were never factored into vaccine efficacy determination nor even commented
on in the trial publication. While the vaccine conferred limited protection against vaccine
preventable outcomes (VPO), as well as showed a slight reduction in severity and
duration of all-cause diarrhea, it remains unknown from the published literature whether
the vaccine had an impact on overall disease profile outside of a clinical definition based
on stool number alone.
In an earlier pivotal field efficacy study in which an inactivated whole cell ETEC
vaccine was evaluated in adult travelers to Guatemala and Mexico, accounting for other
clinical signs and symptoms of TD besides diarrheal stool number as well as impact on
activity actually increased vaccine efficacy estimates (Sack et al., 2007). In this study, the
primary outcome was a VPO as defined as an episode of ETEC diarrhea with an ETEC
organism producing vaccine-relevant antigen(s). In addition to recording the number of
loose stools, participants also recorded daily diary card information on other associated
TD symptomology that interfered with daily activity, such as cramps, abdominal pain,
vomiting, anorexia, nausea, and urgency of defecation. While the vaccine proved
inefficient at protecting against mild symptoms associated with VPO-ETEC, it did
significantly reduce episodes of more severe VPO diarrhea as defined by more than five
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stools in 24 hours (85% protective efficacy, p=0.037) or by symptoms that interfered with
daily activities (77% protective efficacy, p=0.039) (Sack et al., 2007). This latter
example provides preliminary evidence of the potential impact in accounting for other
clinical signs and symptoms of TD and how utilization of a more clinically meaningful
endpoint might lead to better evaluation of vaccine efficacy.

Table 1
Clinical Endpoints in TD-Vaccine Field Studies
Publication
Scerpella et
al., 1995

Vaccine Candidate
Killed whole-cell V. cholerae
O1 with a recombinant Bsubunit of cholera toxin
(WC/rBS)

Study Population (n)
Student travelers to Mexico
(n=502)

Primary Endpoint Definition
≥4 loose stools in 24 hours (or 3 in 8 hours)
plus an additional symptom

Widerman et
al., 2000

Inactivated whole cell ETEC
and Cholera vaccines plus
recombinant B-subunit of
cholera toxin (rCTB)
Live-attenuated oral cholera
vaccine strain CVD 103-HgR

Austrian travelers to tropical or
subtropical destinations (44
different countries in Africa,
Asia, Latin-America) (n=250)
Travelers to Indonesia, India,
Thailand and West Africa
(n=134)
Travelers to Mexico and
Guatemala (n=672)

≥3 liquid stools and ETEC-only pathogen
detected in stool

Leyten et al.,
2005
Sack et al.,
2007

Frech et al,
2008

Inactivated whole cell ETEC
vaccine plus recombinant Bsubunit of cholera toxin
(rCTB)
Heat labile toxin LT-patch

Vaccine Efficacy (VE)
VE against ETEC = 50% (95% CI, 14-71%)
beginning 7 days after the second dose. However,
no efficacy was demonstrated within 7 days of the
second vaccination when 74% of ETEC cases
occurred
ETEC vaccine VE = 79% (p=0.119)
Cholera vaccine VE = 82% (p = 0.0496)

≥3 loose stools in 24 hours, or 2 loose stools
plus additional symptoms

Study terminated early as the primary endpoint
≥50% VE not achieved at point of interim analysis

Primary VPO: ≥3 loose stools in 24 hours plus
≥1 gastrointestinal symptom caused by
homologous ETEC vaccine strain

VE = 24% (n.s.)

Travelers to Mexica and
Guatemala (n=170)

Mild TD: 3 loose stools in 24 hours
VE against moderate-to-severe TD = 75%
Moderate TD: 4-5 loose stools in 24 hours and (p=0.007)
ETEC LT, LT/ST or ST positive
Severe TD: ≥6 loose stools in 24 hours and
VE against severe TD = 84% (p=0.0332)
ETEC LT, LT/ST or ST positive
Bourgeois et
Inactivated whole cell ETEC
Travelers to Mexica and
VPO-ETEC TD: ≥5 unformed or liquid stools
VE = -59 (95% CI, -384-48)
al., 2011
vaccine plus recombinant BGuatemala (n=1406)
in 24 hours plus ≥1 gastrointestinal symptom
subunit of cholera toxin
and homologous ETEC vaccine strain isolated
(rCTB)
within 24 hours of episode
Steffen et al., Heat labile toxin LT-patch
Travelers to India (n=723)
Mild TD: 3 loose stools in 24 hours
VE near zero (p=1.000)
2013
Moderate TD: 4-5 loose stools in 24 hours and
ETEC LT, LT/ST or ST positive
Behrens et
Heat labile toxin LT-patch
Travelers to Mexica and
Severe TD: ≥6 loose stools in 24 hours and
VE against moderate-to-severe TD = 34.6% (95%
al., 2014
Guatemala (n=1644)
ETEC LT, LT/ST or ST positive
CI, -2.2, 58.9)
Note: Table adapted from various vaccine field trials (Scerpella et al., 1995; Widerman et al., 2000; Leyten et al., 2005; Sack et al., 2007; Bourgeois et al., 2011; Steffen et al., 2013; Behrens et
al., 2014) and 2018 VASE Workshop Presentation (Porter, Kotloff, & Gutierrez, 2018)
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Existing Scoring Systems
Scoring Systems in Pediatric Populations
Early vaccine studies for pediatric populations, specifically in the context of
Rotavirus, utilized different definitions of clinically significant diarrhea to measure
vaccine efficacy. These early studies based their primary endpoint on stool output, with
subsequent trials gradually including other clinical signs and symptoms. The use of
scoring systems has now become the norm for how disease severity is defined in
rotavirus vaccine efficacy studies (Bhandari et al., 2014; Clark et al., 1988; Flores et al.,
1987; Isanaka et al., 2017; Mahdi et al., 2016; Vesikari et al., 1984; Vesikari et al., 1985).
While the Vesikari and Clark scoring systems have emerged as the predominant methods
for determining disease severity in vaccine efficacy studies, they utilize different
combinations of symptoms and scoring algorithms to assess disease severity, thus
resulting in limited comparability of vaccine efficacy estimates between studies (GivonLavi et al., 2008). It has been suggested that for more standardized assessment of
Rotavirus vaccine efficacy in future clinical trials, a single scoring system should be used
(Givon-Lavi et al., 2008).
There has been increased recognition that the suitability of the Vesikari, Clark or
modified forms of either scale for trials involving pathogens other than rotavirus can be
called into question, particularly considering its limitations in developing countries where
diarrhea remains a global health priority. For example, some parameters are irrelevant in
many low resource settings, such as hospitalization (children are rarely hospitalized for
diarrhea, even if dehydrated), and temperature (rarely measured to diagnose fever at
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home, and in many health care settings). Additionally, the cardinal signs of diarrheal
diseases (diarrhea, vomiting, dysentery) are heterogeneous even within a single etiology.
Finally, such scores may not include clinical parameters that may contribute to the
severity of nonviral gastroenteritis. Attempts to address such limitations, especially for
etiologies other than rotavirus as new vaccines against ETEC, Shigella and other
pathogens are at the cusp of field evaluation, have accelerated over the past five to ten
years. In addition to the Vesikari and Clark scores, other scales that emerged for the
purpose of assessing gastroenteritis in pediatric populations include the Gorelick Score,
Clinical Dehydration Scale (CDS), and the WHO Integrated Management of Childhood
Illness (IMCI). Six studies have evaluated previously developed and existing diarrheal
disease grading scales (Arifeen et al., 2013; Jauregui et al., 2014; Levine et al., 2015;
Kinlin & Freedman, 2012; Pringle et al., 2011; Tam et al., 2014), whereas two studies
sought to develop a new grading scale for the use in community-based healthcare settings
in developing countries (Lee et al., 2016; Levine et al., 2015).
While the clinical profile of diarrheal disease and severity may vary, dehydration
status remains a central parameter on which treatment of diarrheal illness is based,
especially for pediatric populations. Several scales have been developed for the
estimation of dehydration status and clinical signs associated with diarrheal disease; all
targeted for slightly different age groups and tested for limited validation outside
institutional development origin. The most popular of these include the IMCI scale
developed by WHO, the Gorelick Scale created at the Children’s Hospital of
Philadelphia, and the Clinical Dehydration Scale (CDS) originating from Toronto. The
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WHO scale groups severity of symptoms as a means to classify children and meant for
children 1 month of age to 5 years old; the CDS is for children 1 to 3 years of age and
implements a scoring system for dehydration symptoms; and the Gorelick scale targets a
similar age group to the WHO scale but utilizes a binary system to classify dehydration
status with severity based on number of symptoms present. Two studies evaluated the
effectiveness of the WHO, CDS and Gorelick scores and found none were helpful
predictors of children with diarrhea (Jauregui et al., 2014; Pringle et al., 2011), and one
study found the CDS to be slightly helpful in the assessment of dehydration but cautioned
against its singular use for planning treatment interventions (Kinlin & Freedman, 2012).
Similar to the abovementioned CDS, Gorelick and WHO scales, the DHAKA score was
empirically derived to assess the most relevant dehydration symptoms for specific use in
low-resource settings (Levine et al., 2015). Meanwhile, the Community Diarrheal
Assessment (CODA) score incorporated the six clinical signs and symptoms of nonpathogen specific diarrheal disease that most correlated with poorer weight gain –
diarrhea, anorexia, vomiting, loose stools and maximum number of loose stools in a 24hour episode. Similar to the Vesikari and Clark scores, the CODA score incorporates
other clinical predictors of diarrheal disease; however, it seeks to expand its applicability
beyond just rotavirus disease towards classification of all diarrheal disease (Lee et al.,
2014; Rouhani et al., 2016). Nevertheless, with the addition of these newer index tools
comes the need for validation and further testing in expanded populations.
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Scoring System Use in TD Studies
It has been long-recognized that TD can be associated with varied degrees of
unformed stools ranging from semisolid to liquid states, often developing into an
explosive illness characterized by nausea, fever, and vomiting; with the early years of TD
often leading to dehydration and even death in the most severe cases (Kean & Waters,
1959). The earliest study in which there was an attempt at TD severity delineation was
that of Kean and Waters (1959), in which diarrhea was classified into the following
categories: mild, defined as three or more bowel movements per day with camps and/or
nausea, or diarrhea with three to six bowel movements per day with only mild cramps or
no other symptoms and no impact on daily activity; moderate, defined as diarrhea with
more than four bowel movements per day with cramps, nausea and/or vomiting, with
occasional chill and/or fever with confinement to the room for less than 1 day; or severe,
defined as confinement to the room for more than 1 day and with at least five of the seven
following symptoms: diarrhea with more than four or five bowel movements per day,
nausea, vomiting, cramps, chills, fever, joint pain or back pain (Kean & Waters, 1959).
Building on the above-mentioned study and subsequent research (Kean & Waters,
1959; Kean, 1963) the scoring systems used and publicly available in the peer-reviewed
literature use multiple items for defining TD, with a diarrhea episode defined as three or
more loose stools within a 24-hour period, with some studies including an additional
symptom parameter that may include fever, abdominal pain, nausea, vomiting, tenesmus,
blood in stool, etc. Some studies report a definition of ‘Classic TD’ as three unformed
stools with at least one accompanying symptom; however, even among those studies the
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inclusion of various accompanying symptoms is inconsistent. The WHO and UNICEF
similarly utilize a definition of three or more unformed stools over a 24-hour period for
diarrheal disease; however, inclusion of an accompanying symptom is not required
(WHO, 2017; UNICEF, 2012). It should be noted that both global organizations
concentrate on childhood public health priorities, not adult traveler afflictions.
Epidemiologic studies characterizing the etiology of TD identified the symptoms most
associated with TD gastroenteritis as abdominal pain, fever, nausea, vomiting, tenesmus
and malaise. Because of the frequency with which these symptoms consistently occur in
illness, they have been consistently included in TD investigations. In contrast, other
symptoms/signs like flatulence and borborygmus have been inconsistently included in
disease follow-up evaluations. Furthermore, the abovementioned symptoms are
inconsistently defined from study to study that could further confuse what impact such
symptom has on the clinical endpoint.
Scoring System Use in Challenge Studies
While randomized, placebo-controlled blinded field efficacy studies remain a gold
standard for evaluation of any potential vaccine candidate or TD treatment (Creswell,
2009; Frankfort-Nachmias, & Nachmias, 2008; Riddle et al., 2014), CHIMs enable early
evaluation of potential interventions. Consequently, they should be included in this
literature review as another example of a) how clinical signs and symptoms play an
important role in determining disease profile, and b) how use of only stool output
parameters may mislead intervention development efforts to down-select potentially
promising candidates too early. The CHIM provides a tool for advancing vaccine
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candidates by providing a controlled environment in which to evaluate vaccine efficacy
using an established inoculum dose and during which clinical disease is well-defined and
managed (Riddle et al., 2016; Porter et al., 2017), and it can even be used in late-stage
evaluation efforts. A recent example of CHIM utility for advancing a vaccine candidate
towards licensure by the US Food and Drug Administration (FDA) is that of VaxchoraTM
(PaxVax Redwood City, CA; Chen et al., 2016), in which proof of concept vaccine
efficacy was demonstrated in a human challenge model (Chen et al., 2016). In addition to
cholera, other enteric challenge models have been developed for ETEC (DuPont et al.,
1971; Harro et al., 2011; Levine et al., 1977), Shigella (Porter, Thura, Ranallo, & Riddle,
2013), and Norovirus (Bernstein et al., 2015; Frenck et al., 2012; Riddle & Walker, 2016)
to support vaccine, treatment and therapeutic development efforts. Furthermore, often
CHIMs are used as a down-selection stage-gate mechanism to advance potential
candidates to further field efficacy evaluation and licensure, thus elevating their
importance in the overall development pathway for developers.
For any clinical trial, including CHIMs, standardization of clinical endpoints is
challenging and further complicates interpretation of results across studies and
interventions. Ensuring consistency across objective measures such as diarrhea, vomiting
and fever has been challenging; standardizing definitions of subjective measures such as
myalgia, headache and abdominal pain have proven even more difficult (Porter et al.,
2017).
While the benefits and utility of the CHIM is widely recognized, there remains
challenges with utilization of this tool that extend to clinical disease definitions and
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prioritization of symptomology, highlighting the need for a scoring system that could be
applied to such studies. Potential development of disease-specific scores that incorporates
the conglomeration of signs and symptoms, both objective and subjective in nature, has
been discussed as necessary given the specificity of clinical outcomes as it relates to the
pathogen of interest (Porter et al., 2017). As ETEC is the leading bacterial cause of
childhood diarrheal morbidity and mortality in developing countries for which there is
not yet a licensed vaccine, Porter et al. (2016) attempted to address the aforementioned
challenge and derived a three-parameter composite score based on previously conducted
ETEC CHIM. Akin to the CODA score for endemic pediatric population use, the ETEC
score supported use of additional clinical signs and symptoms more than just stool output
parameters as a more comprehensive measure of clinical disease in an experimental
human challenge model setting. Porter et al. (2018) has most recently followed up with
the development of a Shigella disease complex score, which has been applied to
preliminary immunological analysis of a S. sonnei model refinement CHIM (Frenck,
2018; Clarkson, 2018) and an immunization-challenge trial with a Shigella flexneri 2a
bioconjugate vaccine (Porter et al., 2018). Shimanovich et al., (2016) used a categorical
outcome-based disease index (DI) of four symptoms (maximum body temperature,
bloody stools, loose stools and stool volume) experienced post Shigella flexneri 2a
(2457T) challenge to characterize severity of clinical disease experienced by subjects in a
Phase 2/2b safety, immunogenicity and efficacy study of two different Shigella vaccine
candidates. These characterizations were then used to assess utility of two different
functional assays to predicting protection against shigellosis. Finally, the Vesikari scale
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persists in the CHIMs field for use in norovirus challenge studies, with a modification to
the dehydration and IV treatment point system resulting in a reduction from the original
20-point scale as applied to rotavirus trials to 17-point scale more representative of
norovirus illness (Atmar et al., 2011; Bernstein et al., 2015)
Conceptual Framework
There are two types of instruments most commonly utilized to measure constructs
using a composite score: scales and indexes (DeVellis, 2003). Both instruments
incorporate multiple variables, or items, within the tools. A scale is unidimensional tool
in which all items reflect, or cause, one construct, such as traveler’s diarrhea (DeVellis,
2003; Streiner, 2003). As a result, all items are correlated to some degree; thus, not every
item needs to be represented as one item that is missed will be picked up by another’s
correlated item (Streiner, 2003). The Vesikari and Clark scales are examples of such
instrumentation as it applies to assessment of pediatric rotavirus gastroenteritis. In
contrast, an index is a multidimensional instrument comprised of different non-correlated
items that determine the level of the construct; thus, omit an item and the entire construct
changes (Bollen & Lennox, 1991; Devellis, 2003). Because the variables, or items, within
the secondary datasets to be compared and contrasted in this study are caused by
traveler’s diarrhea, scale development theory is an applicable theoretical framework to
this research.
Scale Development Theories
Scales are an instrumentation method consisting of a cluster of questions to
measure more complex social science concepts having several properties, such as
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socioeconomic status (Frankfort-Nachmias & Nachmias, 2008). Unlike an index that is
constructed by adding up the scores assigned to individual items, a scale utilizes the
differences in intensity among the individual items to suggest that there are varying
degrees to a variable (Frankfort-Nachmias & Nachmias, 2008). The most commonly used
scale in sociological investigation is the Likert Scale, which consists of response
categories including “strongly disagree,” “disagree,” “agree” and “strongly agree”
(Frankfort-Nachmias & Nachmias, 2008). In enteric research and as previously
described, scales have been utilized to characterize the severity of clinical disease,
particularly for pediatric studies (Ferdous et al., 2013; Lee et al., 2016; Levine et al.,
2015; Pringle et al., 2011). The Vesikari Clinical Severity Scale is the most commonly
used example of a composite measure considering specific parameters that constitutes the
clinical profile of rotavirus disease (Lewis, 2011). For the evaluation of acute
gastroenteritis in pediatric populations in both developed and developing countries
research into clinical severity scales has largely focused on the use of the Vesikari Scale
Score (Lewis, 2011; Schnadower, et. al., 2013); however, its applicability to both nonrotavirus diarrheal disease and the adult population is limited. Symptoms such as fever,
abdominal pain, tenesmus with diarrheal stools accompanied by pathological elements
such as blood and mucus typically orient to a bacterial etiology, whereas more frequent
vomiting and aqueous stools tend to orient to a viral etiology, as is the case of rotavirus
(CDC, 2015; Simona et al., 2015). With this clinical profile in mind, the Vesikari Score
highlights commonly observed rotavirus-specific symptoms observed such as vomiting,
watery diarrhea and level of dehydration. Moreover, both commonly used Vesikari and
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Clark score were developed and have since been modified for use in only pediatric
populations, with parameters such as fever, behavioral symptoms and dehydration based
on biological ranges and characteristics of children less than 2 years of age. As a result,
use of the Vesikari or Clark Scores would be inappropriate for assessment of non-viral
disease or adult use in populations.
The two most predominant scale development theories include the item response
theory (IRT) and classic test theory (CTS); often used to guide scale development
through factor analysis and item selection. IRT was first used in the field of
psychometrics to evaluate instruments and assess subjects on their abilities, attitudes, or
other traits (Xinming, & Yung, 2014). Commonly used aptitude tests like the Scholastic
Assessment Tests (SATs) and Graduate Record Exams (GREs) are developed using IRT
as it has been shown to improve reliability and measurement accuracy while improving
efficiency in assessment time (Xinming, & Yung, 2014). Over the years IRT
methodology has become increasingly popular and applied to health outcomes, clinical
research and quality-of-life research (Hays et al., 2000; Xinming, & Yung, 2014). IRT
models have been shown to better reflect actual response patterns in the sample
population, resulting in better estimates of self-reported health outcomes that are more
sensitive to true cross-sectional differences and more responsive to changes in health over
time (Hays et al., 2000). CTS is another psychometric theory used to predict the abilities
of subjects, in which a subject’s observed score on a test is the subject’s true score plus
some error (since it is unlikely that a subject will perform perfectly on a test)
(Tractenberg, 2010). Similar to the IRT, CTS has also been widely used in development
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and selection of endpoint measurements in clinical trials (Tractenberg, 2010), with
advantages and disadvantages cited for using one over the other (Hays et al., 2000).
These frameworks have been relevant to the development of various scales for
gastroenteritis assessment (Cappelleri et al., 2014) and thus remains an applicable
framework for this research to consider.
Conclusion
This chapter began by characterizing TD gastroenteritis and reviewing the
epidemiology and disease burden. The major symptoms of TD vary depending with
etiology; although usually includes diarrhea, vomiting, fever, nausea, and abdominal
pain. The utility of measuring severity of TD in addition to accounting for other clinical
symptomology, history of scoring systems and use of them for use in pediatric
populations and experimental human challenge studies were described. The chapter
closed with a discussion of the conceptual research chosen to guide this research and its
implications for social change.
In summary, this chapter outlines the need to develop an optimized and simplified
scoring system for TD that can be used to better define clinical outcomes for use in
epidemiological research and intervention evaluation. The literature reviewed in this
chapter highlights the potential for better classifying disease outcome through the use of
an optimized scoring system including clinical signs and symptoms in addition to stool
number. It also suggests that research has been completed to further explore this issue in
both pediatric populations and to a more limited extent in experimental human challenge
studies for ETEC, but additional research on the development of a scoring system for TD
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should be conducted. The next chapter focuses on the methods used to conduct this
research and test the study hypotheses outlined in Chapter 1.
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Chapter 3: Research Method
As I outlined in the previous two chapters, TD is the most common travel-related
illness, prompting the development and assessment of primary and secondary disease
prevention efforts such as vaccines and antibiotic treatment. The efficacy of these
interventions is often based on the prevention/management of moderate to severe
diarrheal disease, predominately based solely on the maximum number of loose stools in
a 24-hour period (Behrens et al., 2014; Darsley, Harro, Chakraborty, Sack, & DeNearing,
2015; Frech et al., 2008; Sack et al., 2007). However, reliance on stool-based endpoints
alone may obscure or over-inflate the efficacy of potentially meaningful differences in
illness profiles. Attempts to address this limitation have been advanced for pediatric
populations as well as, most recently, in CHIMs for ETEC and Shigella (Porter et al.,
2016; Porter et al., 2018). However, there is no standardized disease score for diarrheal
illness in adult travelers limiting epidemiologic and interventional studies. In this chapter,
I explain the research methodology used for this quantitative secondary analysis in detail.
The appropriateness of the methodology chosen for this research is justified below. I
detail the sampling methods, study population, inclusion and exclusion criteria, and data
analysis procedures and also present the research questions, hypotheses, and ethical
considerations.
Research Design and Rationale
In this quantitative study, I aimed to answer three research questions and test the
corresponding hypotheses using secondary data analysis. Secondary data analysis is a
common technique of using data previously collected to answer a different research
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question (Cheng & Phillips, 2014). The original trials were designed to estimate the
efficacy of combination antibiotic therapy in treating TD cases (TrEAT TD) and an
inactivated whole cell ETEC vaccine (OEV-118). Both datasets contain information on
common clinical signs and symptoms of TD, as well as duration, severity of symptoms,
and impact on activity. As such, they were ideal for testing hypotheses related to the role
of clinical signs and symptoms on TD severity and assessing whether an optimized
scoring system can be developed for TD intervention studies.
Research Questions and Hypotheses
The research questions are as follows:
Research Question 1: What combination of clinical signs and symptoms best
characterizes TD severity in adult travelers?
Ho1: There are no significant differences in the frequency and severity of clinical
signs and symptoms across disease severity classification.
Ha1: There are significant differences in the frequency and severity of clinical
signs and symptoms of TD on disease severity classification.
Research Question 2: What individual clinical signs and symptoms of TD are
significantly associated with a negative impact on activity among adult travelers?
Ho2: Individual clinical signs and symptoms of TD are not significantly
associated with a negative impact on activity.
Ha2: Individual clinical signs and symptoms of TD are significantly associated
with a negative impact on activity.
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Research Question 3: Does a TD disease score better differentiate treatment
groups than prior estimates of vaccine efficacy when applied to a previously conducted
ETEC vaccine study (Protocol OEV-118)?
Ho3: The estimated vaccine efficacy of the ETVAX vaccine in the OEV-118
Phase 3 trial does not change as a result of using the new disease complex score.
Ha3: The estimated vaccine efficacy of the ETVAX inactivated whole cell vaccine
tested in the OEV-118 Phase 3 trial does change as a result of using the new disease
complex score.
Methodology
Participants and Datasets
Participants included in this quantitative secondary analysis included healthy male
and female adults aged ≥ 18 years from two previously conducted clinical trials, OEV118 and TrEAT TD, both described in greater detail below.
OEV-118. Participants included in the OEV-118 dataset were healthy adults, aged
≥ 18 years at the time of enrollment in a double-blind, randomized, placebo-controlled,
Phase 3 study designed to evaluate the safety and protective efficacy of a two-dose oral
candidate vaccine against enterotoxigenic E. coli induced TD. The candidate vaccine was
prepared from formalin-killed whole cell ETEC strains expressing colonization factor
antigens CFA/I and CS1 through CS5, supplemented with 1 mg of the B subunit of
cholera toxin (CTB) per dose. Study participants were vaccinated twice at 2-week
intervals in the United States 7 days prior to travel to Mexico and Guatemala, both
countries with an intermediate to high TD risk, for a period of at least 7 days and
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followed for 2-4 weeks after arrival. Participants underwent clinical and microbiological
surveillance for diarrhea and other illness while traveling. The oral ETEC vaccine used in
this study had been proven safe in a predecessor trial (OEV-114, VTU no. 982,
unpublished) which was conducted at the same sites in Guatemala and Mexico in May
1998-August 1999 and December 1998-August 1999, respectively. At the time of the
OEV-118 study, approximately 700 participants had been enrolled in the OEV-114 study
with no safety issues reported; OEV-118 was an additional Phase 3 study to address
points raised by regulatory agencies (SBL Vaccin AB/Active Biotech, 2001). The OEV118 vaccine trial was conducted from November 1999 to April 2002.
Inclusion criteria for OEV-118 included healthy adult males and females aged ≥
18 years at the time of enrollment and receipt of the first study vaccination, planning to
travel to one of the clinical trial sites (Cuernavaca, Mexico or Antigua, Guatemala) and
stay for at least 14 days, mostly for language study. Participants had to provide written
documentation from a physician that they had undergone a physical exam within 12
months of enrollment, and they had to (a) live in a household with a telephone in the
United States, (b) sign a consent form, (c) pass a protocol comprehension exam, and (d)
be able and willing to comply with protocol specified procedures. Participants had to be
willing and able to participate in nurse-supervised health counseling sessions as well as
nurse-supervised study product dosing sessions, all conducted over the telephone.
Females could not be pregnant, as verified by urine-pregnancy test, and were willing to
use birth control for the duration of the study. Exclusion criteria included participants
who had (a) clinically significant acute or chronic gastrointestinal disease; (b) recent
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exposure to ETEC; (c) previous travel to a developing country within a year of study
enrollment; (d) an immunodeficiency medical condition; (e) any serious medical
condition; or (f) planned use of antibiotics during the trip (not pertaining to per-protocol
use of antibiotics for the purpose of treating severe diarrhea during travel). Criteria that
excluded participants from being in the per-protocol analysis included (a) use of another
investigational drug or vaccine other than the one evaluated in the trial; (b) administration
of chronic immunosuppressants (inhaled or topical steroids allowed); (c) chronic or
planned intake of antibiotics during the study period, and (d) administration of any
vaccine not foreseen by the study protocol during the study period.
Participants completed a symptom diary card after each vaccination over the
course of 5 days, beginning 1 day prior to each dosing, in which information regarding
severity of gastrointestinal and general symptoms were recorded. The questionnaire also
documented the impact of their symptoms on daily activities in addition to inquiring
about symptoms not specifically solicited.
A total of 1458 subjects received vaccine or placebo and 1435 completed 14-28
days of in-country surveillance. As in the previous OEV-114 field trial with the firstgeneration oral inactivated killed product (Sack et al., 2007), the commercial scale
vaccine produced for the OEV-118 study was extremely well tolerated. Overall there
were no significant differences between the rates of solicited general symptoms in the 3
days after vaccination with the exception of vomiting, which was more common in
vaccinees versus placebos after both Dose 1 (p = 0.03) and Dose 2 (p = 0.001; Bourgeois
et al., 2011).
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Two study offices were established at the field sites to facilitate sample collection,
meet with participants on a weekly basis to discuss any symptoms recorded on the diary
cards, and to report any illness experienced during their stay in-country. Participants were
provided fecal specimen collection containers and diary cards to record daily symptoms.
Diary cards were collected on a weekly basis at the study site. Cards were reviewed with
study staff weekly, at departure and during all TD episodes. Similar to the vaccination
phase of the study, the diary cards collected information on specific gastrointestinal
symptoms as well as general symptoms, associated severity and impact on activity. TD
was defined as ≥ 3 loose stools in a 24-hour period plus one of the following: abdominal
pain/cramps, nausea, vomiting, urgency, gas, and fever. Stools were characterized as
Grade 1-5 where Grade 1 and 2 stools were considered normal, firm, and retaining shape.
Thick liquid stools taking the shape of a container were considered Grade 3, opaque
water stools were graded 4, and rice water stools were graded 5. Grades 3, 4, and 5 loose
or watery stools were all considered “loose.” A diarrhea episode was considered
complete on the last day after which 72 hours passed symptom free with no additional
loose stools. Other solicited gastrointestinal and systemic symptoms were graded as mild
(Grade 1) if they were noticed but did not impact activity; moderate (Grade 2) if they
caused some limitation in activity; and severe (Grade 3) if they impacted activity to the
point of non-participation (Bourgeois et al., 2011). The primary study outcome was a
vaccine preventable outcome (VPO-ETEC TD) which was defined as > 5 unformed or
liquid stools in a 24-hour period accompanied by abdominal pain/cramps, nausea and/or
vomiting of any intensity, plus ETEC sharing vaccine antigens as the sole pathogen and
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isolated in a window of 24 hours before to 72 hours after onset. Secondary endpoints
considered in a post hoc analysis included ETEC TD and more severe ETEC TD. ETEC
TD was like VPO-ETEC TD, except that only > 3 unformed or liquid stool in a 24-hour
period accompanied by abdominal pain/cramps, nausea and/or vomiting of any intensity
were needed to qualify as a case, with ETEC isolated as the sole pathogen anytime during
the diarrhea episode unless otherwise noted. Cases associated with moderate to severe GI
symptoms or changes in activity were considered more severe ETEC TD (MS-ETEC
TD).
Among the participants in the study, 412 of 1435 (29%) experienced TD overall,
including 31% of participants traveling to Guatemala, and 22% traveling to Mexico.
Overall TD incidence was 11.6 cases per 100 person-weeks at risk; in Guatemala the TD
incidence was significantly higher than that observed in Mexico, with 13.3 cases per 100
person-weeks at risk, versus 9.5 cases per 100 person-weeks at risk, respectively
(Bourgeois et al., 2011). The vaccine had a negative point estimate of efficacy in the
primary analysis, yielding a PE of -59 with 95% CI (-384 – 48). Post-hoc point estimate
efficacy was improved against ETEC TD, with a PE of 15 with 95% CFI (-83 – 60).
About half TD cases met the definition of MS-ETEC TD; post-hoc efficacy analysis
against MS-ETEC TD further improved the vaccine efficacy point estimate, as fewer
vaccine than placebo recipients developed MS-ETEC TD (4 of 705 vs. 10 of 701, PE =
60%, p = 0.10). The most common ETEC phenotype outcome (35% of cases) were ST
strains expressing CS6, two antigens not covered by the vaccine formulation (Bourgeois
et al., 2011).
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Dosing was not directly observed for the vast majority of study participants. A
majority of subjects received their vaccine or placebo product under telephonic
supervision by a study nurse, with no direct observation of actual product intake (SBL
Vaccin AB, 2003). Consequently, it was difficult to determine whether all doses were
actually taken by the volunteers as intended (SBL Vaccin AB, 2003). Following
completion of the primary analysis for the trial, a secondary analysis was performed to
assess the impact of vaccine “take” on vaccine efficacy. Serological studies in subjects
providing sera before and after immunization suggested that most mounted strong IgA
responses (~88%) to the CTB component of the vaccine but only modest responses
against the CFA components (15-20%). These observations revealed that the vaccine take
rate may have been more variable than in prior studies using direct-observed vaccination
(Bourgeois et al., 2011). Among vaccine takes (n = 162) there was a strong trend toward
protection against ETEC TD of any intensity (PE = 58%; p = 0.09), with greater
protection seen against MS-ETEC based on change in activity or symptom severity (PE
range 88-100%, p ≤ 0.02 for both comparisons; Bourgeois et al., 2011).
Trial Evaluating Ambulatory Therapy of Travelers’ Diarrhea (TrEAT TD)
study. Participants in the TrEAT TD Study were active-duty US or UK military
personnel or beneficiaries, aged ≥18 years of age, deployed to one of four countries
(Kenya, Djibouti, Afghanistan, or Honduras) who presented with acute-watery diarrhea,
febrile or dysentery illness and who were ambulatory at the time of enrollment (Riddle et
al., 2017). Participants presenting with acute-watery diarrhea were randomized into one
of three treatment groups in a double-blind manner to evaluate the comparative efficacy
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of single-dose azithromycin, levofloxacin, or rifaximin in combination with loperamide.
Participants who presented with febrile or dysentery illness were randomized to receive
azithromycin with or without loperamide. Personnel presenting with suspected TD,
febrile or dysentery illness were evaluated for potential trial inclusion, randomized to
receive one of the aforementioned treatment regimens for direct observed dosing. The
vaccine trial began September 2012 and ended in July 2015.
Inclusion criteria for this study included (a) active-duty (or beneficiaries) adult
males and females aged ≥18 years at the time of enrollment who had to meet the
definition of TD (≥ 3 loose stools in 24 hours or ≥ 2 loose stools in 24 hours with
associated symptoms) of ≤ 96 hours duration; (b) able to comply with protocol specific
procedures; and (c) remain eligible for follow-up 5 days or more after treatment.
Exclusion criteria included participants who (a) reported allergies to any one or more of
the study drugs; (b) received antibiotic therapy (including malaria prophylaxis) within 72
hours of enrollment; (c) reported history of seizures; (d) were taking medications with
known drug-interactions with the study investigational products (IPs); (e) had a positive
urine pregnancy test at enrollment (females of child-bearing potential only); (f) had
dysentery or fever; and (g) used a total of > 4 mg loperamide or any amount of
loperamide for > 24 hours prior to enrollment (Riddle et al., 2017).
The primary efficacy endpoint of this study was the proportion of participants
who achieved clinical cure of their TD within 24 hours of receiving their first treatment
dose; clinical cure was defined as 1) no reported diarrheal stools >24 hours after initiation
of treatment, 2) diarrhea had no impact on activity, and 3) any diarrhea-associated
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symptom present at 24 hours were graded no higher than ‘mild’ (Riddle et al., 2017).
Treatment failure was defined as follows: 1) recurrence of TD diarrhea (utilizing the
study definition) within 72 hours after clinical cure, 2) worsening of symptoms after 24
hours of treatment, or 3) continuing illness after 72 hours. Participants were provided
diary cards on which to record their daily treatment usage, form and number of loose
stools passed, presence of gastrointestinal (abdominal cramping, excessive gas, nausea,
vomiting, fecal urgency, constipation) and systemic symptoms (fever, malaise/fatigue),
and impact of illness on activity (no impact, ≤ 50% impact, > 50% impact, inability to
function).
While randomization occurred based on clinical presentation (acute waterydiarrhea or acute dysentery/febrile diarrhea), only results of the acute watery-diarrhea
portion of the study is published and results summarized in detail here. Of 844
participants assessed for eligibility, 339 were enrolled with acute-watery diarrhea,
randomized to receive either azithromycin (n = 106), rifaximin (n = 107), or levofloxacin
(n = 111) and took the full treatment dose as prescribed for inclusion in the per protocol
analysis (Riddle et al., 2017). Approximately 130, 104, 50, 42 participants were enrolled
in Kenya (40%), Djibouti (32%), Afghanistan (15%) and Honduras (13%), respectively.
Most participants presented for care of diarrheal illness at around 26.8 hours, with 12.6%
presenting with diarrhea between 48 and 72 hours and 4.7% presenting with diarrhea
between 72 and 96 hours, with no difference in proportions between treatment arms
(Riddle et al., 2017). The average number of loose stools reported by participants
regardless of treatment arm who had diarrheal illness ≥ 24 hours was 6.9 (Riddle et al.,
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2017). The most common symptoms reported included cramping (74.3%), vomiting
(18%), fecal incontinence (12.7%), and fever (9.6%) (Riddle et al., 2017). Approximately
three quarters of participants (76.5%) reported some impact of illness on activity, with
approximately 30% reporting significant or complete disability associated with illness
(Riddle et al., 2017).
In regards reaching clinical cure at 24 hours, single-dose levofloxacin, rifaximin
and azithromycin were shown to be comparable for treatment of AWD with 81.4%,
74.8% and 78.3% efficacy, respectively (Riddle et al., 2017). Furthermore, efficacy
among regimens at 48 and 72 hours were essentially equivalent with no differences in
post dose adverse events between treatment arms (Riddle et al., 2017).
Power Calculations
The post hoc power analyses were conducted using G*Power 3.1.9.2. G*Power is
a power and sample size calculation software with capabilities to perform calculations for
a variety of tests, including logistic regression analyses and t-tests (Faul, Erdfelder,
Buchner, & Lang, 2009). A minimum sample size approximately 360 subjects from the
TrEAT TD dataset was included to address research questions 1 and 2 and to develop the
optimized scoring system. Sampling frames and specific power calculations are discussed
further in the data analysis summary for each performed statistical test.
Instrumentation and Operationalization of Constructs
Two diary card instruments for determining severity of TD gastroenteritis
episodes and impact on activity were included in analysis procedures described further
below. These diary cards existed in questionnaire format filled in by the participants and
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verified by study clinicians during clinic follow-up visits. Diary cards from both trials
contained continuous and categorical independent and dependent variables, which are
further outlined in Table 2.

Table 2
Clinical Information Collected in TrEAT TD and OEV-118 Diary Cards
Symptom
Diarrhea

Present?
Yes/No

Subjective Fever

Yes/No

Dysentery

Yes/No

IV Fluids given
Impact of illness on activity
level

Yes/No

Vomiting

Yes/No

Abdominal Cramps

Yes/No

Excessive Gas/Flatulence

Yes/No

TrEAT Diary Card
Information Collected
Max # loose stools/24 hours
Number of loose stools in past 8 hours
Number of loose stools in past 24 hours
Number of loose stools onset to presentation
Duration (# hours)
Mild
Moderate
Severe
Date/Time of Onset

# liters
Normal
Decreased ≤ 50%
Decreased > 50%
Completely unable to function
Duration (# of hours)
# of episodes

Duration (# hours)
Mild
Moderate
Severe
Duration (# hours)
Mild
Moderate
Severe

Symptom
Unformed Stool

OEV-118 Diary Card
Present?
Information Collected
Yes/No
Number of unformed stools per hour

Temperature

Yes/No

Record temperature

Blood in stool

Yes/No

0: Normal/No visible blood
1: minute traces of visible blood in stool or
TP
2: One stool with abundant blood (clots or
liquid)
3: >1 stool with abundant blood (clots or
liquid)

Did you change your
activity for gastrointestinal
symptoms

Yes/No

Vomiting

Yes/No

Cramping

Yes/No

Gas

Yes/No

0: Normal/no vomiting
1: one episode of vomiting
2: 2 or more episodes of vomiting
3: 2 or more episodes of vomiting severe
enough to prevent normal daily activities
1: Mild
2: Moderate
3: Severe
1: Mild
2: Moderate
3: Severe
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Symptom
Nausea

Present?
Yes/No

Ineffective and/or Painful
Straining to pass stool

Yes/No

Tenesmus

Yes/No

Malaise/Fatigue

Yes/No

Fecal Incontinence

Yes/No

Constipation

Yes/No

Other symptoms

Yes/No

TrEAT Diary Card
Information Collected
Duration (# hours)
Mild
Moderate
Severe
Duration (# hours)
Mild
Moderate
Severe
Duration (# hours)
Mild
Moderate
Severe
Duration (# hours)
Mild
Moderate
Severe
Duration (# hours)
Mild
Moderate
Severe
Duration (# hours)
Mild
Moderate
Severe
Duration (# hours)
Mild
Moderate
Severe

Symptom
Nausea

OEV-118 Diary Card
Present?
Information Collected
Yes/No
1: Mild
2: Moderate
3: Severe

Tenesmus: painful,
ineffectual

Yes/No

1: Mild
2: Moderate
3: Severe

Weakness

Yes/No

1: Mild
2: Moderate
3: Severe

Urgency of defecation

Yes/No

1: Mild
2: Moderate
3: Severe

Other Symptoms

Yes/No

1: Mild
2: Moderate
3: Severe

Headache

Yes/No

Lightheadedness

Yes/No

Muscle aches

Yes/No

Chills

Yes/No

Abdominal Pain

Yes/No

1: Mild
2: Moderate
3: Severe
1: Mild
2: Moderate
3: Severe
1: Mild
2: Moderate
3: Severe
1: Mild
2: Moderate
3: Severe
1: Mild
2: Moderate
3: Severe
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(table continues)

Symptom

TrEAT Diary Card
Present?
Information Collected

Symptom
Gurgling stomach

Belching

Decreased appetite

Seek medical advices for
symptoms?

OEV-118 Diary Card
Present?
Information Collected
Yes/No
1: Mild
2: Moderate
3: Severe
Yes/No
1: Mild
2: Moderate
3: Severe
Yes/No
1: Mild
2: Moderate
3: Severe
Yes/No
1: Mild
2: Moderate
3: Severe

(table continues)
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Data Analysis Plan
All analyses except the Multiple Correspondence Analysis (MCA) were
conducted using SPSS 24.0 (IBM Corp, 2012). MCA was performed utilizing SAS and
all graphs depicting TD Score distributions were generated with Microsoft Office 365
Excel software. Table 3 provides a summary of the hypothesis testing analyses that were
conducted.

Table 3
Summary of Quantitative Data Analysis
Research
Question
What severity and
combination of clinical
signs and symptoms best
characterize TD severity in
adult travelers?

Hypothesis
There are significant
differences in association
between clinical signs and
symptoms of TD on
disease severity
classification.

Independent
Variables
a) Fever
b) Vomiting
c) Abdominal Cramps
d) Excessive flatulence
e) Nausea
f) Tenesmus
g) Malaise/fatigue
h) Fecal Incontinence

Dependent
Variables
Diarrhea severity
a) Mild
b) Moderate
c) Severe

Statistical
Test
Spearman Correlation
Univariate linear
regression

Complex Disease Score

Multiple Correspondence
Analysis (MCA)

Impact on activity
a) Normal
b) Decreased ≤ 50%
c) Decreased > 50%
d) Completely unable to
function

Ordinal logistic regression

N/A

Independent samples t-test
Mann-Whitney U test

What individual clinical
signs and symptoms of TD
are significantly associated
with a negative impact on
activity among adult
travelers?

Individual clinical signs
and symptoms of TD are
significantly associated
with impact on activity.

a)
b)
c)
d)
e)
f)
g)
h)
i)

Loose stools
Fever
Vomiting
Abdominal Cramps
Excessive flatulence
Nausea
Tenesmus
Malaise/fatigue
Fecal incontinence

Does a TD disease score
better differentiate
treatment groups than prior
estimates of vaccine
efficacy when it is applied
to a previously conducted
ETEC TD vaccine study
(Protocol OEV-118)?

The estimated vaccine
efficacy of the ETEC
inactivated whole cell
vaccine tested in the OEV118 Phase 3 trial does
change as a result of using
the new disease complex
score.

N/A
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For the purpose of developing the score, detailed clinical information on the signs
and symptoms associated with TD were obtained from the TrEAT TD dataset. To
subsequently validate the complex disease score, the OEV-118 dataset was utilized. To
be included in the dataset for score development, subjects must have complied with
eligibility criteria and enrolled in the TrEAT TD study.
While signs and symptoms were originally defined by each study independently (see
Table 2), for standardization the following signs and symptoms within the final dataset
for analysis were re-defined as follows (based on maximum severity recorded):
•

Abdominal cramps, nausea, tenesmus, malaise/fatigue, excessive flatulence (gas)
and fecal incontinence:
o 0 – none
o 1 – mild (no interference with routine activity)
o 2 – moderate (symptoms cause interference but do not preclude from
participating in routine activity)
o 3 – severe (symptoms prevent routine activity)

•

Fever:
o 0 – None - <100.4° F
o 1 – Mild - 100.4°F – 101.1°F
o 2 – Moderate – 101.2°F – 102.0°F
o 3 – Severe – ≥102.1°F

•

Vomiting:
o 0 - None – 0 episodes in 24 hours
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o 1 - Mild – 1 episode in 24 hours
o 2 - Moderate – 2 episodes
o 3 - Severe – ≥3 episodes
•

Diarrhea (Only for OEV-118)
o 1 - Mild – 1 loose/liquid stool of ≥300 g or ≥2 loose/liquid stools totaling
≥200 g and ≤400 g during a 24-hour period)
o 2 - Moderate – 4 to 5 loose/liquid stools or >401 to 800 g in a 24-hour
period
o 3 - Severe – 6 or more loose/liquid stools or ≥800 g in a 24-hour period
Correlation between signs and symptoms. To test the first hypothesis and

determine if there was significant correlation between clinical signs and symptoms of
TD, Spearman’s correlations were utilized. The Spearman’s rank-order correlation
coefficient is a nonparametric measure of the direction and strength of the association
that exists between two variables measured on an ordinal, interval or ratio scale (Laerd
Statistics, 2013f). As all clinical signs and symptoms were originally classified in the
original TrEAT TD study as none, mild, moderate and severe, the critical assumption that
the included variables fit an ordinal level of measurement was already satisfied prior to
moving forward with analysis.
The sample size for this analysis was calculated in G*Power using an
alpha of 0.05, a power of 0.95 and a medium effect size (p = 0.03) for a two-tailed test
(Faul et al., 2009). Because Spearman’s rank correlation coefficient is computationally
identical to Pearson’s product-moment coefficient (Statistics Solutions, 2010), the
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calculation was performed using software for estimating power of a Pearson’s correlation
(Faul et al., 2009). A minimum total sample size of 111 was sufficient to ensure at least
95% power; the total sample size included in the final analysis was 363 participants.
Correlation between signs and symptoms and frequency of loose stool. As
most, if not all, TD definitions utilized across epidemiologic and interventional studies
incorporate stool output as the primary endpoint (see also Chapter 2), univariate
regression models were conducted to describe the strength of association between the
number of loose stools over a 24-hour period and the TD-attributable signs and
symptoms. While multiple linear regression was originally proposed for this analysis, that
approach resulted in violations of both assumptions of multicollinearity and
homoscedasticity. The risk for multicollinearity between the variables to be analyzed in
this dataset was not unexpected, as Porter et al. (2016 and 2018) found a high degree of
multicollinearity across many of the same clinical signs and symptoms within those
respective datasets when developing a disease complex score for ETEC CHIM.
Therefore, I proceeded with the same approach as Porter et al. (2016) in which univariate
linear regression was utilized. As a critical assumption of linear regression is that there
should be no significant outliers in the data which can impact the regression line and lead
to inaccurate results (Laerd Statistics, 2013c), I identified such datapoints for maximum
24-hour stool frequency in any 24-hour period prior to presentation that fell outside the
first or third quartile; mathematically represented as Q1 - (1.5*IQR) and Q3 + (1.5*IQR),
respectively. I ran each univariate regression model with and without outliers to
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determine if there were differences in the associations between clinical signs and
symptoms and stool output, with detailed results presented in Chapter 4 and Appendix 1.
The sampling frame for testing this hypothesis included participants from the
TrEAT TD study who received treatment, presented with acute-watery diarrhea and had
gastroenteritis severity data collected and stool results available, regardless of treatment
allocation. The sample size for the proposed analysis was calculated in G*Power by
setting the test family to F tests; selecting ‘Linear multiple regression: Fixed model, R2
deviation from zero,’ and selecting to compute required sample size (Faul et al., 2009).
Then, the effect size f2 was set to 0.15 (medium), alpha error probability was set to 0.05,
power was set to 0.95, and the number of predictors was set to one (Faul et al., 2009).
The minimum total sample size for this analysis was calculated to be 89 participants; the
total sample size included in the final analysis for each univariate regression model was
363 participants.
Impact of clinical signs and symptoms in activity level. Ordinal logistic
regression is often used to predict an ordinal dependent variable (i.e., impact on activity)
given one or more predictor variables (i.e., clinical signs and symptoms; Laerd Statistics,
2013b). To test the second hypothesis, separate cumulative odds ordinal logistic
regressions with proportional odds were run to determine the effect of each individual
clinical sign and symptom of TD (e.g., abdominal cramps, nausea, tenesmus, gas,
incontinence, malaise, vomiting, and tenesmus) as well as the traditional TD-illness
metric of stool output (i.e., maximum number of loose/liquid stools in any 24 hours prior
to presentation) to determine the effect of each of those parameters on impact on activity.
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A Classification and Regression Tree (CART) analysis was conducted to determine
optimal cut points of the maximum number of loose stools in 24 hours for this analysis as
well as inclusion in the scoring system. Briefly, CART maximizes the distribution of
observations into different categories that are predicted by another category (Lewis,
2000). For each logistic regression analysis, the data were checked to assess assumptions
of proportional odds (tested with a full likelihood ratio comparing the fit of the
proportional odds model to a model with varying location parameters), and
multicollinearity through generation of a collinearity matrix to determine if
multicollinearity was present (correlation > .90).
In addition to performing this with the individual predictor variables (i.e., clinical
signs and symptoms), I re-ran this analysis utilizing the disease complex score further
described below via multinomial logistic regression to assess whether the new score
improved the estimation of impact on activity over any single individual sign or
symptom.
The sampling frame for testing this hypothesis included participants from the
TrEAT TD study who received treatment, presented with acute-watery diarrhea and had
gastroenteritis severity data collected and stool results available, regardless of treatment
allocation. The sample size for the proposed analysis was calculated in G*Power by
setting the test family to F tests; selecting ‘Linear multiple regression: Fixed model, R2
deviation from zero,’ and selecting to compute required sample size (Faul et al., 2009).
Then, the effect size f2 was set to 0.15 (medium), alpha error probability was set to 0.05,
power was set to 0.95, and the number of predictors was set to eight (Faul et al., 2009).
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The minimum required sample size for this analysis was 160 participants; the total
sample size included was 363 participants.
Development of the disease complex score. To further and graphically describe
the overlap of the severity of all the symptoms in the dataset, a multiple correspondence
analysis (MCA) was performed. MCA, like exploratory factor analysis, is a variablereduction technique that aims to reduce a larger set of variables into a smaller set of
principle components that account for most of the variance in the original variables
(Laerd Statistics, 2013e). There are a number of uses for MCA, including but not limited
to: a) when there are many variables in a dataset and some of the variables may be
measuring the same underlying construct; if these variables are highly correlated, only
those variables most closely representing the construct should be included in the overall
measurements scale; b) in creating a new measurement scale, MCA helps one understand
whether some of the variables chosen are not sufficiently representative of the construct
of interest and whether certain variables should be removed from the new measurement
scale; c) for testing whether an existing measurement scale can be shortened to include
fewer items (Laerd Statistics, 2013e). From the MCA analysis, relevant clusters of
symptoms were identified and then amalgamated in a way to ensure equal distribution
across an ordinal spectrum of illness. This was then combined with an ordinal score
developed from the distribution of stool output (frequency) using the cutpoints
established from the aforementioned CART analysis, resulting in a single, combined
composite ordinal disease severity score.
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Utilizing this methodology for development of the disease complex score for TD
was in line with the same methodology utilized for development of a Campylobacter,
ETEC and Shigella-specific disease complex score, the latter two of which have been
published and validated (Porter et al., 2016; Porter et al., 2018).
Application of complex disease score to OEV-118. The new TD disease
complex score was ‘externally validated’ by applying it to a previously conducted Phase
3 vaccine field efficacy trial (OEV-118) to test the hypothesis that disease score
significantly differentiates interventions. This analysis was conducted for the entire
dataset as well as multiple subgroups representing different endpoints and definitions of
interest within the OEV-118 dataset, defined in Table 4.

Table 4
Travelers’ Diarrhea (TD) Endpoints (OEV-118 Dataset) for Hypothesis 3 Testing
Endpoint
All
Travelers’
Diarrhea
(TD)
All ETEC
Infections
ETEC TD

Abbreviation N
Definition
Rationale for Testing
ALL
1435 Subjects enrolled in the OEV-118 study who received one or Full database analysis
two doses of vaccine, traveled to Mexico or Guatemala and
had symptom data available for analysis
TD
412 ≥3 loose or watery stools in a 24-hour period accompanied
Classic TD Endpoint
by ≥1 accompanying gastrointestinal (GI) symptom
ALL-ETEC

188

ETEC TD

27

Vaccine
VPO-ETEC
Preventable TD
ETEC TD

13

ETEC with
Mixed
Infections

14

ETEC-MX

ETEC as sole pathogen isolated in any subject who received
one or two doses of vaccine, traveled to Mexico or
Guatemala, and had symptom data available for analysis
≥3 loose or watery stools in a 24-hour period accompanied
by abdominal pain or cramps, nausea, or vomiting of any
intensity, plus ETEC sharing antigens1 with the vaccine as
sole pathogen isolated
≥5 loose/watery stools in 24 hours plus ≥1 of abdominal
pain/cramps, nausea and/or vomiting, plus ETEC sharing
antigens1 with the vaccine as sole pathogen and isolated in
window of 24 hours before to 72 hours after illness onset
among subjects completing 2-dose regimen, traveling during
window of 7 to 14 days post 2nd dose and completing 14-28
days surveillance.
ETEC along with (an)other pathogen(s) isolated by culture
in any subject who received one or two doses of vaccine,
traveled to Mexico or Guatemala and had symptom data
available for analysis

To determine vaccine efficacy
against infection with any ETEC
Recommended by OEV-118 Data
Safety Monitoring Board*

Original Study Endpoint

To determine vaccine efficacy
against infection with any ETEC
plus one or more enteric pathogens

1

LT, LTST, CFA/I, CS1, CS2, CS3, CS4 or CS5
*AL Bourgeois, personal communications
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To do this, a disease score was calculated for each subject in the OEV-118 study
that met one of the definitions outlined in the table above, and the mean score between
placebo and vaccine recipients was compared utilizing the independent samples t-test for
each subgroup. The independent samples t-test compares the means between two
unrelated groups on the same continuous dependent variable (Green & Salkind, 2014).
For each subgroup analysis, all critical assumptions of the independent t-test were met
except the assumption of normality. If this assumption is violated, there are four options
available to continue with analysis. First, the data can be transformed to be normally
distributed and then the independent t-test run on this transformed data. The second
option is to run a non-parametric test such as the Mann-Whitney U-test. The third option
is to proceed with analysis despite the violation, as the independent t-test is robust to
deviations from normality (Laerd Statistics, 2013a). Fourth and finally, test comparisons
can be run in which an independent samples t-test on transformed and non-transformed
data is performed, analyzed and upon comparison if they appear similar the nontransformed original data is used for final interpretation (Laerd Statistics, 2013a). I
proceeded with conducting an independent t-test analysis for each subgroup in addition to
performing a Mann-Whitney U test as the nonparametric alternative to the independent
samples t-test to ensure due diligence was achieved with this research. Results of both
statistical approaches are presented in detail in Chapter 4. Finally, I re-calculated
estimates of vaccine efficacy within each subgroup using the formula below:
MeanScoreplacebos – MeanScorevaccinees
MeanScoreplacebos

74
The sampling frame for the validation of the disease score and assessment of
utility as applied to the ETEC vaccine included various subgroups of participants from
the OEV-118 trial who had clinical gastroenteritis severity data collected and stool results
available regardless of whether they received a vaccination with inactivated ETEC
vaccine or placebo, with primary consideration to the original per-protocol VPO
endpoint. As the sample size was already known for the original study endpoint analysis
(i.e., among the participants in the study, 14 met the criteria as a VPO event), G*Power
was utilized to calculate what statistical power would be obtained given a sample size of
26, an effect size of 0.3 (medium) or 0.5 (large), and a 2-sided alpha of 0.05. The posthoc test for achieved power for this particular analysis was calculated in G*Power by
setting the test family to t tests; selecting ‘Means: differences between two independent
means (two groups) for the statistical test; and selecting ‘Post hoc: Compute achieved
power – given alpha, sample size, and effect size’ (Faul et al., 2009). Then, the number of
tails was set to one, effect size set to either 0.5 or 0.8 (two calculations performed), alpha
error probability was set to 0.05, sample size of group 1 was set to 8 (to represent the
vaccinees group) and the sample size of group 2 was set to 5 (to represent the placebo
recipients) (Faul et al., 2009). The calculated power for a set medium effect size of 0.5
was 0.205, or 21%; the calculated power for a set large effect size of 0.8 was 0.371, or
37%.
Threats to Validity
Internal validity is a means to measure whether or not research is sound and
conducted appropriately (Frankfort-Nachmias & Nachmias, 2008). The higher the
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internal validity, the more confidence there is in the observed changes to the dependent
variable being attributable to the independent variables rather than other possible causes,
or confounders (Frankfort-Nachmias & Nachmias, 2008). Threats to internal validity of
this study as applicable to the dataset that were utilized from the original TrEAT study
are automatically minimized via the experimental and randomized nature of the clinical
trial. For example, threats to internal validity include but are not limited to changing
instruments during the study, participants dropping out, and failure for participants to
complete protocols (Cheng & Phillips, 2014; Frankfort-Nachmias & Nachmias, 2008).
Because eligibility criteria for participants enrolling in both the original TrEAT and
OEV-118 studies required adherence to all protocol-specified procedures, the attrition
rate and risk of participants failing to complete the study was reduced at study initiation.
Furthermore, a standardized diary card was utilized for the collection of TD-associated
clinical signs and symptoms for all enrolled participants in both trials with no change of
that critical instrument nor the data it collected, thus minimizing the threat to internal
validity of the original datasets and carrying over to this secondary analysis.
External validity refers to the degree to which results can be applied across
settings, individuals, times and other investigations (Frankfort-Nachmias & Nachmias,
2008). Similar to internal validity, external validity of this study was assured through the
randomized placebo-controlled experimental nature of the original TrEAT and OEV-118
clinical trials by minimizing the risk of selection biases and the experimental treatment.
Validity of a new measurement tool such as an optimized TD disease scoring
system is assessed by evaluating three components: content, criterion, and construct
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(Frankfort-Nachmias & Nachmias, 2008). Criterion validity was not assessed as there is
not an existing scoring system for measuring TD (Streiner & Norman, 2008). Content
validity is based on the content of the scale as assessed by experts (Streiner & Norman,
2008). Since the clinical signs and symptoms that were considered in the new scoring
system have been included as common and expected solicited symptoms in the original
clinical trial and as established throughout multiple TD trials as described in Chapter 2, it
is expected that the newly proposed scale has adequate content validity.
Construct validity seeks to establish if the instrument measures what it is intended
to measure (Frankfort-Nachmias & Nachmias, 2008). As this study followed similar
methodology as that to establish ETEC and Shigella-specific disease severity scores
(Porter et al., 2016; Porter et al., 2018), beginning with ensuring empirical validity
through estimation of predictive validity through determining correlation coefficients
between criterion included in the scale (Frankfort-Nachmias & Nachmias, 2008),
followed by a multiple correspondence analysis that has been demonstrated to result in
high construct validity for their respective disease-specific gastroenteritis, it is anticipated
that this study resulted in an optimized TD severity score with adequate construct
validity.
Ethical Procedures
Protection of Participants. Before collecting information regarding TD
gastroenteritis, the adults included in both OEV-118 and TrEAT TD datasets all signed
informed consent forms to participate in the respective trials. All study documentation for
the OEV-118 trial was approved by the Joint Committee on Clinical Investigation at
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Johns Hopkins University (SBL Vaccin AB, 2003); the TrEAT TD study was approved
by the Uniformed Services University’s Infectious Disease Institutional Review Board,
the UK Ministry of Defense Research Ethics Committee, and the Kenyan Medical
Research Institute’s Institutional Review Board (Riddle et al., 2017). As this analysis
does not involve direct contact with the participants to collect additional data and dose
not increase the risk to study participant’s rights, safety, welfare or affect the integrity of
the data as originally collected, this secondary analysis does not require special
participant protection.
Risk to Participants. As the data used in this secondary analysis were already
coded using identification codes and I do not have access to these identification codes,
the risk to study participants that their individual level data would be disclosed is
nonexistent.
Ethical Committee Review. This research was reviewed and approved by two
ethical committees: the Naval Medical Research Center Institutional Review Board (IRB)
and the Walden University IRB. I was added identified as a co-Investigator for the
purpose of utilizing the TrEAT TD dataset as owned by Dr. Chad K. Porter at the Naval
Research Medical Center, and this research was considered ”Exempt” human participants
research from that IRB. The OEV-118 dataset was obtained from the study Principal
Investigator Dr. Lou Bourgeois. As this research was completed using existing datasets
with deidentified data, I pursued archival research review by the Walden University IRB
and completed the IRB application according to guidance outlined in the Guide for
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Archival Researchers Completing the Walden IRB Application (IRB Approval #10-2918-0491914).
Summary
This chapter further elaborated on the proposed research design and rationale
behind this secondary data analysis. Summaries of the population, instrumentation and
procedures used in the original TrEAT TD and OEV-118 clinical trials were described.
Detailed data analysis plans were presented to answer each of the proposed research
questions, including sampling frames and power calculations as applicable to each
statistical test. This chapter closed with an exploration into threats to validity and
strategies to address the various ethical considerations inherent to this research. Chapter 4
addresses the results from the study and Chapter 5 provides a synthesis of the results,
including recommendations and implications for social change.
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Chapter 4: Results
While efforts to expand beyond solely stool-based endpoints to assess the efficacy
of treatments and/or prophylactics against moderate to severe diarrheal disease have
advanced for pediatric populations and certain CHIMs by inclusion of other
symptomology into a clinical disease score, there remains no standardized disease score
for TD. In addition, a TD disease score has not been previously studied to assess its
potential utility in differentiating illness among a population receiving treatment(s) or
intervention(s) for TD. The quantitative secondary data analyses presented below enabled
the following:
1. An evaluation of which TD associated signs and symptoms were most
strongly associated with negative impact of illness on activity.
2. Development of a complex TD disease score accounting for the most relevant
signs and symptoms and their associated illness severity.
3. Determination of whether the TD disease score proved a useful tool for

potential use in intervention studies as a measure of protective efficacy or
reduced disease severity in cases.
In Chapter 4, I present the results of the analysis in order of generation: (a) the
determination of correlation between individual TD signs and symptoms, including
output of loose stools; (b) examination of which TD signs and symptoms impact most
negatively on activity level; (c) generation of a proposed TD disease complex scoring
system; and (d) validation of the resulting model. In Chapter 5, I discuss the results
presented below.
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Secondary Data Analysis
I obtained datasets from two trials from Dr. Chad Porter of the Naval Medical
Research Center (NMRC) and Dr. Lou Bourgeois, Principal Investigator of the OEV-118
study, and used them to generate the results presented below. Chapter 3 includes a full
description of both secondary datasets. Briefly, the TrEAT TD dataset contained basic
demographic information and all the variables necessary to generate a disease scoring
system for TD, whereas the OEV-118 dataset contained the basic demographic
information and TD symptom variables needed to validate the disease severity score. The
analysis I completed includes the precursor analyses conducted to check assumptions as
outlined in Chapter 3 as well as to address each of the three research questions.
Quality Control
Prior to analysis, I received the TrEAT TD and OEV-118 datasets from Dr. Chad
Porter and Dr. Lou Bourgeois, respectively, in the form of excel spreadsheets and
accompanying data dictionaries. In each dataset, one row of data corresponded to all data
obtained for each participant during the study. Because I received the complete datasets
from both trials, I determined which data fields were pertinent for answering the research
questions and hypothesis testing. Since my analysis included re-analysis of the optimized
scoring system on both the TrEAT TD and OEV-118 datasets, I calculated the
hypothesis-defined TD severity score for each study participant.
Precursor Analyses
Demographic variables and symptoms experienced by participants enrolled
in the TrEAT TD and OEV-118 studies. While separately and partially published,
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Table 5 shows the collated demographic characteristics of the participants enrolled in the
two datasets. Briefly, the mean age of participants enrolled in the TrEAT TD and OEV118 studies were 29.3 and 34.7 years, respectively. An overwhelming majority of the
participants in the TrEAT TD study were male (n = 300, 92%) whereas there was a more
equal distribution of gender in the OEV-118 study, with approximately 66% females (n =
945) and 34% males (n = 490). Both studies enrolled approximately an equal proportion
of white participants (84.0% and 86.8% in TrEAT TD and OEV-118, respectively), with
9.4 to 2.5% of participants identifying as ‘black’ and 6.6 and 10.5% of participants
identifying their race as “other” in the TrEAT TD and OEV-118 studies, respectively.
Table 5
Demographic Characteristics of Participants Enrolled in TrEAT TD and OEV-118
Characteristic
Mean age, (std. dev)
Gender
Male, No. (%)
Female, No. (%)
Race
White, No. (%)
Black, No. (%)
Other, No. (%)

TrEAT TD
(n = 363)
29.3 (8.5)

OEV-118
(n = 1435)
34.7 (14.2)

300 (92.0)
26 (8.0)

490 (34.1)
945 (65.9)

89.0 (84.0)
10 (9.4)
7 (6.6)

1246 (86.8)
36 (2.5)
151 (10.5)

As shown in Table 6, the most commonly observed subjective symptoms among
those enrolled in TrEAT TD were abdominal cramps (75.4%) and malaise (64.3%),
followed by nausea reported in approximately half the subjects (52.5%), gas (38.9%),
tenesmus (29.1%), and fecal incontinence (14.3%). In contrast, the more objective signs
of vomiting and fever were less frequently observed (20.4% and 15.8%, respectively). In
OEV-118, among those subjects who experienced travelers’ diarrhea ( ≥ 3 loose or
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watery stools in a 24-hour period accompanied by ≥ 1 GI symptom), the most commonly
observed subjective symptoms were gas (75.0%), malaise (69.0%) and fecal incontinence
(66.2%), followed by abdominal cramps (61.9%), and nausea reported in approximately
half the subjects. In contrast to the TrEAT TD study, reports of tenesmus were low
(4.8%). Meanwhile, the more objective signs of vomiting and fever were less frequently
observed than all subjective symptoms except tenesmus (14.6% and 11.9%, respectively).

Table 6
Frequency (%) of Signs and Symptoms in the TrEAT TD and OEV-118 Datasets
Cramps
Malaise
TrEAT TD (n = 363)
None 24.6
35.7
Mild 29.8
23.4
Moderate 35.4
33.2
Severe 10.2
7.7
Any Severity 75.4
64.3
OEV-118 Dataset (TD endpoint* only, n = 412)
None 38.1
31.1
Mild 28.2
22.1
Moderate 25.2
28.9
Severe 8.5
18.0
Any Severity 61.9
69.0

Nausea

Vomiting

Fever**

Tenesmus

Incontinence

Gas

47.5
30.2
18.7
3.6
52.5

79.6
5.2
5.8
9.4
20.4

84.3
5.8
7.2
2.8
15.8

70.8
14.3
12.9
1.9
29.1

85.7
5.8
6.3
2.2
14.3

61.2
16.8
18.5
3.6
38.9

51.9
25.5
15.8
6.8
48.1

85.2
7.5
2.7
4.4
14.6

88.1
5.8
2.9
3.2
11.9

95.1
2.2
2.4
0.2
4.8

33.7
27.4
26.7
12.1
66.2

25.0
55.6
15.0
4.4
75.0

Note. *Classic Traveler’s Diarrhea (TD) endpoint defined per protocol as ≥3 loose or watery stools in a 24-hour period accompanied by ≥1 gastrointestinal
(GI) symptom
Note. **Temperature was recorded on a daily basis in the OEV-118 study; severity classification for the purpose of this table and the severity score for
OEV-118 subjects were made using the same severity classifications as the TrEAT TD study as follows: mild = 100.4-101.1°F; moderate = 101.2-102.0°F;
severe = 102.1-104°F.
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The majority of subjects enrolled in the TrEAT TD study presented with acute
watery diarrhea (n = 320; 87.4%), whereas only 46 (12.6%) enrolled with acute dysentery
or febrile illness (Table 7).
Table 7
Frequency (%) of Diarrhea Based on Protocol-Specific Classifications (TrEAT TD
dataset; N = 363)
Classification
TrEAT TD
Acute watery diarrhea
Acute dysentery or febrile illness

Frequency (%)
87.4
12.6

When stratified by age (Table 8), the two youngest cohorts (18-25 and 26-35 years old)
experienced the highest proportion of TD, presenting with acute watery diarrhea (39.4%
and 40.7%, respectively) or acute dysentery or febrile illness (56.5% and 26.1%,
respectively). Incidence of TD (acute watery diarrhea, acute dysentery or febrile illness)
consistently declined as age increased, with only three cases of acute watery diarrhea
(0.8%) and no cases of acute dysentery or febrile illness in the oldest age cohort (56-65
years old). Of the 317 cases of acute watery diarrhea, 93.1% were in males compared to
6.9% in females (n = 22); and of the 46 cases of acute dysentery or febrile illness, 95.7%
were in males (n = 44) compared to only 4.3% in females (n = 2; Table 8).
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Table 8
Distribution of Age and Gender by Diarrhea Classification (TrEAT TD dataset; N = 363)

Age
18-25 years
26-35 years
36-45 years
46-55 years
56-65 years
Gender
Male
Female

Diarrhea classification
Acute watery diarrhea
(n = 317)

Acute Dysentery or febrile illness
(n = 46)

125 (39.4%)
129 (40.7%)
41 (12.9%)
19 (6.0%)
3 (0.9%)

26 (56.5%)
12 (26.1%)
7 (15.2%)
1 (2.2%)
0 (0.0%)

295 (93.1%)
22 (6.9%)

44 (95.7%)
2 (4.3%)

Of the 1435 subjects enrolled in the OEV-118 study, 412 met the defintion of TD.
When stratifed by age, 40% of those cases occurred in the youngest age cohort of 18-25
year old travelers, followed by 27.4% in 26-35 year olds (Table 9). The 46-55 year old
group had a slightly higher proportion of TD cases (12.1%) compared to 36-45 year olds
(10.7%); and 8.3% and 1.5% of TD cases were experienced in the two oldest cohorts of
56-65 year olds and ≥ 66 years old, respectively. When stratified by gender, the majority
of TD cases was observed in females (66.7%) compared to males (33%). Distribution of
TD cases were approximately equal between vaccinees and placebos for all age groups
and by gender (Table 9).
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Table 9
Distribution of Age and Gender with TD by Treatment Group (OEV-118; N = 412)

Age
18-25 years
26-35 years
36-45 years
46-55 years
56-65 years
≥ 66 years
Gender
Male
Female

Treatment group
Placebo
(n = 200)
78 (39.0%)
56 (28.0%)
18 (9.0%)
30 (15.0%)
17 (8.5%)
1 (0.5%)

Vaccine
(n = 212)
87 (41.0%)
57 (26.9%)
26 (12.3%)
20 (9.4%)
17 (8.0%)
5 (2.4%)

Total
(N = 412)
165 (40.0%)
113 (27.4%)
44 (10.7%)
50 (12.1%)
34 (8.3%)
6 (1.5%)

67 (33.7%)
132 (66.3%)

69 (32.5%)
143 (67.5%)

136 (33.0%)
275 (66.7%)

Note. *Classic TD endpoint defined per protocol as ≥ 3 loose or watery stools in a 24-hour period
accompanied by ≥ 1 gastrointestinal (GI) symptom.

A total of 77.4% (n = 284) of subjects enrolled in TrEAT TD reported some
negative impact on activity due to their illness, with 45.2% (n = 166) reporting a mild
decrease in activity (less than or equal to 50%), 26.2% (n = 96) reporting a decrease in
activity of > 50%, and 6% (n = 22) of subjects reporting TD illness precluding the
subject’s ability to function (Table 10). In the OEV-118 study, among those subjects with
classic travelers’ diarrhea (n = 412), one-third (33.1%) indicated they would change their
plans due to either their gastrointestinal or general symptoms. When further stratified by
treatment group, the proportion of subjects who would have changed their plans due to
the severity of their symptoms was roughly equal between vaccine and placebo recipients
(Table 10).
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Table 10
Number and Frequency (%) of Impact on Activity
Impact on Activity
TrEAT TD Dataset (n = 363)
Normal
Decreased ≤ 50%
Decreased > 50%
Completely unable to function
OEV-118 Dataset (TD endpoint* only, n=412)
Vaccinees
Change
No change
Placebos
Change
No change

N (%)
79 (21.5)
166 (45.2)
96 (26.2)
22 (6.0)

72 (34.0)
140 (66.0)
64 (32.2)
135 (67.8)

Note. *Classic TD endpoint defined per protocol as ≥ 3 loose or watery stools in a 24-hour period
accompanied by ≥1 GI symptom.

The maximum stool output in the TrEAT TD dataset as indicated by the
maximum number of loose/liquid stools in a 24 hour period prior to presentation is shown
in Figure 1. Stooling was not normaly distributed, positively skewed (2.187, SE = 0.128)
and leptokurtic (7.16, SE = 0.26), with the highest proportion of subjects (n = 214;
58.9%) producing between ≥ 3 and ≤ 6 loose/liquid stools per 24 hours with a median of
6 loose stools (IQR: 4, 8). Figure 2 confirms the non-normal and right-skewed
distribution of stooling frequency via Q-Q plot. The percent of subjects reporting 7 (n =
31), 8 (n = 28) or 10 (n = 26) loose stools over 24 hours prior to presentation were similar
(8.5%, 7.7% and 7.2%, respectively) whereas only 8 subjects reported 9 loose stools
(2.2%). 2-4% of subjects reported 12 (n = 13; 3.6%), 15 (n = 10; 2.8%) or 20 (n = 8;
2.2%) loose stools in a 24 hour period, while less than 1% of subjects reported 11 (n = 3;
0.8%), 13 (n = 1; 0.3%), 16 (n = 1; 0.3%), 18 (n = 1; 0.3%) or 30 (n = 2; 0.6%) loose
stools in any 24 hour period prior to enrollment. It is important to note that a relatively
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high proportion of subjects reported for care within 24 hours of illness onset. Therefore,
these estimates may be lower than what would be observed if subjects waited longer than
24 hours before reporting illness and subsequently being treated as part of the study.

Figure 1. Maximum stool output (frequency; TrEAT TD dataset).
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Figure 2. Maximum stool output (frequency; TrEAT TD dataset) Q-Q plot.
The maximum stool output of TD cases in the OEV-118 dataset as indicated by
the number of loose/liquid stools in a 24 hour period during the period of overseas travel
is shown in Figure 3. Stooling frequency was not normally distributed, positively skewed
(3.87, SE = 0.12) and leptokurtic (23.37, SE = 0.24), with the highest proportion of
travelers (n=313; 76%) producing between ≥3 and ≤6 loose/liquid stools per 24 hours
with a median of 4 loose stools (IQR: 3, 6). Figure 4 confirms the non-normal and rightskewed distribution of stooling frequency via Q-Q plot. The percent of subjects reporting
7 (n = 25), 8 (n = 20) or 9 (n = 21) loose stools over 24 hours were similar (6.1%, 4.9 and
5.1%, respectively); and the number of subjects reporting a maximum of 10 (n = 7), 11 (n
= 5) or 12 (n = 6) loose stools over any 24 hour period during travel were similar (1.7%,
1.2% and 1.5%, respectively). Less than 1% of subjects reported ≥13 loose stools in any
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24 hour period during travel, with 1 subject (0.2%) experiencing a maximum stool output
of 38 stools, the highest reported stooling frequency in the study.

Figure 3. Maximum stool output (frequency; OEV-118 dataset, TD cases).
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Figure 4. Maximum stool output (frequency; OEV-118 dataset, TD cases) Q-Q plot.
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The results presented in the above descriptive statistics analyses for the TrEAT
TD and OEV-118 datasets provided good background information to the hypothesis
testing analysis. Hypothesis testing was conducted as originally outlined in Chapter 3 and
is presented below.
Quantitative Hypothesis Testing Analyses
Hypothesis 1: There are no significant differences in the frequency and
severity of clinical signs and symptoms across disease severity classification. The
relationship between objective signs (i.e., vomiting, fever) and subjective symptoms (i.e.,
nausea, malaise, tenesmus, abdominal cramps, fecal incontinence) was assessed using
Spearman’s correlation. Statistically significant correlations were observed between
various signs and symptoms of TD-attributable illness; and among those signs and
symptoms that were significantly correlated, the strength of correlation varied (Table 11).
The strongest correlation observed was between nausea and vomiting (ρ = 0.49; p <
0.001) although only 21.3% of participants reported vomiting. Malaise was positively
correlated with all signs and symptoms, with the strongest correlation with nausea (ρ =
0.43; p < 0.001), vomiting (ρ = 0.34; p < 0.001), fever (ρ = 0.30; p < 0.001) and
abdominal cramps (ρ = 0.31; p < 0.001). Similarly, abdominal cramps were positively
correlated with all analyzed signs and symptoms, with smaller correlations observed
between nausea (ρ = 0.25; p < 0.001) and tenesmus (ρ = 0.21; p < 0.001). Gas was only
significantly correlated with malaise (ρ = 0.13; p = 0.01) and fecal incontinence was only
significantly correlated with malaise (ρ = 0.13; p = 0.01), nausea (ρ = 0.11; p = 0.03) and
abdominal cramps (ρ = 0.14; p = 0.007). Tenesmus showed small statistically significant
correlations with all signs and symptoms except fever and fecal incontinence.
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Table 11
Spearman Correlations of Ordinal Signs and Symptoms (TrEAT TD Dataset; N = 363)
Signs/Symptoms

Fever

Vomiting

Abdominal
Cramps

Gas

Correlation
estimate (ρ)

Vomiting
Abdominal
Cramps
Gas
Nausea
Tenesmus
Malaise/fatigue
Fecal
Incontinence
Abdominal
Cramps
Gas
Nausea
Tenesmus
Malaise/fatigue
Fecal
Incontinence
Fever
Gas
Nausea
Tenesmus
Malaise/fatigue
Fecal
Incontinence
Fever
Vomiting
Nausea
Tenesmus
Malaise/fatigue
Fecal
Incontinence
Fever
Vomiting
Abdominal
Cramps

p-value

0.24
0.12

Correlation estimate
(p) 95% confidence
limits
Lower
Upper
0.12
0.37
0.01
0.22

-0.04
0.29
0.07
0.30
0.06

-0.14
0.20
-0.04
0.21
-0.06

0.06
0.38
0.19
0.38
0.18

0.43
<0.001
0.16
<0.001
0.25

0.13

0.03

0.23

0.011

-0.07
0.49
0.14
0.34
0.08

-0.17
0.40
0.03
0.25
-0.03

0.04
0.57
0.25
0.42
0.12

0.188
<0.001
0.007
<0.001
0.15

0.24
0.14
0.25
0.21
0.31
0.14

0.12
0.04
0.14
0.11
0.22
0.04

0.37
0.24
0.35
0.30
0.41
0.23

<0.001
0.007
<0.001
<0.001
<0.001
0.007

0.12
0.13
0.37
0.12
0.13
0.04

0.01
0.03
-0.07
0.002
0.03
-0.06

0.22
0.23
0.14
0.23
0.24
0.14

0.03
0.01
0.48
0.32
0.01
0.45

-0.42
-0.07
0.14

-0.14
-0.17
0.04

0.06
0.04
0.24

0.43
0.19
0.01

<0.001
0.03
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Signs/Symptoms

Nausea

Tenesmus

Malaise/fatigue

Fecal incontinence

Correlation
estimate (ρ)

Tenesmus
Malaise/fatigue
Fecal
Incontinence
Fever
Vomiting
Abdominal
Cramps
Gas
Malaise/fatigue
Fecal
Incontinence
Fever
Vomiting
Abdominal
Cramps
Gas
Nausea
Fecal
Incontinence
Fever
Vomiting
Abdominal
Cramps
Gas
Nausea
Tenesmus
Fever
Vomiting
Abdominal
Cramps
Gas
Nausea
Tenesmus
Malaise/fatigue

p-value

0.14
0.43
0.11

Correlation estimate
(p) 95% confidence
limits
Lower
Upper
0.03
0.24
0.33
0.52
-0.01
0.24

0.29
0.49
0.25

0.20
0.40
0.14

0.38
0.57
0.35

<0.001
<0.001
<0.001

0.04
0.23
-0.03

-0.07
0.13
-0.12

0.14
0.32
0.09

0.48
<0.001
0.64

0.07
0.14
0.21

-0.04
0.03
0.11

0.19
0.25
0.30

0.16
0.007
<0.001

0.11
0.14
0.13

0.002
0.03
0.03

0.23
0.24
0.24

0.03
0.01
0.01

0.30
0.34
0.31

0.21
0.25
0.22

0.38
0.42
0.41

<0.001
<0.001
<0.001

0.13
0.43
0.23
0.06
0.08
0.14

0.03
0.33
0.13
-0.06
-0.03
0.04

0.24
0.52
0.32
0.18
0.19
0.23

0.01
<0.001
<0.001
0.25
0.15
0.007

0.40
0.11
-0.03
0.13

-0.06
-0.01
-0.12
0.03

0.14
0.24
0.09
0.24

0.45
0.03
0.64
0.01

0.01
<0.001
0.03

Note. Ordinal values of signs and symptoms: 0, none; 1, mild; 2, moderate; 3, severe

(table continues)
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Correlation between signs and symptoms and frequency of loose stool.
Univariate regression models (Table 12) showed statistically significant associations
between the maximum 24-hour stool output and each of the signs and symptoms except
gas and tenesmus. Variability in these signs and symptoms accounted for 2% to 6% of the
variability in the maximum 24-hour stool output.
Table 12
Univariate Regression between TD-attributable Signs and Symptoms and Maximum 24hour Stool Output (N = 363)
Sign/symptom

Abdominal cramps
Fever
Nausea
Vomiting
Fecal incontinence
Gas
Tenesmus
Malaise/fatigue

Maximum number of loose/liquid stools in any 24-hour period prior
to presentation
Adjusted R2
β
p-value
0.04
0.20
<0.0001
0.04
0.22
<0.0001
0.04
0.19
<0.0001
0.02
0.16
0.003
0.05
0.23
<0.0001
-0.30
0.003
0.95
-0.20
0.09
0.3
0.06
0.25
<0.0001

Note. These results represent analyses with all datapoints. Removal of outliers, defined as those values
being greater than three standard deviations away from the mean, were removed for maximum 24 hour
stool frequency in any 24-hour period prior to presentation, resulted in a greater number of statistically
significant associations between each of the signs and symptoms and stool output (results presented in
Appendix 1).

Based on the results presented in this section, I reject the null hypothesis that there are no
significant differences in the frequency and severity of clinical signs and symptoms
across disease severity classification.
Hypothesis 2: Individual clinical signs and symptoms of TD are not
significantly associated with a negative impact on activity. Separate cumulative odds
ordinal logistic regression models with proportional odds were developed to estimate the
association between individual clinical signs and symptoms of TD (e.g., abdominal
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cramps, nausea, tenesmus, gas, incontinence, malaise, vomiting, and tenesmus) as well as
the traditional TD-illness metric of stool output (i.e., maximum number of loose/liquid
stools in any 24-hours prior to presentation) on activity impact. The association between
the severity gas and activity level is shown in Table 13; gas was the only solicited
symptom that was not significantly associated with activity in TrEAT TD (Χ2 = 5.16, p =
0.160) (Table 14).
Table 13
Proportion of Gas Severity at Presentation and Impact on Activity (N = 363)

Gas severity at
presentation

Impact on Activity
Normal
Decreased ≤
50%

Decreased >
50%

None
Mild
Moderate
Severe

57 (72.2%)
14 (17.7%)
8 (10.1%)
0 (0.0%)

49 (51.0%)
20 (20.8%)
24 (25.0%)
3 (3.1%)

100 (60.2%)
25 (15.1%)
32 (19.3%)
9 (5.4%)

Completely
unable to
function
16 (72.7%)
2 (9.1%)
3 (13.6%)
1 (4.5%)

Table 14
Ordinal Logistic Regression Analysis of the Relationship between Gas Severity and Impact on Activity (TrEAT TD Dataset) (N
= 363)
Variable
Impact on Activity (ref:
completely unable to
function)
Normal
Decreased≤50%
Decreased≥50%
Gas (ref: None)
Mild
Moderate
Severe

β

Standard
Error

Adjusted
OR

95% CI for
OR

p-value

-1.13
0.90
2.92

0.15
0.14
0.24

0.32
2.47
18.60

0.24-0.43
1.88-3.25
11.65-29.71

<0.0001
<0.0001
<0.0001

0.19
0.54
0.58

0.27
0.26
0.53

1.21
1.72
1.78

0.72-2.05
1.04-2.86
0.63-5.01

0.47
0.06
0.27
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The association between the severity of fever at presentation and activity level is
depicted in Table 15. Increasing fever severity was associated with an increasing negative
effect on activity level, X2 = 32.875, p < 0.0001, as shown in Table 16. The deviance
goodness-of-fit test also indicated the model was a good fit for the observed data, X2(6) =
9.762, p = 0.135. The odds of having one’s activity impacted by experiencing mild and
severe fever were 4.3 (95% CI 1.857-9.905) and 3.867 (95% CI 1.193-12.537), times
greater, respectively, than those experiencing no fever; both with statistically
significantly effects, X2(1) = 11.743, p = 0.001 for mild and X2(1) = 5.078, p = 0.024 for
severe fever. The odds of those experiencing moderate fever and reporting a greater
impact on activity was the highest compared to those reporting no fever, with an OR of
5.622 (X2(1) = 19.446, p < 0 .0001).

Table 15
Proportion of Fever Severity at Presentation and Impact on Activity (TrEAT TD Dataset; N = 363)

Fever severity at
presentation

Impact on Activity
Normal
Decreased ≤
50%

Decreased >
50%

None
Mild
Moderate
Severe

78 (98.7%)
1 (1.3%)
0 (0.0%)
0 (0.0%)

75 (78.1%)
8 (8.3%)
10 (10.4%)
3 (3.1%)

143 (86.1%)
8 (4.8%)
10 (6.0%)
5 (3.1%)

Completely
unable to
function
10 (45.5%)
4 (18.2%)
6 (27.3%)
2 (9.1%)

Table 16
Ordinal Logistic Regression Analysis of the Relationship between Fever Severity and Impact on Activity (TrEAT TD Dataset;
N = 363)
Variable
Impact on Activity (ref:
completely unable to
function)
Normal
Decreased≤50%
Decreased≥50%
Fever (ref: None)
Mild
Moderate
Severe

β

Standard
Error

Adjusted
OR

95% CI for
OR

p-value

-1.11
1.01
3.15

0.13
0.137
0.24

0.33
2.74
23.29

0.26-0.43
2.14-3.52
14.50-37.44

<0.0001
<0.0001
<0.0001

1.46
1.73
1.35

0.43
0.39
0.60

4.30
5.62
3.87

1.86-9.91
2.61-12.11
1.19-12.54

0.001
<0.0001
0.02
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The association between the severity of abdominal cramps at presentation and
activity level is depicted in Table 17. The severity of abdominal cramps is significantly
associated with a negative effect on activity, X2 = 28.585, p < 0.0001, as shown in Table
18. The odds of having one’s activity impacted by abdominal cramps increased
approximately two-fold as the severity level category increased. Specifically, the odds of
those experiencing moderate abdominal cramps compared to those experiencing none and
reporting a greater degree of impact on activity was 2.764 (95% CI, 1.649-4.632) with a
statistically significant effect, X2(1) = 14.879, p < 0.0001. Subjects with mild abdominal
cramps (compared to no) abdominal cramps reporting a greater impact on activity was
0.676 (95% CI, 0.661-1.894), X2(1) = 0.174 and not statistically significant (p = 0.676).
Meanwhile, the odds of those with severe abdominal cramps were 4-fold more likely to
report a greater impact on activity compared to those without abdominal cramps, with an
OR of 4.401 (95% CI, 2.126-9.109; p < 0.0001).
Table 17
Proportion of Abdominal Cramps Severity at Presentation and Impact on Activity
(TrEAT TD Dataset; N = 363)

Abdominal
Cramps severity
at presentation
None
Mild
Moderate
Severe

Impact on Activity
Normal
Decreased ≤
50%

Decreased >
50%

34 (43.6%)
32 (41.0%)
11 (13.1%)
1 (1.3%)

19 (19.8%)
24 (25.0%)
40 (41.7%)
13 (13.5%)

30 (18.1%)
50 (30.1%)
68 (41.0%)
18 (10.8%)

Completely
unable to
function
6 (27.3%)
2 (9.1%)
9 (40.9% )
5 (22.7%)

Table 18
Ordinal Logistic Regression Analysis of the Relationship between Abdominal Cramps Severity and Impact on Activity (TrEAT
TD Dataset; N = 363)
Variable
Impact on Activity (ref:
completely unable to
function)
Normal
Decreased≤50%
Decreased≥50%
Abdominal Cramps (ref:
None)
Mild
Moderate
Severe

β

Standard
Error

Adjusted
OR

95% CI for
OR

p-value

-0.80
1.35
3.42

0.21
0.22
0.30

0.45
3.87
30.51

0.30-0.68
2.53-5.923
17.05-54.59

<0.0001
<0.0001
<0.0001

.11
1.02
1.48

0.27
0.26
0.37

1.12
2.76
4.40

0.66-1.89
1.65-4.63
2.13-9.11

0.68
<0.0001
<0.0001
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The association between severity of fecal incontinence at presentation and activity
level is depicted in Table 19. Increasing fecal incontinence severity was significantly
associated with a negative effect on activity, X2 = 24.251, p < 0.0001, as shown in Table
20. The deviance goodness-of-fit test also indicated the model was a good fit for the
observed data, X2(6) = 10.361, p = 0.110. Interestingly, the odds of those who
experienced mild or severe fecal incontinence and reporting a negative impact on activity
were higher (OR = 3.534, 95% CI 1.544-8.090, X2 = 8.923, p = 0.003 and OR = 10.801,
95% CI 2.816-41.429, X2 = 12.036, p = 0.001, respectively) than the odds of those who
experienced moderate incontinence and reporting a negative impact on activity (OR =
2.617, 95% CI, 1.189-5.762, X2 = 5.710, p = 0.017).
Table 19
Proportion of Fecal Incontinence Severity at Presentation and Impact on Activity (TrEAT
TD Dataset; N = 363)

Fecal
incontinence
severity at
presentation
None
Mild
Moderate
Severe

Impact on Activity
Normal
Decreased ≤
50%

Decreased >
50%

Completely
unable to
function

78 (98.7%)
1 (1.3%)
0 (0.0%)
0 (0.0%)

76 (79.2%)
7 (7.3%)
10 (10.4%)
3 (3.1%)

14 (63.6%)
4 (18.2%)
1 (4.5%)
3 (13.6%)

143 (86.4%)
9 (5.4%)
12 (7.2%)
2 (1.2%)
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Table 20
Ordinal Logistic Regression Analysis of the Relationship between Fecal Incontinence Severity and Impact on Activity (TrEAT
TD Dataset; N = 363)
Variable
Impact on Activity (ref:
completely unable to
function)
Normal
Decreased≤50%
Decreased≥50%
Incontinence (ref: None)
Mild
Moderate
Severe

β

Standard
Error

Adjusted
OR

95% CI for
OR

p-value

-1.15
0.94
3.06

0.13
0.13
0.24

0.33
2.57
21.30

0.25-0.41
2.01-3.28
13.32-34.08

<0.0001
<0.0001
<0.0001

1.26
0.96
2.38

0.69
0.40
0.42

3.53
2.62
10.80

1.54-8.09
1.19-5.76
2.82-41.43

0.003
0.02
0.001
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The association between severity of malaise at presentation and activity level is
depicted in Table 21. Increase in severity of malaise was significantly associated with an
increasing negative effect on activity, X2 = 127.864, p < 0.0001, as shown in Table 22.
The odds of having one’s activity impacted by malaise increased approximately threefold as the severity level category of the solicited symptom increased. Specifically, the
odds of those who experienced mild malaise and reporting a negative impact on activity
compared to no malaise and reporting a negative impact on activity was 5.851 (95% CI
3.291-10.402), X2 = 36.213, p < 0.0001, and the odds of those who experienced moderate
malaise compared to none and reporting a negative impact on activity was 14.110 (95%
CI 8.009-24.858, X2 = 83.924, p < 0.0001). Those who experienced severe malaise were
three-times more likely than those who experienced moderate malaise, and 44 times more
likely than those who experienced no malaise to report a negative impact on activity
(OR=44.290, 95% CI 18.477-106.165, X2 = 72.225, p < 0.0001).
Table 21
Proportion of Malaise Severity at Presentation and Impact on Activity (TrEAT TD
Dataset; N = 363)

Malaise severity
at presentation

Impact on Activity
Normal
Decreased ≤
50%

Decreased >
50%

None
Mild
Moderate
Severe

66 (83.5%)
8 (10.1%)
5 (6.35)
0 (0.0%)

16 (16.7%)
21 (21.9%)
51 (53.1%)
8 (8.3%)

47 (28.3%)
54 (32.5%)
55 (33.1%)
10 (6.0%)

Completely
unable to
function
0 (0.0%)
2 (9.1%)
10 (45.5%)
10 (45.5%)

Table 22
Ordinal Logistic Regression Analysis of the Relationship between Malaise Severity and Impact on Activity (TrEAT TD
Dataset; N = 363)
Variable
Impact on Activity (ref:
completely unable to
function)
Normal
Decreased≤50%
Decreased≥50%
Malaise (ref: None)
Mild
Moderate
Severe

β

Standard
Error

Adjusted
OR

95% CI for OR

p-value

-3.07
2.61
4.91

0.17
0.25
0.33

0.93
13.61
135.37

0.66-1.30
8.41-22.03
70.94-258.32

0.67
<0.0001
<0.0001

1.77
2.65
3.79

0.29
0.29
0.45

5.85
14.11
44.29

3.29-10.40
8.01-24.86
18.48-106.17

<0.0001
<0.0001
<0.0001

105

106

The association between severity of nausea at presentation and activity level is
depicted in Table 23. Increasing severity of nausea was associated with a significantly
decrease in activity, X2 = 84.375, p < 0.0001, as shown in Table 24. The deviance
goodness-of-fit test also indicated the model was a good fit for the observed data, X2(6) =
6.681, p = 0.351. Those who experienced mild nausea were almost three times as likely
to report a negative impact on activity (OR = 2.745, 95% CI 1.724-4.399) compared to
those experiencing no nausea (X2 = 17.968, p < 0.0001). Those who experienced
moderate nausea were approximately 9 times more likely to report a negative impact on
activity (OR = 9.193, 95% CI 5.164-16.363) compared to those who experienced no
nausea, X2 = 56.860, p < 0.0001; and those who experienced severe nausea were 37 times
more likely to report a decrease in normal activity (OR = 37.073, 95% CI 11.781116.661) compared to those reporting no nausea (X2 = 38.154, p < 0.0001).
Table 23
Proportion of Nausea Severity at Presentation and Impact on Activity (TrEAT TD
Dataset; N = 363)
Impact on Activity
Nausea severity at Normal
Decreased ≤
presentation
50%

Decreased >
50%

None
Mild
Moderate
Severe

28 (29.2% )
32 (33.3%)
32 (33.3%)
4 (4.2%)

62 (78.5%)
14 (17.7%)
3 (3.8%)
0 (0.0%)

79 (47.6%)
61 (36.7%)
23 (13.9%)
3 (1.8%)

Completely
unable to
function
3 (13.6%)
3 (13.6%)
10 (45.5%)
6 (27.3%)

Table 24
Ordinal Logistic Regression Analysis of the Relationship between Nausea Severity and Impact on Activity (TrEAT TD Dataset;
N = 363)
Variable
Impact on Activity (ref:
completely unable to
function)
Normal
Decreased≤50%
Decreased≥50%
Nausea (ref: None)
Mild
Moderate
Severe

β

Standard
Error

Adjusted
OR

95% CI for OR

p-value

-0.66
1.69
4.05

-0.15
0.18
0.30

0.52
5.44
57.11

0.38-0.70
3.79-7.79
31.99-101.96

<0.0001
<0.0001
<0.0001

1.01
2.22
3.61

0.24
0.29
0.59

2.75
9.19
37.07

1.72-4.40
5.16-16.36
11.78-116.66

<0.0001
<0.0001
<0.0001
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The association between severity of vomiting at presentation and activity level is
depicted in Table 25. The severity of vomiting was associated with a significant decrease
in activity, X2 = 55.697, p < 0.0001, as shown in Table 26. The deviance goodness-of-fit
test also indicated the model was a good fit for the observed data, X2(6) = 3.420, p =
0.755. The odds of those experiencing mild and moderate vomiting and reporting a
negative impact on activity were very similar – 5.422 and 5.344, respectively – compared
to those experiencing no vomiting (X2 = 14.001, p < 0.0001, mild vomiting; X2 = 15.079,
p < 0.0001, moderate vomiting). Those experiencing severe vomiting were approximately
8 times more likely to report a negative impact of illness on activity level than those who
experienced no vomiting (OR 8.38, 95% CI 4.135-16.989) (X2 = 34.784, p < 0.0001).
Table 25
Proportion of Vomiting Severity at Presentation and Impact on Activity (TrEAT TD
Dataset; N = 363)

Vomiting severity
at presentation

Impact on Activity
Normal
Decreased ≤
50%

Decreased >
50%

None
Mild
Moderate
Severe

76 (96.2%)
0 (0%)
1 (1.3%)
2 (2.5%)

60 (62.5%)
10 (10.4%)
10 (10.4%)
16 (16.7%)

144 (86.7%)
7 (4.2%)
7 (4.2%)
8 (4.8%

Completely
unable to
function
9 (40.9%)
2 (9.1%)
3 (13.6%)
8 (36.4%)

Table 26
Ordinal Logistic Regression Analysis of the Relationship between Vomiting Severity and Impact on Activity (TrEAT TD
dataset; N = 363)
Variable
Impact on Activity (ref:
completely unable to
function)
Normal
Decreased≤50%
Decreased≥50%
Vomiting (ref: None)
Mild
Moderate
Severe

β

Standard
Error

-1.04
1.17
3.44
1.69
1.68
2.13

Adjusted
OR

95% CI for
OR

p-value

0.13
0.14
0.23

0.35
3.23
31.20

0.27-0.46
2.48-4.22
18.79-51.78

<0.0001
<0.0001
<0.0001

0.45
0.43
0.36

5.42
5.34
8.38

2.24-13.14
2.29-12.45
4.14-16.99

<0.0001
<0.0001
<0.0001
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The association between severity of tenesmus at presentation and activity level is
depicted in Table 27. The severity of tenesmus was associated with a significant decrease
in activity, X2=13.031, p = 0.005, as shown in Table 28. Only those who experienced
moderate tenesmus in the TrEAT TD trial reported were statistically significantly more
likely to report a negative impact on activity (OR = 2.790, 95% CI 1.557-4.998, X2 =
11.898, p = 0.001) compared to those who experienced no tenesmus. The odds of those
who experienced mild tenesmus and reporting a negative impact on activity (OR = 1.289,
95% CI 0.741-2.243; X2 = 0.808, p = 0.369) was similar to that of those who experienced
severe tenesmus and reported a negative impact on activity (OR = 1.745, 95% CI 0.4357.001; X2 = 0.617, p = 0.432).
Table 27
Proportion of Tenesmus Severity at Presentation and Impact on Activity (TrEAT TD
Dataset; N = 363)
Tenesmus
severity at
presentation
None
Mild
Moderate
Severe

Impact on Activity
Normal
Decreased ≤
50%

Decreased >
50%

67 (84.8%)
10 (12.7%)
1 (1.3%)
1 (1.3%)

63 (65.6%)
17 (17.7%)
16 (16.7%)
0 (0%)

114 (68.7%)
24 (14.5%)
24 (14.5%)
4 (2.4%)

Completely
unable to
function
13 (59.1%)
1 (4.5%)
6 (27.3%)
2 (9.1%)

Table 28
Ordinal Logistic Regression Analysis of the Relationship between Tenesmus Severity and Impact on Activity (TrEAT TD
Dataset; N = 363)
Variable
Impact on Activity (ref:
completely unable to
function)
Normal
Decreased≤50%
Decreased≥50%
Tenesmus (ref: None)
Mild
Moderate
Severe

β

Standard
Error

Adjusted
OR

95% CI for
OR

p-value

-1.12
0.94
2.98

0.14
0.13
0.24

0.33
2.55
19.68

0.25-0.43
1.97-3.32
12.37-31.30

<0.0001
<0.0001
<0.0001

0.25
1.03
0.56

0.28
0.30
0.71

1.29
2.79
1.75

0.74-2.24
1.56-5.00
0.44-7.00

0.37
0.001
0.43
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The association between number of loose stool output in any 24-hour period prior
to presentation and activity level is depicted in Table 29. A Classification and Regression
Tree Analysis (CART) was conducted to quickly determine the optimal cut points of the
maximum number of loose stools in 24-hours for inclusion in the scoring system. The
maximum number of loose stools in 24-hours period prior to presentation as defined by
the following three categories: 2-4 stools/24 hours, 5-7 loose stools/24 hours, ≥8 loose
stools/24 hours, is significantly associated with a negative effect on activity statistically
significant effect on activity, X2(2) = 62.703, p <0.0001 (Table 30). For this analysis
utilizing an ordinal distribution of stool maximum stool frequency, the assumption of
proportional odds was met, as assessed by a full likelihood ratio test comparing the fit of
the proportional odds location model to a model with varying location parameters, X2(4)
= 8.401, p = 0.078. The deviance goodness-of-fit test indicated that the model was a good
fit to the observed data, X2(4) = 8.401, p = 0.078. The final model statistically
significantly predicted the dependent variable over and above the intercept-only model,
X2(2) = 67.627, p < 0.0001. Subjects who reported 5-7 loose stools in 24-hours were
approximately 4-fold more likely to report a greater impact on activity compared to those
who reported 2-4 loose/liquid stools in 24-hours, with an OR of 3.848 (95% CI, 2.3716.243; p < 0.0001). As stooling increased with 8 or more loose stools in a 24-hour period,
the odds of reporting a negative impact on activity also increased dramatically, with an
OR of 8.508 (95% CI, 4.963-14.585; p < 0.0001). This analysis further supports the
proposed stool output categories (i.e., 2-4 stools/24 hours, 5-7 loose stools/24 hours, ≥8
loose stools/24 hours) are appropriate cut points for inclusion in the TD disease complex
score. Finally, and as demonstrated throughout this section, I reject the null hypothesis
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that there are no significant individual clinical signs and symptoms of TD associated
with a negative impact on activity in adult travelers.
Table 29
Proportion of Loose Stool Output in any 24-hour Period Prior to Presentation and
Impact on Activity (TrEAT TD Dataset; N = 363)

Maximum number of loose
stools in any 24-hour period
prior to presentation
2-4 loose/liquid stools
5-7 loose/liquid stools
≥8 loose/liquid stools

Impact on Activity
Normal
Decreased ≤
50%

Decreased >
50%

56 (70.9%)
17 (21.5%)
6 (7.6%)

15 (15.6%)
41 (42.7%)
40 (41.7%)

53 (31.9%)
71 (42.8%)
42 (25.3%)

Completely
unable to
function
5 (22.7%)
4 (18.2%)
13 (59.1%)

Table 30
Ordinal Logistic Regression Analysis of the Relationship between Stool Frequency
(Maximum Number of Loose Stools in any 24-hour Period Prior to Presentation –
Ordinal) and Impact on Activity (TrEAT TD Dataset; N = 363)
Variable

β

Standard
Error

Adjusted
OR

95% CI for
OR

p-value

Impact on Activity (ref:
completely unable to
function)
Normal
Decreased≤50%
Decreased≥50%

-0.37
1.98
4.13

0.17
0.21
0.30

0.69
7.27
62.23

0.49-0.97
4.80-10.99
34.81111.24

0.03
<0.0001
<0.0001

1.34

0.25

3.85

2.37-6.24

<0.0001

2.14

0.28

8.51

4.96-14.59

<0.0001

Maximum number of
loose stools (ref: 2-4
loose stools in 24-hours
prior to presentation)
5-7 loose stools in 24hours prior to
presentation
≥8 loose stools in 24hours prior to
presentation
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Development of the disease complex score. Multiple Correspondence Analysis
was performed using SAS and all observations within the TrEAT TD dataset (no outliers
removed) and showed covariability in multiple signs and symptoms with severity being
the most common factor associated with similar dimensions in a two-dimensional space
(Figure 5). It should be noted that the CART-defined stool classifications were included
in the MCA analysis, with the two lowest categories of stool frequency (0-1 loose
stools/24 hours and 2-4 loose stools/24 hours) clustered with the lack of any objective
signs and symptoms. Meanwhile, the highest loose stool category (≥8 loose stools/24
hours) appeared most proximal to mild and moderate symptoms. Mild fever, vomiting,
fecal incontinence, nausea and malaise clustered tightly with moderate abdominal cramps
and fecal incontinence; whereas moderate nausea and vomiting clustered with more
severe abdominal cramps and ≥8 loose stools/24 hours. Interestingly, mild tenesmus
grouped with the aforementioned cluster with more moderate to severe symptoms,
resulting in its elevated scoring of ‘2’ in the final disease severity score. As expected,
most severe signs and symptoms (with the exception of abdominal cramps and ≥8 loose
stools/24 hours) tended to cluster together, with moderate fever and tenesmus also
included in this grouping, the latter two parameters receiving a maximum score of ‘3’ in
the final disease severity score. Based on the grouping of clinical outcomes in the MCA
and taken together with the results of the correlation, univariate logistic regression
analyses, a three-component disease score was developed utilizing the objective signs,
subjective symptoms and stool frequency yielding a score ranging from 0 (no disease) to
9 (most severe disease) (Table 31).

Figure 5. Multiple correspondence analysis of signs and symptoms of travelers’ diarrhea (TrEAT TD dataset).
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Table 31
Travelers’ Diarrhea (TD) Disease Complex Score
Parameter

Outcome

Score

Objective Signs

Severe: ≥3 episodes vomiting OR

3

Moderate to severe fever

3

2 episodes vomiting
1 episode vomiting OR Mild fever
No objective symptoms
Severe: Tenesmus, Malaise, Nausea, Fecal
Incontinence OR
Moderate Tenesmus
Severe Abdominal cramps OR
Moderate Nausea OR
Mild Tenesmus
Moderate: Abdominal cramps, Fecal Incontinence,
Malaise OR
Mild: Abdominal cramps, Nausea, Malaise, Fecal
Incontinence
No subjective symptoms
≥8 loose stools/24 hours

2
1
0
3

5-7 loose stools/24 hours
2-4 loose stools/24 hours
0-1 loose stools/24 hours

2
1
0

Subjective Symptoms

Loose stool output
(max 24 hour freq)

3
2
2
2
1
1
0
3
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Utilizing this new disease complex score and prior to application to the OEV-118 dataset
as part of Hypothesis 3, an ordinal logistic regression was performed to assess whether
the new score better estimated of TD impact on activity than any single individual sign
or symptom.
Assessment of whether the new score benefits the estimation of impact on
activity over any single individual sign or symptom. The distribution of subjects by
TD severity and impact on activity is depicted in Table 32 and Figure 6. The new TD
disease complex score was associated with a significant decrease in activity, X2 =
127.156, p < 0.001, as shown in Table 33. The assumption of proportional odds was met,
as assessed by a full likelihood ratio test comparing the fit of the proportional odds
location model to a model with varying location parameters, X2(16) = 16.28, p = 0.434.
The deviance goodness-of-fit test indicated the model was a good fit to the observed data,
X2(16) = 15.971, p = 0.455, with the final model statistically significantly predicting the
dependent variable over and above the intercept-only model, X2(8) = 164.997, p < 0.001.
As TD disease complex score increased, so did the odds of reporting a negative impact on
activity, with a slight exception between those with a TD score of 6 versus 7, in which
the latter resulted in a slightly lower odds ratio compared to the former (OR = 167.54,
95% CI 40.97-685.19 and OR = 126.00, 95% CI 29.66-535.23, respectively) (Table 33).
Those scoring highest (TD Score = 9) were 1423 times as likely to report a negative
impact on activity (OR = 1422.84, 95% CI 244.69-8273.63) compared to those with the
lowest score (TD Score = 1). Even those who scored a 2 were 6.5 times more likely to
report a negative impact on activity (OR = 6.53, 95% CI 1.78-23.86) compared to those
with the lowest score (TD Score = 1). It should be noted a TD Score of 0 was not
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included in this analysis, as all participants who enrolled in the TrEAT TD study were
required to have at least 2 loose stools within 24 hours and subsequently a minimum
score of ‘1’.
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Table 32
Proportion of TD Disease Score and Impact on Activity (TrEAT TD Dataset; N = 363)
TD Score

1
2
3
4
5
6
7
8
9

Impact on Activity
Normal
Decreased ≤
50%

Decreased >
50%

20 (86.9%)
29 (50.9%)
17 (20.7%)
6 (9.1%)
6 (14.6%)
1 (2.9%)
0 (0.0%)
0 (0.0%)
0 (0.0%)

1 (4.3%)
4 (7.0%)
15 (18.3%)
19 (28.8%)
16 (39.2%)
17 (48.6%)
6 (25%)
14 (58.3%)
4 (36.4%)

2 (8.7%)
24 (42.1%)
49 (59.8%)
39 (59.1%)
18 (43.9%)
12 (34.3%)
14 (58.3%)
7 (29.2%)
1 (9.1%)

Completely
unable to
function
0 (0.0%)
0 (0.0%)
1 (1.2%)
2 (3.0%)
1 (2.4%)
5 (14.3%)
4 (16.7%)
3 (12.5%)
6 (54.5%)

100
90
80

Percent

70
60
50
40
30
20
10
0
1

2

3

4

5

6

7

8

9

TD Disease Severity Score
Normal

Decreased ≤ 50%

Decreased > 50%

Completely unable to function

Figure 6. Proportion of TD disease score and impact on activity (TrEAT TD dataset).

Table 33
Ordinal Logistic Regression Analysis of the Relationship between TD Disease Score and Impact on Activity (TrEAT TD
Dataset; N = 363)
Variable
Impact on Activity
(ref: completely
unable to function)
Normal
Decreased≤50%

β

Standard Error

Adjusted OR

95% CI for OR

p-value

1.857
4.631

0.6097
0.6415

6.407
102.667

0.002
<0.0001

Decreased≥50%
TD Score
(ref: TD Score 1)
TD Score 2
TD Score 3
TD Score 4
TD Score 5
TD Score 6
TD Score 7
TD Score 8
TD Score 9

7.124

0.6872

1241.159

1.939-21.167
29.20360-98
322.77-4772-69

1.876
3.200
3.929
4.093
5.121
4.836
5.417
7.260

0.6615
0.6549
0.6714
0.6978
0.7186
0.7380
0.7573
0.8982

6.525
24.532
50.842
59.947
167.539
126.001
225.169
1422.835

1.78-23.86
6.77-88.56
13.64-189.55
15.27-235.38
40.97-685.19
29.66-535.23
51.04-993.39
244.69-8273.63

0.005
<0.0001
<0.0001
<0.0001
<0.0001
<0.0001
<0.0001
<0.0001

<0.0001
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Hypothesis 3: The estimated vaccine efficacy of the ETVAX vaccine in the
OEV-118 Phase 3 trial does not change as a result of using the new disease complex
score. In an attempt to assess TD severity score’s potential utility, it was applied to a
previously conducted Phase 3 vaccine field efficacy trial (OEV-118) to determine
whether the disease score significantly differentiated illness between vaccine and placebo
recipients. This analysis was conducted for the entire OEV-118 dataset, as well as
multiple subgroups within OEV-118, defined in Chapter 3, Table 4 (see also Table 40).
In the dataset, comprised of subjects enrolled in the OEV-118 study who received
one or two doses of vaccine, traveled to Mexico or Guatemala and had symptom data
available for analysis (N = 1435) (‘ALL’), there were 722 vaccinees and 713 placebos.
The distribution of the TD score by treatment group is depicted in Table 34 and Figure 7.
TD scores for neither treatment group were normally distributed, as assessed by ShapiroWilk’s test (p < 0.05); however, there was homogeneity of variances, as assessed by
Levene’s test for equality of variances (p = 0.17). While the placebo mean TD score
(1.82±1.93) was slightly higher than vaccinees mean TD score (1.73±1.82), the
difference was not statistically significant, = -0.10, 95% CI [-0.29, 0.10], t(1433) = 0.97, p = 0.33 (Table 40).
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Table 34
Distribution of TD Disease Score in All Subjects Enrolled in OEV-118 by Treatment
Group (OEV-118 Dataset; N = 1435)
TD Score

Treatment Group (N = 1435)
Vaccinees
Placebos
(n = 722)
(n = 713)
206 (28.5%)
202 (28.3%)
192 (26.6%)
185 (25.9%)
155 (21.5%)
142 (19.9%)
68 (9.4%)
63 (8.8%)
37 (5.1%)
56 (7.9%)
26 (3.6%)
18 (2.5%)
16 (2.2%)
18 (2.5%)
12 (1.7%)
16 (2.2%)
6 (0.8%)
8 (1.1%)
4 (0.6%)
5 (0.7%)
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Figure 7. Proportion of TD disease score and subjects meeting TD endpoint by treatment
group (OEV-118 dataset).
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Among those with TD independent of etiology (subset ‘TD’), there were 212
vaccine and 200 placebo recipients. The distribution of the TD score among this subset
stratified by treatment group is depicted in Table 35 and Figure 8. There were no outliers
in this subset, as assessed by inspection of a boxplot. TD scores for each treatment group
were not normally distributed, as assessed by Shapiro-Wilk’s test (p < 0.05); however,
there was homogeneity of variances, as assessed by Levene’s test for equality of
variances (p = 0.73). While the placebo mean TD score (3.77±1.93) was slightly higher
than vaccinees mean TD score (3.60±1.86), the difference was not statistically
significant, M= -0.17, 95% CI [-0.54, 0.20], t(410) = -0.91, p = 0.36 (Table 40). Based on
this analysis the TD severity scores distribution in both groups were comparable.
Table 35
Distribution of TD Disease Score and Subjects Meeting TD Endpoint by Treatment
Group (OEV-118 Dataset; N=412)
TD Score

1
2
3
4
5
6
7
8
9

Treatment Group (N = 412)
Vaccinees
Placebos
(n = 212)
(n = 200)
8 (3.8%)
7 (3.5%)
67 (32.1%)
58 (28.5%)
51 (23.6%)
43 (22%)
31 (14.6%)
37 (18.5%)
23 (10.8%)
16 (8.0%)
10 (4.7%)
16 (8.0%)
11 (5.2%)
11 (5.5%)
7 (3.3%)
7 (3.5%)
4 (1.9%)
5 (2.5%)
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Figure 8. Proportion of TD disease score and subjects meeting TD endpoint by treatment
group (OEV-118 dataset).
In the ‘Vaccine Preventable ETEC TD (VPO-ETEC TD)’ subset, defined as those
experiencing ≥5 loose/watery stools in 24 hours plus ≥ of abdominal pain/cramps, nausea
and/or vomiting, plus ETEC sharing antigens with the ETVAX vaccine as the sole
pathogen and isolated in a window of 24 hours before to 72 hours after illness onset
among subjects completing the full 2-dose regimen and traveling during the window of 7
to 14 days post 2nd dose and completing 14 to 28 days surveillance, there were 8 vaccine
and 5 placebo recipients. The proportion of subjects by treatment groups across the new
TD score is depicted in Table 36 and Figure 9. In an independent t-test, there was
homogeneity of variances, as assessed by Levene’s test for equality of variances (p =
0.73), but the TD scores for vaccinees were not normally distributed with a Shapiro-
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Wilk’s value of p = 0.03. TD scores between placebos (M = 4.80, SD = 1.64) and
vaccinees (M = 4.13, SD = 1.25) who met the VPO-ETEC TD endpoint definition did not
show a statistically significant difference, M = -0.68, 95% CI [-2.44, 1.09], t(11) = -0.84,
p = 0.42 (Table 40).
Table 36
Distribution of TD Disease Score and Subjects Meeting VPO-ETEC TD Endpoint by
Treatment Group (OEV-118 Dataset; N = 14)
TD Score

Treatment Group (N = 14)
Vaccinees
Placebos
(n=8)
(n=5)
0 (0.0%)
0 (0.0%)
0 (0.0%)
0 (0.0%)
3 (37.5%)
1 (25.0%)
3 (37.5%)
2 (40.0%)
0 (0.0%)
0 (0.0%)
2 (25%)
1 (33.3%)
0 (0.0%)
1 (33.3%)
0 (0.0%)
0 (0.0%)
0 (0.0%)
0 (0.0%)
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Figure 9. Proportion of TD disease score and subjects meeting VPO-ETEC TD endpoint
by treatment group (OEV-118 dataset).
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In the ‘ETEC TD’ subset, defined as those experiencing ≥3 loose or watery stools
in a 24 hour period accompanied by abdominal pain or cramps, nausea, or vomiting of
any intensity, plus ETEC sharing antigens with the vaccine as the sole pathogen isolated
anytime during the TD episode, there were 10 vaccinees and 19 placebos who met this
particular endpoint as recommended by the OEV-118 Data Safety Monitoring Board
(DSMB). The proportion of subjects by treatment group across the new TD score is
depicted in Table 37 and Figure 10. An independent t-test to assess differences in the
scores between vaccine and placebo recipients within this subset demonstrated TD scores
for each treatment group were normally distributed, as assessed by Shapiro-Wilk’s test
(p>.05), and there was homogeneity of variances, as assessed by Levene’s test for
equality of variances (p = 0.182). The mean disease score for vaccinees (M = 3.40, SD =
1.174) was lower than the mean disease score for placebos (M = 4.74, SD = 1.851), a
statistically significant difference, M = -1.34, 95% CI [-2.67, -0.01], t(27) = -2.07, p =
0.05 (Table 40).
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Table 37
Distribution of TD Disease Score and Subjects Meeting ETEC TD endpoint by Treatment
Group (OEV-118 Dataset; N = 29)
TD Score

Treatment Group (N = 29)
Vaccinees
Placebos
(n = 10)
(n = 19)
0 (0%)
0 (0.0%)
2 (20.0%)
3 (15.8%)
4 (40.0%)
1 (5.3%)
3 (30.0%)
5 (26.3%)
0 (0.0%)
5 (26.3%)
1 (10.0%)
1 (5.3%)
0 (0.0%)
2 (10.5%)
0 (0.0%)
2 (10.5%)
0 (0.0%)
0 (0.0%)
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Figure 10. Proportion of TD disease score and subjects meeting ETEC TD endpoint by
treatment group (OEV-118 dataset).
In the ‘ALL ETEC TD’ subset, defined as those who had any ETEC-attributable
TD, there were 100 vaccinees and 87 placebos who met this particular criterion. The
proportion of subjects by treatment group across the new TD score is depicted in Table
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38 and Figure 11. There was a homogeneity of variances as assessed by Levene’s test for
equality of variances (p = 0.59). However, the TD scores for both vaccine and placebo
groups were not normally distributed with a Shapiro-Wilk’s value of p < 0.05. TD scores
between placebos (M = 2.61, SD = 1.90) and vaccinees (M = 2.59, SD = 1.90) who met
the ALL-ETEC TD endpoint definition did not show a statistically significant difference,
M = -0.19, 95% CI [-0.57, 0.53], t(185) = -0.07, p = 0.95 (Table 40).
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Table 38
Distribution of TD Disease Score and Subjects Meeting ALL-ETEC TD Endpoint by
Treatment Group (OEV-118 Dataset; N = 187)
TD Score

Treatment Group (N = 187)
Vaccinees
Placebos
(n = 100)
(n = 87)
10 (10.0%)
10 (11.5%)
17 (17.0%)
18 (20.7%)
31 (31.0%)
18 (20.7%)
19 (19.0%)
16 (18.4%)
9 (9.0%)
13 (14.9%)
7 (7.0%)
6 (6.9%)
2 (2.0%)
1 (1.1%)
2 (2.0%)
3 (3.4%)
1 (1.0%)
2 (2.3%)
2 (2.0%)
0 (0.0%)
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Figure 11. Proportion of TD disease score and subjects meeting ALL-ETEC TD endpoint
by treatment group (OEV-118 dataset).
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In the ‘ETEC-MX’ subgroup, defined as those who received one or two doses of
vaccine, traveled to Mexico or Guatemala, had symptom data available for analysis and
had ETEC as well as another enteric pathogen isolated in their stool by culture methods
per protocol, there were only 6 vaccinees and 7 placebos who met this endpoint. The
proportion of subjects by treatment group across the new TD score is depicted in Table
39 and Figure 12. TD scores for each treatment group were normally distributed, as
assessed by Shapiro-Wilk’s test (p > 0.05), and there was a homogeneity of variances as
assessed by Levene’s test for equality of variances (p = 0.89). TD scores for vaccinees (M
= 4.83, SD = 1.72) and placebos (M = 3.86, SD = 2.27) did not show a statistically
significant difference M = 0.98, 95% CI [-1.52, 3.48], t(11) = 0.89, p = 0.41 (Table 40).
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Table 39
Distribution of TD Disease Score and Subjects Meeting ETEC-MX Endpoint by
Treatment Group (OEV-118 Dataset; N = 13)
TD Score

Treatment Group (N = 13)
Vaccinees
Placebos
(n = 6)
(n = 7)
0 (0.0%)
0 (0.0%)
0 (0.0%)
1 (14.3%)
0 (0.0%)
1 (14.3%)
2 (33.3%)
1 (14.3%)
1 (16.7%)
2 (28.6%)
0 (0.0%)
1 (14.3%)
2 (33.3%)
0 (0.0%)
1 (16.7%)
0 (0.0%)
0 (0.0%)
1 (14.3%)
0 (0.0%)
0 (0.0%)
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Figure 12. Proportion of TD disease score and subjects meeting ETEC-MX endpoint by
treatment group (OEV-118 dataset).
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As the assumption of normality was violated for some of the above-analyzed
OEV-118 population subsets, I performed a Mann-Whitney U test for each subset as the
nonparametric alternative to the independent samples t-test. Consistent with the results of
the independent t-test, the Mann-Whitney U test revealed similar results for each group
and are summarized in Table 40. For the entire analysis dataset (N = 1435), the median
TD score for vaccinees (1.00) and placebos (1.00) was not statistically significantly
different, U = 262,140, z = 0.61, p = 0.54. For the TD endpoint population (n = 412), the
median TD score for vaccinees (3.00) and placebos (3.00) was not statistically
significantly different, U = 20,010.5, z = -1.01, p = 0.31 (Table 38). For the VPO-ETEC
TD subset (n = 13), the median TD score for vaccinees (4.00) and placebos (4.00) was
not statistically significantly different, U = 25.5, z = 0.846, p = 0.44 (Table 39). For the
ETEC TD subset (n = 28), the median TD score for vaccinees (3.29) and placebos (4.60)
was statistically significantly different, U = 139, z = 2.06, p = 0.05; the only statistically
significant comparison seen amongst all analysis subsets. For the ALL-ETEC TD subset
(n=187), the median TD score for vaccinees (1.00) and placebos (2.00) was not
statistically significantly different, U = 4298.5, z = -0.142, p = 0.87; and for those 13
subjects who met the ETEC-MX definition, the median TD score for vaccinees (5.00)
and placebos (4.00) was not statistically significantly different, U = 27, z = 0.87, p = 0.45
(Table 40).

Table 40
Comparison of 3-Component TD Disease Complex Score in Placebo and Vaccinated Subjects (OEV-118 dataset)
Endpoint
Population

ALL
TD
ALL-ETEC TD
ETEC TD
VPO-ETEC-TD
ETEC MX

Group

Placebo
Vaccine
Placebo
Vaccine
Placebo
Vaccine
Placebo
Vaccine
Placebo
Vaccine
Placebo
Vaccine

N

Independent t-test

Mann-Whitney U Test

713
722
200
212
87
100
19
10
5
8
7
6

Mean (std)
Score
1.82
1.73
3.77±1.93
3.60±1.86
2.61±1.90
2.59±1.90
4.74±1.85)
3.40±1.17)
4.80±1.64
4.13±1.25
3.86±2.67
4.83±1.72

Median
Score
1.00
1.00
3.00
3.00
2.00
1.00
4.60
3.29
4.00
4.00
4.00
5.00

2 sided
p-value
--0.33
--0.36
--0.95
--0.05
--0.42
--0.41

2 sided
p-value
--0.54
--0.31
--0.89
--0.05
--0.44
--0.45
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Percent reduction of disease severity (PE) was calculated for the entire dataset as well as
each OEV-118 endpoint subgroup. The results are summarized in Table 41. When the TD
disease complex score was utilized and applied to the entire dataset, a PE of 9 was
observed. When the score was applied to those who met the classic TD definition, a PE of
4.5 was observed. When the new score was applied to the per-protocol VPO-ETEC TD
primary analysis subset, a PE of 14 was observed; a major improvement over the original
point estimate of efficacy of -59. PE calculations for the ETEC-TD, ALL-ETEC TD, and
ETEC-MX subgroups were 28.3, 0.7 and -25.1, respectively (Table 41). Excluding the
ETEC-TD subanalysis, there were no statistically significant differences in TD score
between treatment groups in the various subpopulation analyses (i.e., ALL, TD, ALLETEC TD, VPO-ETEC-TD, and ETEC MX). However, the TD score better predicted
reduction in overall clinical disease severity in vaccine versus placebo recipients
compared to previous PE estimates, especially as it pertained to the primary VPO
endpoint (VPO-ETEC TD). For this reason, as well as others provided in this section, I
reject the null hypothesis that a TD disease score does not better differentiate treatment
groups than prior estimates of vaccine efficacy when applied to a previously conducted
ETEC vaccine study (OEV-118).

Table 41
TD Score Impact on Severity (PE) Estimates for Various Population Subsets in OEV-118
Endpoint

Abbreviation

N

Definition

Rationale for Inclusion

All

ALL

1435

Full database analysis

Travelers’ Diarrhea
(TD)

TD

412

Classic TD Endpoint

4.5

All ETEC

ALL-ETEC

188

ETEC TD

29

To determine percent
reduction in disease severity
against infection with any
ETEC
Recommended by OEV-118
Data Safety Monitoring
Board*

0.8

ETEC TD

Vaccine Preventable
ETEC TD

VPO-ETECTD

13

OEV-118 Study Endpoint

14

ETEC with Mixed
Infections

ETEC-MX

14

Subjects enrolled in the OEV-118 study who received
one or two doses of vaccine, traveled to Mexico or
Guatemala and had symptom data available for analysis
≥3 loose or watery stools in a 24-hour period
accompanied by ≥ 1 accompanying gastrointestinal (GI)
symptom
ETEC as sole pathogen isolated in any subject who
received one or two doses of vaccine, traveled to
Mexico or Guatemala, and had symptom data available
for analysis
≥3 loose or watery stools in a 24-hour period
accompanied by abdominal pain or cramps, nausea, or
vomiting of any intensity, plus ETEC sharing antigens1
with the vaccine as sole pathogen isolated
≥5 loose/watery stools in 24 hours plus ≥1 of abdominal
pain/cramps, nausea and/or vomiting, plus ETEC
sharing antigens1 with the vaccine as sole pathogen and
isolated in window of 24 hours before to 72 hours after
illness onset among subjects completing 2-dose
regimen, traveling during window of 7 to 14 days post
2nd dose and completing 14-28 days surveillance.
ETEC along with another pathogen(s) isolated by
culture in any subject who received one or two doses of
vaccine, traveled to Mexico or Guatemala and had
symptom data available for analysis

TD Score PE
Estimate
9

To determine percent
reduction in disease severity
against infection with any
ETEC plus one or more enteric
pathogens

-25.1

28.3

Note. 1 LT, LTST, CFA/I, CS1, CS2, CS3, CS4 or CS5
Note. *AL Bourgeois, personal communication
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Summary of Results
The above results answer the quantitative research questions and objectives
outlined in Chapter 3. Three hypotheses were tested by the secondary quantitative
analysis of two clinical trial datasets. Descriptive statistics, ordinal logistic regression,
univariate linear regression, multinomial logistic regression, Spearman’s correlation
coefficients, multiple correspondence analysis, parametric t tests and non-parametric
Mann-Whitney U tests were used for data analysis. The findings presented in this chapter
are discussed in-depth in Chapter 5.
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Chapter 5: Summary, Conclusions, and Recommendations
Chapter 5 is a summary of the study and findings, recommendations for actions,
implications for social change, and a concluding statement. After reading this chapter, the
reader will have a clear understanding of how this research may impact future TD
research and areas of additional potential research.
Overview
Primary and secondary outcomes for TD interventions have been predominately
limited to loose stool output. However, reliance on stool-based endpoints alone may
minimize meaningful differences in illness profiles. In addition to obtaining further
information on how TD symptomology correlate with stool output metrics, as well as
determining to what extent TD signs and symptoms negatively impact activity, it would
be advantageous to have a single standardized and validated disease severity score (Porter
et al., 2018). I designed the quantitative secondary data analysis presented here to
describe the distribution of TD signs and symptoms, determine their association with
impact on activity, develop a TD severity score, and determine whether the TD severity
score could be utilized to differentiate illness by treatment arms in an interventional
study. It was also performed to inform ongoing and future TD vaccine and therapeutic
trials.
I utilized two clinical trial datasets. TrEAT TD data were used to analyze the
correlation between TD signs and symptoms and stool output, determine which of the
clinical signs and symptoms most negatively impacted activity, and develop a TD score.
The OEV-118 dataset was used to validate the developed TD score by applying it to a
previously conducted vaccine trial to re-estimate reduction in illness among vaccine and
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placebo recipients. Specifically, I used the TrEAT TD dataset to answer two research
questions related to the testing of two hypotheses (Steps 1 and 2). I also performed a
multiple correspondence analysis to facilitate TD score development (Step 3). This
disease complex score was then used to assess whether the disease score could be utilized
to predict reduction in activity level beyond individual signs and symptoms (Step 4). The
final research step was conducting an analysis utilizing the OEV-118 dataset in order to
answer the third research question and test one hypothesis (Step 5). The five research
steps and the three research questions/objectives and hypotheses are summarized below:
•

Step 1: Research Question 1 and Hypothesis.
o

Research Question 1: What combination of clinical signs and symptoms
best characterizes TD severity in adult travelers?
▪

Hypothesis 1. There are significant differences in the frequency
and severity of clinical signs and symptoms of TD impacting on
disease severity classification.

•

Step 2: Research Question 2 and Hypothesis
o Research Question 2: What individual clinical signs and symptoms of TD
are significantly associated with a negative impact on activity among adult
travelers?
▪

Hypothesis 2. Individual clinical signs and symptoms of TD are
significantly associated with a negative impact on activity.

•

Step 3: Development of the TD disease complex score

•

Step 4: Re-assessment of impact on activity utilizing the TD disease complex
score
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•

Step 5: Research Question 3 and Hypothesis
o Research Question 3: Does a TD disease score better differentiate
treatment groups than more traditional estimates of vaccine efficacy when
applied to a previously conducted ETEC vaccine study (Protocol OEV118)?
▪

Hypothesis 3. The estimated vaccine efficacy of the ETVAX
inactivated whole cell vaccine tested in the OEV-118 Phase 3 trial
does change as a result of using the new disease complex score.
Summary of Findings

In the following section I discuss the quantitative results presented in Chapter 4.
Before conducting analyses to answer each research question, I performed descriptive
statistical analyses using the TrEAT TD secondary dataset in order to determine how the
major data features sorted and determined if key assumptions were met. These
descriptive statistics and precursor analyses are also discussed below.
Descriptive Statistics and Precursor Analyses
Demographic characteristics and symptoms experienced by participants
enrolled in the TrEAT TD and OEV-118 datasets. While partially published elsewhere
(Riddle et al., 2017) and as presented in Chapter 4, collated demographic characteristics
of the participants enrolled in the two secondary datasets used for this study show male
gender dominance in the TrEAT TD dataset, with a more equal gender distribution in the
OEV-118 dataset (Table 4). Despite the higher proportion of men enrolled in the TrEAT
TD study, the gender distribution and overall demographic characteristics of that study
population is reflective of deployed military personnel (Hameed et al., 2016; Porter et al.,
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2015; Trivedi et al., 2011). The heavy skew toward males may be important as the
disease severity score was developed based on the TrEAT TD dataset. However, the new
score was applied using a population more generalizable to the adult travel population,
thereby lending more credibility to its potential application to both target traveler groups.
The role of gender in TD risk is unclear. While some studies have shown no association
between gender and TD risk (Diemert, 2006; Evans, Shickle & Morgan, 2001; Steffen,
2017; Steffen et al., 2004), others have reported an apparent confounding effect of gender
on acquiring illness (Schlagenhauf et al., 2010; Vilkman et al., 2016). Meanwhile, the
OEV-118 study gender distribution among classic TD cases was more consistent with
what has been observed recently in the published literature. It should also be noted that
CHIMs studies with the B7A and H10407 strains of ETEC have identified some gender
differences in illness profiles, with females complaining of gastrointestinal disturbances
such as nausea and abdominal cramps (p = 0.026, p = 0.034, respectively) more often
than males (Coster et al., 2007). In contrast, the incidence of fever for males was
significantly higher for males than females (p = 0.04; Coster et al., 2007). After further
stratifying the symptomology for OEV-118 by gender, females experienced all symptoms
at a greater frequency than males across all severity levels (data not shown), with the
most striking gender differences between genders in reporting of abdominal cramps,
nausea, and vomiting. There was also a statistically significant difference in mean (p =
0.03) and median (p = 0.003) TD score between males and females when analyzed via
independent t-test and Mann-Whitney U test, respectively, with females exhibiting a
propensity to more severe disease.
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Age has long been established as an important risk factor for diarrheal disease,
with highest incidence rates among children under the age of five in developing countries
and younger adults traveling from industrialized nations to high-endemic areas
(approximately 1.6 illnesses/traveler; DuPont & DuPont, 2006; Fischer Walker, Perin,
Aryee, Boschi-Pinto, & Black, 2012; Hill, 2000; Steffen, 2005; Steffen et al., 2004;
WHO, 2017). The age distribution of classic TD cases in the OEV-118 dataset is
consistent with what has been see in published literature, with highest rates in the
youngest age cohort (18-25 years; 40%), followed by a 27% burden in 26-35-year-old
travelers (Table 9). TD burden within the OEV-118 study decreased as age increased,
with lowest frequency in the oldest group and relatively equal distribution between
vaccine and placebo recipients (Table 9), perhaps attributable to what has been seen
before with younger travelers’ proclivity for more adventure travel (Kollaritsch, 1989;
Steffen 2005; Steffen et al., 2015) and lack of vigilance in avoiding high risk foods
(Diemert, 2006; Hoge et al., 1996; Pitzurra et al., 2010). Meanwhile, the age distribution
of TD cases in the TrEAT TD dataset is consistent with what has been previously seen in
traditional travelers’ studies, for which younger age cohorts tend to have a greater risk of
acquiring TD. However, published studies in the military subpopulation have shown that
the direction of age effect is inverse to that of other traveler cohorts, in that risk of TD
increases with increased age (Riddle et al., 2006; Sanders et al., 2004). Although the age
distribution across TD cases in the TrEAT TD contrasts with prior studies in this
population, because I developed the disease complex score using this dataset with the
intention to apply it across all traveler populations, it seems apropos that the age
distribution of cases more align to the more traditional traveler subgroup.
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The most commonly reported gastrointestinal symptom was abdominal cramps,
reported in approximately 75% of enrolled participants in TrEAT TD (Table 6) and 62%
of participants in OEV-118. It should be noted (as outlined in Chapter 3) that in OEV-118
“abdominal pain” and “cramps” were captured as two separate and distinct TD
symptoms, and only abdominal cramps were considered. Abdominal cramps are the most
consistently and commonly reported gastrointestinal symptom in TD studies (Bourgeois
et al., 2011; Riddle et al., 2011; Sack et al., 2007; Stoney et al., 2017), followed closely
by nausea, vomiting, and fever (Putnam et al., 2006; Riddle et al., 2011). These data are
similar to the signs and symptoms in these secondary datasets. Reported symptomology
within both datasets reflected similar trends to those observed in previous TD studies,
especially with regards to nausea, vomiting, and fever. Malaise, tenesmus, gas, and fecal
incontinence have not been as consistently reported across TD studies, yet approximately
64%, 29%, 39% and 14% of participants in TrEAT TD reported experiencing those
symptoms, respectively. Malaise was reported in OEV-118 participants at a similar
frequency, with higher reporting of fecal incontinence and gas compared to TrEAT TD
and published literature. While tenesmus of varying severity was reported in 29% of
participants in the TrEAT TD study, it was only reported in 4.2% of OEV-118 study
participants. Tenesmus is a common symptom of infectious gastroenteritis often
associated with infection from Shigella sp., Salmonella sp., and E.coli (Adachi et al.,
2001; Jensen et al., 2014; McGregor & Wright, 2015). As the burden of ETEC and
EAEC infections in the TrEAT TD dataset was relatively high—24.6% and 38.6%
isolated as the sole pathogen in 114 subjects, respectively (Riddle et al., 2017)—perhaps
it is unsurprising that with the higher proportion of infections from these etiologies comes
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a higher reporting of tenesmus as a significant symptom. Meanwhile, in the OEV-118
study, the burden of ETEC infections was not as high (13.1%), with no isolation of
EAEC, which might have resulted in a lower reporting of tenesmus as a significant TD
symptom.
While impact on activity varies across studies and subpopulations, both TrEAT
TD and OEV-118 highlight the negative effects of TD on activity. As shown in Table 10,
6% of participants in the TrEAT TD dataset were completely unable to function as a
result of their illness. This is a much lower proportion of inconvenience attributed to
severe TD than what was seen by Soonawala, Vlot & Visser (2011), but slightly higher
than studies in which 1% of participants required hospitalization (Kollaritsch, 1989;
Peltola & Gorbach, 1997; Steffen et al., 2015). Nevertheless, 78.5% of participants within
the TrEAT TD dataset reported some degree of negative effect on activity, a comparable
proportion to what has been seen in some studies (Tribble et al., 2007; Sanders et al.,
2007; Sanders et al., 2002) and even higher than what has been presented in other
published literature (Soonawala et al., 2011; Ryan & Kain, 2000; Diemert, 2006; Hill,
2000; Sebeny et al., 2012; Steffen et al., 2004; Steffen et al., 2015). This negative impact
on activity is especially important for a military population, since it could result in loss of
duty days and reduced operational readiness. Also, consistent with previous studies
(Lalani et al., 2015; Olson, Hall, Riddle & Porter, 2019; Soonwala et al., 2011; Steffen et
al., 2015), approximately 33% of participants in OEV-118 reported a need to change their
activity due to illness. For the business or leisure traveler, the impact of TD has potential
large implications for business and tourism industries, resulting in financial loss and
increased economic burden (Steffen, 2017; Wang et al., 2008).
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Quantitative Hypothesis Testing Analysis
Hypothesis 1: There are significant differences in the frequency and severity
of clinical signs and symptoms of TD on disease severity classification. As noted in
Table 11, there were positive significant correlations between various clinical signs and
symptoms of TD and an individual’s disease severity classification. Malaise was
positively correlated with all signs and symptoms, perhaps unsurprising given its very
definition of “a general feeling of discomfort, illness or uneasiness whose exact cause is
difficult to identify” (Oxford University Press, 2019). Abdominal cramps were similarly
significantly and positively correlated with all other signs and symptoms as has been
previously reported (Bourgeois et al., 2011; DuPont & DuPont, 2006; Fischer Walker,
Perin, Aryee, Boschi-Pinto, & Black, 2012; Hill, 2000; Riddle et al., 2011; Sack et al.,
2007; Stoney et al., 2017; Steffen, 2005; Steffen, et al., 2004). Gas was only correlated
with malaise and was excluded as a parameter from the TD disease complex score.
Correlation between signs and symptoms and frequency of loose stool. Each
sign and symptom (except gas and tenesmus) was significantly associated with the
maximum 24-hour stool output as measured by frequency (Table 12). The lack of
significant association between gas and stool frequency was consistent with its negligible
effect on activity (see Hypothesis 2 analyses). Gas was subsequently excluded as a
parameter in the TD disease complex score.
In contrast, while tenesmus was prevalent in TrEAT TD and significantly
associated with a negative impact on activity (see Hypothesis 2 analyses) it was not
significantly associated with stool output, perhaps unsurprising given its clinical
definition. Because of the prevalence of tenesmus in the TrEAT TD its significant
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association with subject activity, and its significant clustering with other more severe
symptoms in the MCA, tenesmus was shown to be an important clinical parameter to
include in the overall disease complex score. Furthermore, despite not being significantly
associated with stool output but shown in correlation, various regression and multiple
correspondence analyses to be a meaningful clinical TD parameter tenesmus is an
excellent example of how other symptoms, independent of stool frequency, might play an
important role in TD severity.
Meanwhile, all other signs and symptoms were significantly correlated with stool
frequency. These primary analyses, as presented in Chapter 4, include all TrEAT TD
subjects who met the sampling frame for this research, including ‘outlier’ subjects
(maximum 24-hour stool frequency >3 standard deviations from the mean), as it was
considered important to still include these participants since such people would exist in a
real-world scenario setting. Nevertheless, when these outliers were removed and the
analysis re-run (data not shown), there was a significant association between tenesmus
and maximum 24-hour stool frequency, while gas remained not significant.
Hypothesis 2: Individual clinical signs and symptoms of TD are significantly
associated with a negative impact on activity. All signs and symptoms (excluding gas)
were significantly associated with a negative impact on activity. Generally, as the
severity of the sign or symptom increased so did the negative impact on activity;
however, there were a few interesting exceptions. Moderate tenesmus was associated
with a higher likelihood of reporting a negative impact on activity compared to mild or
severe tenesmus, which were not significantly associated with impact on activity.
Similarly, experiencing moderate fever (temperature 101.2°F – 102.0°F) resulted in a

146

higher likelihood of reporting a negative impact on activity compared to experiencing
either mild or severe fever; however, all fevers were statistically significant. Meanwhile,
experiencing mild vomiting (≥1 episode in 24-hours) resulted in a slightly higher
likelihood of reporting a negative impact on activity (OR = 5.42) compared to
experiencing moderate vomiting (≥2 episodes in 24-hours; OR = 5.34), although the
confidence intervals overlap. As expected, those experiencing severe vomiting (≥3
episodes in 24-hours) were times more likely to report a negative impact on activity
compared to mild or moderate vomiting. However, mild vomiting resulted in a slightly
higher likelihood of reporting a negative impact on activity (OR= 5.42) compared to
moderate vomiting (OR = 5.34), both highly significant. While the grading scale for
vomiting classifies severity as mild, moderate and severe, the actual numerical difference
between the severity levels is a factor of 1, which may not manifest as two distinct
clinical pictures when experiencing only one or two episodes of vomiting. This may be
the reason behind mild and moderate vomiting having similar likelihoods of reporting a
negative impact on activity compared to severe vomiting. Nevertheless, this definition
has been the standard definition for all TD studies conducted to date and is even
consistent with the FDA Toxicity Grading Scale for Healthy Adult and Adolescent
Volunteers Enrolled in Preventive Vaccine Clinical Trials (US DHHS, FDA CBER,
2007), a commonly used grading scale in many clinical trials. Similar to the results for
vomiting, those experiencing moderate fecal incontinence were less likely to report a
negative impact on activity (OR = 2.62) than those who experienced mild fecal
incontinence (OR = 3.53), although both were statistically significant and with
overlapping confidence intervals. Regardless, severe fecal incontinence increased the
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odds of a participant reporting a negative impact on activity, a trend seen with every other
analyzed sign and symptom graded as ‘severe’ (except fever and tenesmus).
Another interesting observation is that the likelihood of reporting a negative
impact on activity among those experiencing severe nausea was 37 times that of those
experiencing no nausea; however, severe vomiting only yielded an odds ratio of 9. One
interpretation could be that nausea is more detrimental to one’s ability to function than
actually vomiting. This may be because vomiting potentially alleviates the feeling of
being nauseous and enables one to resume activity.
Optimal cut points for stooling frequency over a 24-hour period were established
and assigned to an ordinal scale for inclusion into the TD disease complex score. Via a
CART analysis, these categories are as follows: None = 0-1 loose stool/24 hours; Mild =
2-4 stools/24 hours; moderate = 5-7 loose stools/24 hours; severe = ≥8 loose stools/24
hours. As expected, an increase in stooling frequency was significantly associated with a
greater likelihood to report a negative impact on activity. As stooling frequency is the
single most consistent TD disease parameter utilized, these results confirm its
importance; however, based on the results described above, its use as the sole parameter
to define TD illness is likely sub-optimal.
As this analysis was conducted using data from a predominantly active-duty
military population, with some beneficiaries, it is important to consider that there may be
risk of reporting bias by participants underemphasizing the effect their TD illness had on
their ability to function. As Mary Roach stated in her 2016 New York Times magazine
article describing the TrEAT TD study, “For every person who shows up at the morning
sick call, four tough it out.” As a result, it should be considered that such a population
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might be ‘different’ than the normal population and thus their symptom profile may not
be generalizable to a broader traveler population. While reporting bias may be considered
a potential limitation, previous studies with military participants report a moderate rate of
care-seeking behavior for their TD (Olson et al., 2019; Putnam et al., 2006). Furthermore,
a recent review revealed an increase in care-seeking behavior for the treatment of TD
illness by affected individuals in both military and long-term travel populations, up from
16% in studies published between 1996-2005 to 38% in studies published between 20062015 (Olson et al., 2019).
Association of TD Disease Severity Sore and impact on activity. There was a
statistically significant and consistently increasing trend between higher TD disease
severity scores and likelihood of reporting negative functional impairment, with a slight
exception between those with a TD score of 6 versus 7, in which the latter resulted in a
slightly lower odds ratio compared to the former (OR = 167.54, and OR = 126.00,
respectively), but with greatly overlapping confidence intervals (Table 33). As presented
in Chapter 4, those who reported a TD score of 9 were 1423 times more likely to
experience functional impairment compared to those who scored a 1, an exponentially
larger likelihood than observed for any individual signs or symptom. In fact, a TD score
of ≥5 resulted in odds ratios that were in the hundreds or thousands, compared to a TD
score < 5 that yielded comparable odds ratios to some individual signs and symptoms.
This further suggests that the TD disease severity score might be a more useful tool for a
more refined assessment on functional impact, especially for more severe disease.
These data begin to address a relevant research topic in the field of travel
medicine (Riddle et al., 2017). Assessment of whether or not the most commonly
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solicited signs and symptoms of TD actually contribute to a negative impact on activity
facilitates understanding of the TD as a complex syndrome, and assists with evolving the
field away from stool frequency-based definitions (Riddle et al., 2017). These results
support the current guidelines for the prevention and treatment of TD. Specifically, all
signs and symptoms should be classified by an individual’s assessment that his/her illness
is tolerable, distressing, or incapacitating (Riddle et al., 2017). Furthermore, as the TD
disease severity score is a predictor of impact on activity, its application to the field is
aligned with the new recommendations to adopt definitions based on functional impact.
Hypothesis 3: The estimated vaccine efficacy of the ETVAX inactivated
whole cell vaccine tested in the OEV-118 Phase 3 trial does change as a result of
using the new disease complex score. There was no significant difference (p = 0.42) in
the mean or median (p = 0.44) disease scores between vaccine and placebo groups
meeting the original per-protocol primary endpoint definition (VPO ETEC TD). This is
consistent with the per-protocol analysis demonstrating no significant efficacy of the
vaccine in the population (PE = -59, - 95% CI -384 – 48) (Bourgeois et al., 2011). There
was a 14% reduction in overall TD disease severity among vaccinees, a finding not
observed in the per protocol analysis, suggesting that the vaccine might have had reduced
overall clinical illness.
As described in Chapter 3 dosing was not directly observed for the vast majority
of study participants, making it difficult to assess whether all doses were actually taken as
intended (SBL Vaccin AB, 2003). In reviewing the initial PE results, the Data Safety
Monitoring Board (DSMB) recommended exploration of other endpoint definitions in a
set of post-hoc secondary analyses, including those that were limited to potential ETEC
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cases (Bourgeois, personal communication), one of which (ETEC TD) is included in this
dissertation analysis. When the analysis was limited to ETEC TD (considered in post-hoc
analysis and recommended by the OEV-118 DSMB), the disease score indicated a more
readily apparent vaccine effect, compared to the a priori analysis. For the ETEC TD
subgroup, there was a 28% reduction (p = 0.05) in the mean disease scores between
vaccine (3.40) and placebo (4.74) recipients. This finding is especially important as the
ETEC-TD endpoint definition is focused on a more realistic scenario for which this
vaccine candidate would be considered beneficial. The VPO-definition may have been
unnecessarily limiting to more severe disease and a tighter window around ETEC
isolation. In contrast, ETEC-TD included milder TD cases and an expanded window for
ETEC isolation. Thus, the fact that the vaccine demonstrated an approximately 30%
reduction in disease severity compared to a 14% reduction in disease severity (VPO
endpoint) exhibits the potential utility of the TD score, but also the efficacy of the
vaccine.
When percent reduction of disease severity (PE) was calculated for the entire
OEV-118 dataset, there was a 9% reduction in TD disease severity in vaccine recipients
compared to placebo recipients, an important finding given the vaccine was intended only
for circulating ETEC strains that matched the vaccine and not all participants became ill.
When the analysis was limited to the subgroup meeting the classic TD definition, there
was no statistically significant difference (p = 0.36) in the mean disease scores between
vaccine (3.60) and placebo (3.77) groups, nor the median disease scores (3.00, p = 0.31).
However, when PE was re-calculated using the new TD score, there was a 4.5%
reduction in disease severity among vaccinees compared to placebos, offering a first look
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into how the vaccine fared against all-cause TD illness. While perhaps not unexpected
that the vaccine did not perform as well for all-cause TD as it would for VPO-ETEC-TD,
as similar observations were noted with the LT-patch against all-cause diarrhea (defined
as ≥4 unformed stools in 24 hours), the ETVAX vaccine performed better in reducing
overall TD illness than the LT-patch technology did in protecting against all-cause TD
(PE = -12.3, 95% CI -40 to 10) (Behrens et al., 2014). While Behren’s et al. (2014) noted
significant reductions in duration of all-cause diarrheal episodes and frequency of
unformed stools per all-cause diarrheal episodes, those secondary endpoints still
represent the more traditional outcome measures with no consideration for the TD illness
spectrum for which the LT-patch may have benefited.
For the ALL-ETEC TD subgroup, another definition of interest in seeing how the
vaccine differentiated TD illness regardless of whether or not the vaccine matched
antigens isolated from the field, there was no significant difference in the mean (p = 0.95)
or median (p = 0.89) disease scores between vaccine and placebo recipients; and there
was only an 0.8% reduction in TD disease severity between the two treatment arms.
While it is recognized that there were a significant number of ETEC infections that were
ST-only or ST-CS6 strains (n = 101), two antigens not covered by the vaccine, it is
perhaps unsurprising that the vaccine did not reduce disease severity in this particular
subpopulation. Behrens et al (2014) observed similar results in their Phase 3 evaluation of
the LT-patch, which did not confer significant protection against strains expressing ST.
Finally, for the ETEC-MX subgroup for which ETEC along with other pathogens
(e.g., Salmonella, Shigella, Campylobacter, Giardia, etc.) were isolated during the TD
episode, there was no statistically significant difference in the mean (p = 0.41) or median
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(p = 0.45) TD scores. Furthermore, there was a 25% increase in disease severity among
vaccinees with mixed ETEC infections compared to placebos.
Despite minimal or insignificant differences in the disease scores between vaccine
and placebo recipients, there was a trend towards lower TD scores in most analyses.
Utilization of the TD score allowed for consideration of important clinical parameters
(i.e., tenesmus, malaise, fever), not previously considered, enabling further differentiation
of illness between treatment groups. For example, while the ETEC-TD subgroup
included subjects with ≥3 loose/watery stools in 24 hours with abdominal pain/cramps,
nausea or vomiting of any intensity and ETEC as the sole pathogen isolated, TD scores
were based on inclusion of other symptoms not otherwise specified in the ETEC-TD
definition. As a result, it appeared that the vaccine had a significant impact on reducing
overall illness. Furthermore, and perhaps most importantly, re-estimating protective
efficacy using the TD score demonstrated a reduction in overall TD illness in vaccine
recipients compared to placebo recipients, indicating some vaccine effect against various
categories of ETEC TD illness. These results suggest that utilization of a TD disease
severity score could prove a more useful tool for assessing an intervention’s efficacy
compared to reliance on a more narrowly focused outcome.
Recommendations for Action
Results obtained from Hypothesis 1 and 2 testing and the MCA analysis led to the
development of a disease severity score for TD to characterize TD severity. The new
scoring system was identified using symptom data from a recently completed TD study
conducted in adults ≥18 years of age deployed to four high-risk countries. An initial
attempt to externally validate the score on a different traveler population was performed
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using an existing clinical trial dataset evaluating the field efficacy of an inactivated whole
cell ETEC vaccine. Before this new TD disease severity score is routinely used, it should
be assessed in other clinical trials to determine if a similar utility is achieved.
Although the TD Score yielded only a single statistically significant difference in
scores between treatment groups in OEV-118, there was a benefit to re-estimation of
vaccine efficacy using the entire dataset as well as alternate considered definitions. While
this is only one attempt at external validation, there is historic evidence that disease
severity scores have been useful for application in pediatric studies (Arifeen et al., 2013;
Jauregui et al., 2014; Lee et al., 2016; Levine et al., 2015; Kinlin & Freedman, 2012;
Pringle et al., 2011; Tam et al., 2014) and more recently there is accumulating evidence
that disease severity scores are proving valuable in CHIM studies (Porter et al., 2016;
Porter et al., 2018). Moreover, disease severity scores have a demonstrated value in
application to in-depth analysis of immune response profiles and identification of
potential correlates of protection (Clarkson, 2018; Porter et al., 2018). It is hoped that this
TD disease score could also be applied in a number of ways beyond just estimating
impact on activity, as scores for other syndromes have demonstrated broad utility beyond
just illness characterization. For example, the Rome Criteria for the diagnosis of IBS
were originally established to guide researchers, but have undergone several revisions
with the intent of making them clinically useful and relevant for both patients and health
care providers. The most recent revision included further classification of IBS subtypes,
which now helps focus treatment plans for patients in addition to focusing clinical trials
for IBS in collecting more relevant information to more accurately categorize IBS
subtypes (Drossman, 2016; Lacy & Patel, 2017). Another example includes the coronary
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artery calcium score, which not only plays an important role in showing significant
association with occurrence of major cardiovascular events, but has also been shown to
demonstrate utility in further stratifying coronary risk in various populations (e.g.,
asymptomatic or diabetic patients) (Neves, Andrade & Moncao, 2017) thus informing
more accurate treatment options (American College of Cardiology, 2018).
As has been acknowledged in the development of scoring systems for ETEC and
Shigella (Porter et al., 2016; Porter et al., 2018), a potential solution to mitigate unequal
distribution of stool output as a measure of disease severity is to establish new stool
frequency/volume cut points based on existing data. Such analyses were performed here.
Interestingly, when these new stool frequency classifications were included in the MCA
analysis, the two lowest categories of stool frequency (0-1 loose stools/24 hours and 2-4
loose stools/24 hours) clustered with the lack of any objective signs and symptoms.
Meanwhile, the highest loose stool category (≥8 loose stools/24 hours) appeared most
proximal to mild and moderate symptoms. This not only suggests that stool frequency
alone may not be as useful as a predictive measure of more serious disease, but also lends
support that symptoms outside of stooling frequency contribute as much, if not more, to a
more severe illness profile. While this score proposes new stool frequency cut points for
the TD score, it was on a single dataset and might benefit from further study to see if
these cut points are consistent.
If future trials are to utilize this proposed TD scoring system, there will be
inherent caveats. Given the relatively small community conducting TD studies, some
consistency in endpoints has occurred; which have been further reinforced by national
regulatory authorities such as FDA through the provision of Guidances for Industry such
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as toxicity grading scales for use in clinical trials (FDA, 2007). Nevertheless, variations
exist in that some studies have related severity classifications to interference with daily
activities (Bourgeois et al., 2007; Sack et al., 2007), while some have only used stoolbased endpoints with one or more individual symptoms and no consideration of
functional impact in the primary outcome assessment (Behrens et al., 2014; Steffen et al.,
2013). It is recognized that the field would benefit from more standardization of
definitions of TD disease signs symptoms, with official recommendations to utilize
definitions based on functional impact (Riddle et al., 2017). As the scoring system has
been shown to better predict the likelihood of reporting a negative impact on activity than
any individual sign or symptom, its utility in interventional studies warrants further
exploration (Riddle et al., 2017).
Public health professionals, enteric disease experts, clinical trial scientists, and
policy makers need to be aware of these results and the recommendations resulting from
this research. As these three audiences are reached through different media, I recommend
disseminating results via peer-reviewed journal publications to target enteric disease,
public health and clinical trial experts; while policy makers are likely best reached
through key public health conferences.
Study Limitations
As referenced in Chapter 1, while the sample size of the dataset on which the TD
score was developed was relatively large and covered four high-risk countries, it was
based on self-reported data from a military population, thus potentially limiting its
generalizability to a civilian travel population. Although the clinical signs and symptoms
included in the scoring system are common and expected solicited symptoms consistent
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with the published literature, there is recognition that content validity of the proposed
score might be reduced if there are other relevant symptoms that were not included.
Finally, host-specific factors such as baseline stooling habits, microbiome and diet were
not included in these analyses which may impact disease outcome measures, and it is
acknowledged that such factors may play an important role in both stool output and nonstool related outcomes not currently captured in the current scoring system.
Recommendations for Further Research
Despite an effort in this research to validate the new TD disease complex score on
another dataset, I recommend focusing future research on application of the TD score to
additional clinical trial and epidemiologic settings. While it has been proposed that use of
a standardized TD scoring system is ideal, the optimized disease score as a result of this
research requires additional use prior to relying solely on it for identification of TD
gastroenteritis in a study setting. As it was developed using a single database from one
study, it would be important to validate its accuracy against other travel populations in
different study settings to increase its generalizability.
As it pertains to the OEV-118 study, specifically, further analysis on stratified
data could yield other important insights as to the utility of the proposed TD severity
score to characterize disease and re-estimating vaccine efficacy for additional
subpopulations, including those with more severe disease. Additionally, limiting analysis
to those with immunological “take” would be especially interesting and consistent with
DSMB recommendations. Finally, as this study collected important health card
information regarding impact of symptoms on daily activities and inclination to seek
medical advice due to illness, an analysis similar to what was done with TrEAT TD could
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be performed to see if the TD score benefits estimation of impact on activity for this
travel group.
As the proposed scoring system is intended for use across all-cause travelers’
diarrhea, future assessment of the TD score’s usefulness in characterizing disease across
different etiologies is increasingly necessary. If there is limited utility of this score due to
the inherent differences in clinical disease profiles across diarrheal pathogens, then there
may benefit to focusing on developing pathogen-specific scoring systems, similar to what
has been done for pediatric Rotavirus gastroenteritis, ETEC and Shigella CHIMs. As an
ETEC CHIM severity score has already been developed and validated, and the proposed
TD score has been preliminary applied to an ETEC vaccine study as part of this research,
it would be interesting to compare the two different scores and how they might
differentiate ETEC disease in a controlled experimental setting versus more realistic field
exposure.
Implications for Social Change
Building upon recent efforts to better quantify disease severity in ETEC and
Shigella CHIMs as well as extensive prior research to characterize pediatric diarrhea, a
similarly developed and validated score for all-cause TD could be applied to future field
studies evaluating new preventive interventions for TD. Positive results from such
efficacy studies would potentially lead to licensure of a vaccine for use in travelers.
Development of a single optimized scoring system provides a better metric to standardize
endpoints, thereby appropriately setting the bar for advancement and licensure of TD
vaccines and treatments which can reduce morbidity of TD. Reduction in TD disease
burden would confer substantial economic benefit at both the country- and individual-
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level, as it relates to decreased lost revenue for tourism countries, lowered medical costs
associated with overseas medical care or hospitalizations, and reduced health-care costs
and productivity losses due to ill-returning travelers. Additionally, this research proves
especially relevant at this time as a recent convening of various enteric vaccine
intervention stakeholders held a workshop regarding clinical endpoints for efficacy trials
during which the attendees agreed that development of disease scoring algorithms, such
as the one proposed here, would be important for the field (Porter, Gutierrez & Kotloff,
2019). Finally, if such a scoring system could aid in a more accurate characterization of
TD gastroenteritis, result in a more clinically meaningful endpoint, and be implemented
for more comparable measurements of intervention efficacy across trials, it could aid
funders, policy makers and manufacturers as they attempt to prioritize their valuable
resources in vaccine development and implementation efforts.
Conclusions
This quantitative secondary data analysis aimed to determine which combination
of clinical signs and symptoms best characterizes TD severity in adult travelers,
determine whether there were significant differences in frequency and severity of clinical
signs and symptoms on disease severity classification, assess whether those individual
symptoms were significantly associated with impact on activity, ascertain whether the
new score benefits the estimation of functional impairment over the individual
parameters, and determine whether a standardized TD scoring system could differentiate
treatment groups when applied to a previously conducted ETEC vaccine study. The item
response theory and classic test theory provided the conceptual frameworks for this
research as they provide explanations for the various challenges, advantages and
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methodologies associated with assessment of self-reported health outcomes and scale
development. The literature demonstrated the variability in TD endpoint definitions, a
gap in knowledge with existing scoring systems (especially in the context of assessing
TD severity), and that the development of a simple and standardized tool for measuring
disease outcomes severity could benefit the travel medicine field. Finally, these results
support the potential utilization of a single optimized scoring system that may provide the
field a better metric for future studies to use a more clinically meaningful endpoint;
thereby more appropriately setting the bar for advancement and licensure of TD vaccines
and treatments which may ultimately lead to reduced TD-attributable morbidity in
travelers.
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Appendix: Ordinal Logistic Regression with Stool Frequency as Continuous Variable
When the ordinal logistic regression analysis was performed utilizing maximum
number of loose stools in any 24 hour period prior to presentation as a continuous
variable (Table 35), the final model statistically significantly predicted the dependent
variable over and above the intercept-only model, X2(2) = 46.525, p < .0001 and the
independent variable has a statistically significant effect on the prediction of whether
activity will be impacted, X2(2) = 43.094, p < .0001. An increase in stool number was
associated with an increase in the odds of experiencing a more negative impact on
activity, with an odds ratio of 1.190 (95% CI, 1.130-1.254), X2(1) = 43.094, p < .0001.
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Table A1
Ordinal Logistic Regression Analysis of the Relationship between Stool Frequency (Maximum
Number of Loose Stools in any 24-hour Period Prior to Presentation – Continuous) and Impact
on Activity (TrEAT TD dataset; N = 363)
Variable

B

Standard
Error

Adjusted
OR

95% CI for
OR

p-value

Impact on Activity
(ref: completely
unable to function)
Normal
Decreased≤50%

-0.252
1.940

0.197
0.217

0.777
6.961

0.201
<0.0001

Decreased≥50%

4.122

0.329

61.695

Maximum number of
loose stools in any 24
hour period prior to
presentation

0.174

0.027

1.190

0.528-1.143
4.55310.640
32.408117.450
1.130-1.254

<0.0001
<0.0001

